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Abstract
Headache is the most common pain problem reported by people with schizophrenia,
with 12 month prevalence rates of around 50%. Despite this little research has been
conducted into the characteristics, impact and management of headaches in this
population. There is evidence to support the efficacy of physiotherapy treatment of
cervicogenic headache and tension type headache and determining the prevalence,
impact and current management of these types of headache was of particular interest.

A pilot study was first undertaken to identify and refine an appropriate headache
questionnaire, develop an algorithm to use for classification of headache and test the
repeatability and reliability of using the algorithm to classify headache types. A
previously validated questionnaire was identified and slightly modified for the mental
health population. A two part algorithm, which utilized information from the
questionnaire, was designed to classify headaches into cervicogenic (CGH), migraine
(MH) or tension type (TTH) headache against the International Classification of
Headache Disorder criteria. Participants whose headache characteristics did not enable
them to be classified into one of these three categories were coded as Other Headache
(OH) type. A convenience sample of 12 chronic headache suffers not currently
receiving care for their headache completed the questionnaire on two occasions,
separated by 6-weeks. On each occasion two independent reviewers used the algorithm
to characterise the headache type. The algorithm was shown to have high inter rater
reliability (weighted-κ=.827) and moderate test re-test reliability (weighted-κ=.636).

A cross-sectional observational cohort study of people with schizophrenia or
schizoaffective disorder was then undertaken to determine the prevalence,
characteristics, impact and management of headache in this population. Using the
validated headache questionnaire, data was collected about headache prevalence and
characteristics from 100 consecutive people diagnosed with schizophrenia or
schizoaffective disorder. Headaches were classified using the algorithm by two
independent reviewers and any disagreement settled by consensus. Clinical
information, demographic data and information on current management of headache
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was collected and questions from the SF-36 questionnaire were included to assess
quality of life.

Males made up 66% of the sample cohort. The mean age of participants was 38.8 years
and on average participants had been diagnosed with schizophrenia or schizoaffective
disorder for 14.6 years. The most common comorbid physical illness was diabetes. All
participants were taking antipsychotic medication, with 66/100 people taking some
form of medication that listed headache as a common or very common side effect.

Twelve month prevalence of headache (57%) was slightly higher than in the general
population (46%). The two reviewers demonstrated excellent agreement on headache
classification (weighted-κ=.85). Prevalence of CGH (5%) and MH (18%) were
comparable to the general population and TTH had a much lower prevalence (16%)
than that found in the general population (42%). OH was the most prevalent (19%).

When considering the whole population we found no evidence of a relationship
between mental health clinical characteristics and the presence of headache. The
presence of any headache was not related to inpatient/outpatient status (OR=2.07, 95%
CI [0.92-4.68]), length of time from diagnosis of mental illness (OR=0.99, 95% CI
[0.95-1.03])) or taking medication with a side effect of headache (OR=0.94, 95% CI
[0.40-2.19]). Similarly, there was no relationship between clinical status and the
individual specific headache types. These data suggest that the specific headache types
are independent of the mental health problem. We did find an association between OH
type and medication use (OR=0.32, 95% CI [0.11-0.90]) and inpatient/outpatient
status (OR=5.76, 95% CI [1.74-19.07]), suggesting those whose headache is not
classifiable using International Headache Society (IHS) criteria might be suffering
from headache which is secondary to their mental health problems.

A similar analysis was undertaken utilising only data from the headache population.
These data suggest that there is a relationship between age and CGH (OR=1.14, 95%
CI [1.01–1.29]), medication use and MH (OR=6.14, 95% CI [1.24-30.44]) and
inpatient/outpatient status and TTH (OR=0.28, 95% CI [0.08-0.95]) when considering
only those people who suffer from headache.
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The quality of life of headache sufferers in this cohort was lower than seen in healthy
populations. Importantly, the frequency of headache was shown to be negatively
correlated with Social Functioning (ρ=-.44, p<.001), Bodily Pain (r=-.44, p<.001) and
Role Physical (ρ=-.32, p=.01), suggesting that headache may contribute to the reduced
quality of life experienced by people with mental health problems. It was evident that
very few people were receiving appropriate treatment for their

headache. No

participant with MH had been prescribed migraine specific medication and
physiotherapy was not included in the management of headache of any participant with
CHG or TTH. It is recommended that better education is provided for both patients
and mental health workers about headache and its management as well as the role of
physiotherapy in managing the physical health and mental wellbeing of people
accessing mental health services.
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CHAPTER ONE
A Pilot Study to identify and refine an appropriate questionnaire
for data collection of headache symptoms and to develop and
evaluate repeatability and inter-rater reliability of an algorithm
to guide headache classification.

1.1

Introduction

Knowledge of the headache sufferer’s symptoms gathered from a comprehensive
history, provides the clinician with essential information about the headache
characteristics and enables classification of the headache against the International
Headache Society’s (IHS) International Classification of Headache Disorder (ICHD)
framework. Headache questionnaires are widely accepted tools commonly used to
elicit this information, especially in the research environment. The purposes of this
pilot study were threefold, firstly to identify and refine an appropriate headache
questionnaire for data collection within the schizophrenic and schizoaffective disorder
population, secondly to develop an algorithm to guide headache classification based
on data collected from the questionnaire and thirdly to evaluate the repeatability and
inter-rater reliability of the process of classifying headache using the questionnaire and
algorithm. Headaches were to be classified into cervicogenic headache (CGH),
migraine headache (MH), tension type headache (TTH) and a classification of other
headache (OH) for all headaches that did not fit the other three classifications.

1.2

Review of Literature

1.2.1 Questionnaires for research
There are many forms of headache with very different mechanisms underpinning
symptom production. Correct classification of the headache type is essential if the
clinician is to provide appropriate and effective treatment for the headache sufferer.
Only with a thorough assessment will the clinician collect the evidence required to
guide effective clinical reasoning and reach the correct classification or diagnosis
(Liebert, Rebbeck, Elias, Hawkins, & Adams, 2013; Stovner et al., 2007; Zito, Jull, &
Story, 2006). In clinical practice, physiotherapists initially undertake a comprehensive
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subjective assessment of all people presenting with headache, including but not limited
to pain characteristics and distribution, associated symptoms, aggravating and easing
factors, headache behaviour and progression, functional limitations and management
strategies. Most of the diagnostic power in headache classification is found in
information obtained from the subjective assessment, though in some instances
additional information from the physical examination can aid the diagnostic process.
However, the physical examination is generally utilised to provide clinicians with
information about contributing factors to the clinical condition, information that is
more important for treatment planning than diagnosis.

When headaches are being investigated for research a definitive knowledge of
contributing factors is not always essential, mitigating the necessity for a full physical
assessment. For this reason stand-alone questionnaires have been designed to collect
participants subjective information to provide investigators with appropriate clinical
information that will guide classification of headache against the ICHD framework
(Borhani Haghighi, Aflaki, & Ketabchi, 2008; Dong et al., 2012; Jull, Amiri, BullockSaxton, Darnell, & Lander, 2007; Li et al., 2012; Pfaffenrath et al., 2009; Queiroz et
al., 2009; Sjaastad, 2008; Zielman, Veenstra, Zwet, & Berg, 2012).

The World Health Organisation (WHO), Lifting the Burden; The Global Campaign to
Reduce the Burden of Headache worldwide study exposed shortcomings and
inconsistencies between headache studies (Stovner et al., 2014). An expert consensus
group was subsequently formed and conducted a review of headache surveys with the
aim to provide recommendations to improve the quality of future studies exploring
headache prevalence and burden. The expert group suggested guidelines to encourage
uniformity in research and thus allow for comparison between studies (Stovner et al.,
2014). The review identified that most questionnaires collect data based on the ICHD
classification system and recommended that this be the standard. This requires
collecting data on severity, duration, location and frequency of headache, associated
symptoms as well as aggravating and alleviating symptoms of headaches.
Recommendations from their review include:


Reduce bias by ensuring the sample selection represents the population of
interest



Reduce bias by ensuring all interviews follow the same protocol

9



If it is not possible for all interviews to be administered by the same person
ensure that bias is reduced through adequate training of all interviewers



Report participation rate as the proportion of eligible people who were
contacted and engaged in a meaningful way in the study



The study instrument (questionnaire) should be suited to the purpose of the
study and capture the necessary data and include
o Identification
o Demographics of at least age and gender
o Screening questions (do you have headache or not)
o One year prevalence of headache
o Diagnostic questions on headache that explore severity, duration,
location, frequency, associated symptoms, aggravating and alleviating
symptoms
o Gathering information on only one headache type per questionnaire.
Participants should identify and provide information on their most
bothersome headache first and then complete a separate questionnaire
of other headache types
o Elements of burden related to the purpose of the study must be
measurable



The questionnaire should be prepared and tested



The questionnaire should be validated to prove diagnostic capability



An algorithm developed against the ICHD criteria must be developed and used
for classification purposes after the questionnaire is completed.

Many questionnaires also gather information on medication use and comorbidities
(Borhani Haghighi et al., 2008; Dong et al., 2012; Jull et al., 2007; Li et al., 2012;
Pfaffenrath et al., 2009; Queiroz et al., 2009; Sjaastad & Bakketeig, 2008b; Zielman
et al., 2012). Dong et al., (2012) and Jull et al. (2007) included questions about
previous treatments for headache and family history of headache. A study by Li et al.
(2012) also included questions on quality of life exploring any perceived restriction on
daily and social activities caused by the headache. The majority of questionnaires used
in research about headache also gather information about socio-demographics and
utilisation of healthcare systems.
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Pfaffenrath et al. (2009) suggest that questionnaires should be administered face-toface so that clarification could be provided around misunderstanding of questions. This
is in line with the recommendation by Stovner et al. (2014). Many other studies have
also used this method (Borhani Haghighi et al., 2008; Dong et al., 2012) although one
study conducted in Brazil and another in Germany used a questionnaire administered
over the telephone which may have impacted on results (Queiroz et al., 2009; Radtke
and Neuhauser, 2009). To reduce recall bias most studies met the recommendations
and were conducted on people who had experienced headache in the previous twelve
months (Pfaffenrath et al., 2009; Queiroz et al., 2009).

Any headache questionnaire being used to classify headache in order to determine
prevalence, should have high agreement between the questionnaire classification and
the eventual diagnosis (Hagen, Zwart, Vatten, Stovner, & Bovim, 2000; Jull et al.,
2007; Stovner et al., 2014). Jull et al. (2007) developed and validated such a
questionnaire to classify headache types based on symptoms described by the ICHD.

This questionnaire was designed to collect information about the frequency and
intensity of headache as well as specifics about the location of pain, associated pain,
accompanying symptoms, possible triggers and possible measures that provide relief
of symptoms. The tool was used to collect data on characteristics of headache in order
to classify intermittent MH with and without aura, TTH, medication overuse headache
and CGH. To validate that the tool was able to distinguish between CGH and other
headache types, after the headache was classified Jull and colleagues conducted a
physical examination to determine presence or absence of cervical musculoskeletal
impairments. The purpose was to find if there was a specific pattern of musculoskeletal
impairments in CGH that could differentiate it from other headache types. To test interrater reliability of the questionnaire, using an algorithm to guide classification, two
researchers and a neurologist independently classified headache types of 11 people and
compared classifications. There was 82% agreement (9/11). The validity of the
questionnaire was supported by two studies both of which showed clear differences in
neuro-musculoskeletal impairment in the upper cervical spine of subjects classified as
having CGH compared to those with an alternative classifications (Amiri, Jull,
Bullock-Saxton, Darnell, & Lander, 2007; Jull et al., 2007).
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1.2.2 Differential classifications of headaches and development of an
algorithm
For research purposes an algorithm is important to aid classification of headache and
it must be developed applying the criteria of the ICHD (Stovner et al., 2014). The
algorithm must be sensitive enough to differentiate each headache into only one
classification but at the same time comprehensive enough to be able classify every
case (Stanton et al., 2011).

It is evident that there is considerable overlap of clinical symptoms across CGH, MH
and TTH (Fleming, Forsythe, & Cook, 2007; Frese & Evers, 2008; Sjaastad &
Bakketeig, 2008a; Zito et al., 2006). Thirty percent of people with CGH meet ICHD
criteria for MH and 3% of people with CGH meet the criteria for TTH (Hall, Briffa, &
Hopper, 2008). Neck pain, which is considered a key indicator of CGH is also reported
by 70% of headache patients with mixed intermittent headache (Hall et al., 2007) and
69% of patients with MH (Florencio et al., 2014). Pfaffenrath et al. (2009) describe
this situation of headache types not being mutually exclusive as a major problem of
the ICHD classification system.

Given the overlap between characteristics in different headache types it is clear that
simple data collection is not enough to enable classification, and clinical reasoning of
all data presented is required. Algorithms and other decision making tools have been
used in previous studies to assist clinical decision making and guide classification. For
headache studies the algorithm used must be comprehensive enough to facilitate
classification of headache type into only one classification. As with the development
of algorithms to classify back pain, an algorithm to guide classification of headache
type from questionnaire responses may require an hierarchical system of criteria to
help determine ‘best’ fit (Stanton et al., 2011; Stovner et al., 2014). Stovner et al.
(2014) suggest that secondary headache should be diagnosed before primary headache
and migraine should be diagnosed before TTH. A classification of migraine should
only be given when all key criteria are met (Stovner et al., 2014).

The first step to developing such an algorithm is identifying key defining
characteristics of each headache type. Tables 1, 2 and 3 list the defining characteristics
for CGH, MH and TTH used to develop the algorithm for this study. Table 1 lists
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defining characteristics for CGH based on the classification developed by Sjaastad and
the Cervicogenic Headache International Study Group (CHISG) in 1990 (Fleming et
al., 2007).

All people aged between 18 and 65 years in the town of Våga in Norway (n=2075)
were invited to participate in a study exploring differences between MH without aura
and CGH. There was a response rate of 88.6% (1838/2075). It was identified that CGH
is the only headache where people present with unilateral pain starting posteriorly in
the neck and moving anteriorly to the frontal region (Sjaastad & Bakketeig, 2008).
Antonaci and Sjaastad (2011) reported cervicogenic headache almost always presents
with unilateral pain, decreased neck range of motion, ipsilateral shoulder and/or arm
pain brought on by either awkward neck position or pressure on the occipital structure.

Table 1 - CHISG Characteristics of CGH
Reproduced from Fleming et al. 2007.
CHISG DIAGNOSTIC CRITERIA FOR CGH
A

Signs and symptoms of neck involvement:
a. Precipitation of head pain similar to the usually occurring one:
1. By

neck movement and/or sustained awkward head

posturing, and/or
2. By external pressure over the upper cervical or occipital
region on the symptomatic side
b. Restriction of the range of motion (ROM) in the neck
c. Ipsilateral neck, shoulder, or arm pain of a rather vague nonradicular nature or, occasionally, arm pain of a radicular nature
B

Confirmatory evidence by diagnostic anaesthetic blockades

C

Unilaterality of head pain without side shift.
For a diagnosis of CGH to be appropriate, one or more aspects of
Point 1 must be present, with 1a sufficient to serve as a sole
criterion for positivity or 1b and 1c combined.

Migraine with aura headache is distinguished from most other headaches by the
associated visual and/or sensory aura. Flickering lights, spots in the field of vision,

13

numbness or pins and needles may be present and importantly are all fully reversible
within 60 minutes (Hall et al., 2008). The headache associated with migraine with aura
is normally unilateral with severe pulsating pain lasting 24 to 72 hours. In the case of
migraine without aura the headache also usually presents as unilateral, pulsating or
throbbing, moderate to severe pain lasting between 24 and 72 hours.

The onset of most MH is anterior in the head and is only infrequently brought on by
neck position, unlike CGH. In MH pain is aggravated by activities such as climbing
stairs, standing from a lying position or bending from an upright position. Nausea,
photophobia, phonophobia, heightened sensitivity to smell, cognitive, emotional and
motor disturbances may also be present (Noseda & Burstein, 2013). MH sufferers
report nausea, photophobia, phonophobia, and pulsating pain more frequently than any
other headache group. Like Stovner et al. (2007), for the purposes of prevalence of
MH we did not differentiate between migraine with aura and migraine without aura as
they are not too dissimilar in terms of aetiology and impact on the individual.
Table 2 – ICHD Characteristics of MH without Aura
The International Classification of Headache Disorder – 2nd Edition (2004)

CHARACTERISTICS OF MIGRAINE WITHOUT AURA
A

At least 5 attacks fulfilling criteria B-D

B

Headache attack lasting 4-72 hours (untreated or unsuccessfully treated)

C

Headache has at least two of the following characteristics
1. Unilateral location
2. Pulsating quality
3. Moderate or severe pain intensity
4. Aggravation by or causing avoidance of routine physical activity
(eg walking or climbing stairs

D

During headache at least one of the following
1. Nausea and/or vomiting
2. Photophobia and phonophobia

E

Not attributed to another disorder
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Tension Type Headache is a headache that has a diverse clinical profile, however the
most classical symptoms include band like, mild to moderate, bilateral pressing or
tightening pain lasting from between 30 minutes to 7 days. TTH are aggravated by
stress and normal physical activity does not classically aggravate symptoms. Nausea,
vomiting, photophobia and phonophobia are not normally associated with TTH,
however, if the headaches are chronic in nature then these symptoms may be present
in a mild form thus complicating the classification process. In some studies TTH has
been diagnosed by an absence of features found in other headache types or as a
headache of just head pain with no other features (Fumal & Schoenen, 2008). In this
study we have chosen to define TTH based on the ICHD guidelines. During this study
headache not fitting any of the above criteria for CGH, MH or TTH were classified as
OH.

Table 3 – ICHD Characteristics of TTH
The International Classification of Headache Disorder – 2nd Edition (2004)
CHARACTERISTICS OF TENSION TYPE HEADACHE
(INFREQUENT EPISODIC TYPE)
A

At least 10 episodes occurring on <1/day per month on average (<12 days
per year) and fulfilling criteria B-D

B

Headache lasting from 30 minutes – 7 days

C

Headache has at least two of the following characteristics
5. Bilateral location
6. Pressing/tightening (non-pulsating) quality
7. Mild or moderate intensity
8. Not aggravated by routine physical activity (eg walking or
climbing stairs

D

Both of the following
3. No nausea or vomiting (anorexia may occur)
4. No more than one of photophobia or phonophobia

E

Not attributed to another disorder
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1.3

Method

1.3.1 Design
We conducted a longitudinal cohort study on 12 people with known history of
headache within the previous 12 months. This study received institutional ethics
approval and all participants provided written informed consent.
1.3.2 Tools
Knowing that the questionnaire used by both Jull et al. (2007) and Amiri et al. (2007)
was a validated tool it was taken to two experts in the psychiatric field, a Consultant
Psychiatrist and a Mental Health Nurse who both worked across the acute inpatient
hospital setting, the community setting and on the Psychiatric Emergency Response
Team. Both experts reviewed the questionnaire for its suitability for use with people
with schizophrenia and schizoaffective disorder. Both identified that the questionnaire
was lengthy but felt that all bar one of the statements/comments exploring the
possibility of migraine headache was suitable for this population. It was suggested to
change the words ‘visual aura’ to ‘flashing or zigzag light’ as the words visual aura
has specific connotations in the psychiatric community and may easily be
misinterpreted.

Based on the fact that this was a validated questionnaire and it was deemed appropriate
for people with schizophrenia and schizoaffective disorder by mental health
practitioners and following consultation with Professor Gwen Jull it was decided to
use what will be referred to as the ‘Jull headache questionnaire’ as the basis for data
collection and classification for this current study. At the time this decision was made
the recommendations from Stovner et al. (2014) had not been published but it is
reassuring to know that the Jull questionnaire met their recommendations for headache
questionnaires.

Questions were added to the pilot study questionnaire to gather data on the basic
demographics of age, gender and current medication of participants. The word ‘aura’
was changed according to the expert’s suggestions. A copy of the final questionnaire
used in the main study can be found in Appendix 1.
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As is evident from the literature there are some defining characteristics unique to each
headache type as well as many characteristics that are similar across headache types.
No one characteristic in isolation can define a headache diagnosis. An algorithm is
required to assist with the clinical decision making process and allow for classification
of headaches based on the individual’s signs and symptoms as identified in their
questionnaire responses. Researchers have developed algorithms to aid headache
classification but these were not appropriate to be used in this study as the combination
of specific headaches types chosen for classification did not match. The algorithm for
this study required researchers to differentiate between the primary headaches of MH
with and without aura and TTH, the secondary headache of CGH as well as allow for
classification of OH for all headaches that could not be classified as MH, TTH or CGH.
It is anticipated that within this population some of these OH may be headache
attributed to psychiatric disorder or medication related headache.

An algorithm (Figure 1) was designed to assist with the classification of headaches
based on the ICHD classification for MH and TTH and the CHISG classification for
CGH. OH included headache that did not fit the classification for either MH, TTH or
CGH. Once completed this algorithm was reviewed by Professor Gwen Jull who
determined that it was a suitable tool to aid classification and suggested no changes
were required.

The algorithm (Figure 1) was developed to be sensitive enough to allow classification
of each participant’s headache into only one headache type but ensure that every
headache could be classified (Stanton et al., 2011). It was divided into two sections.
Part A included characteristics that were definitive of ‘classic’ CGH, MH or TTH. In
the instance when responses to the questionnaires met all characteristics within Part
A, then the headache could be classified without having to proceed to Part B. Part B
included more detailed information derived from the ICHD, the CHISG and clinical
studies to facilitate clinical reasoning and enable classification. It was expected that
only a few participants would have ‘classic’ symptoms and that the information in Part
B would be required for clinical reasoning to classify the majority of headaches.
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Figure 1 – Algorithm for headache classification
Is the headache unilateral and side locked, precipitated
by neck movement and/or sustained awkward neck
position and pain starts in neck?

Yes

Cervicogenic headache

N
No

Does this person have unilateral, moderate to severe,
pulsating/throbbing, time locked pain which
prohibits activity with associated aura?

Yes

Migraine Headache with aura

No
Does

this

person

have

mild

to

moderate,

pressing/tightening pain which is always bilateral and
no neck symptoms?

Yes
Tension Type Headache

No
Which classification best does the patient best suit?
CGH Defining factors

Migraine Defining

TTH Defining factors

factors

Other Defining
factors

Less episodic

Lasting 4-72 hours

lasting 30 min – 7 days

Motor weakness

Chronic/continuous

Episodic

Less episodic

Triggered by
medication

*Unilateral without side shift

Time locked

Chronic/continuous

Starts in neck

Fronto-temporal location

Starts in head

Neck stiffness/injury

Starts in head

Headache precipitated by 1 or more of
*Neck movement
*sustained awkward head position
*pressure over upper cervical or
occipital region on symptomatic side

2 of the following
*Unilateral
*Pulsating/throbbing/shar
p/stabbing
*Moderate to severe
*Aggravated by routine
exercise, food,
environment, stress,

At least 2 of the following
*Bilateral
*Pressing/tightening
pain/bandlike
*Mild to moderate pain
*Not aggravated by exercise

Ipsilateral neck, shoulder or arm pain
Varying duration of moderate – severe
pain
Ache/ sharp/ non-throbbing, nonlancinating pain or fluctuating
continuous pain
May have associated nausea,
photophobia or phonophobia,
dizziness, ipsilateral blurred vision,
difficulties swallowing ,
ipsilateral eye oedema,
Aggravated by sport/exercise, stress
Relief with hotpacks, neck exercises,
change of position, massage, relaxation

At least one of the
following
*Nausea/Vomiting
photophobia or
phonophobia
May have associated fully
reversible aura including
visual –flickering lights,
spots, lines or loss of
vision
Sensory-pins and needles,
numbness
Relief with medication,
rest
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Least pain
Both of the following
*no nausea/vomiting
*no more than one of
photophobia or phonophobia
Unless chronic then mild
nausea may be associated
Not made worse by normal
physical activity
Aggravated by stress
Relief with physical activity,
relaxation, massage, rest
alcohol

Inconsistent
characteristics of
other three
headache types
Aggravated by
food, alcohol,
lifestyle,
environment, stress
Eased by alcohol,
street drugs

1.3.3 Procedure
A convenience sample of twelve people without schizophrenia or schizoaffective
disorder known to have experienced a headache in the last 12 months were invited to
complete the questionnaire. The inclusion criteria for participation in the pilot study
were being over 18 years of age, proficient in written English and having experienced
regular headache within the previous 12-months. Participants were excluded if they
were unable to provide consent or reported any major extant medical condition for
which headache was a likely symptom. Participants meeting selection criteria were
given the questionnaires to complete. The questionnaires were de-identified for the
purpose of classification.

To establish the headache classification for each participant the principal researcher
and one other physiotherapist (raters) independently reviewed the questionnaires and
using the algorithm to guide clinical reasoning, classified each participant’s headache
type. Results were compared. Where there was disagreement on classification of a
participant’s headache type, discussion was undertaken to reach consensus agreement
between the two raters. If consensus could not be reached a third physiotherapy expert
was to be consulted to enable final adjudication. Following this process the algorithm
was reviewed by both raters and any changes deemed necessary to improve
classification were made.

The same twelve people were asked to complete the same questionnaire again 6 weeks
later. Following the guidelines determined by Peat (2002) to test repeatability


the questionnaire was administered in an identical way



the participants were blinded to initial results



a short enough time had elapsed so that the condition had not changed but long
enough time that the respondent could not remember their original answers.

A further six weeks elapsed (12 weeks in total) before the raters once again
independently classified the headaches using the revised algorithm. Classifications
were compared and after this a consensus classification was assigned to each
participant using the process outlined above. It was decided that 12 weeks was an
adequate time to elapse so that the raters would not be able to remember the previous
classification allocated to each participant (Peat 2002).
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Inter-rater reliability of the algorithm was determined by evaluating agreement
between the two raters across all 24 completed questionnaires. Test/retest reliability of
the tool was determined based on agreement of the consensus headache classification
for the first questionnaire to consensus classification for the repeat questionnaire.

At the end of this process the raters reviewed the algorithm against the disagreed
questionnaires from both rounds and discussed their interpretations in a process of
moderation. Some minor adjustments were made to the algorithm in an attempt to
clarify the points of difference.
1.3.4 Analysis of Data
Each participant was allocated an individual identification number (ID) for the first
and second rounds. Continuous data was checked for normal distribution. Descriptive
statistics were used to describe the participant characteristics. The Kappa Measure of
Agreement was used to quantify agreement between raters across all 24 questionnaires.
To evaluate the test-retest reliability of the tool, comparison of the agreed
classifications for the first questionnaire were compared against those for the second
questionnaire also using the Kappa Measure of Agreement. In keeping with Peat
(2002) a value of 0.5 was used to represent moderate agreement, greater than 0.7 to
represent good agreement and greater than 0.8 to represent very good agreement.

1.4

Results

There were 4 males and 8 females in the pilot study with an age range from 17 years
to 56 years and a mean age of 39.8 years (SD=11.8 years). One person had a comorbid
medical condition and was taking medication for this. The medication had a possible
side effect of headache.

Agreement between raters was 87.5% with consensus reached on 21 out of 24
headache classifications. One rater classified 8/24 headache as MH, 7/24 as TTH, 6/24
as CHG. and 3/24 as OH while the other rater identified 8/24 as MH, 7/24 as TTH,
7/24 as CHG. and 2/24 as OH. The Kappa Measure of Agreement value was 0.83, 95%
CI [0.65-1.00] indicating very good agreement according to Peat (2002).
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In the first round of testing 3/12 of the participants were classified CGH, 5/12 were
classified MH and 4/12 were classified TTH. In the second round classifications were
4/12 CGH, 5/12 MH, 2/12 TTH and 1/12 OH. Three of the 12 participants were
classified differently across the two time points. The Kappa value for agreement
between the two rounds was 0.636, 95% CI [0.28-0.99] indicating moderate test retest
reliability across a six week interval.

1.5

Discussion

The purpose of this pilot study was to identify and refine an appropriate questionnaire
for data collection of headache symptoms and to develop and evaluate test-retest
reliability and inter-rater reliability of an algorithm to guide headache classification
into CGH, MH, TTH and OH. The ‘Jull headache questionnaire’ was identified as a
suitably validated questionnaire to use to gather clinical information to allow
classification of headache within the general population. Two independent mental
health practitioners deemed the ‘Jull questionnaire’ appropriate for use with people
with schizophrenia and schizoaffective disorder with one minor adjustment to wording
to clarify aura in the headache context. The experts identified that the tool was lengthy
and cautioned that participants with schizophrenia or schizoaffective disorder may
have trouble completing it. After discussions around any possible changes that could
reduce the length of the questionnaire it was determined that any significant
modification would impact on its validity. The experts agreed with the decision and
gave endorsement to use it in the main study with a suggestion that the researcher be
present and participate in the interview process rather than give the questionnaire to
participants to complete independently. The participants for this pilot study, however,
did not have schizophrenia or schizoaffective disorder and so while experts had
considered the questionnaire suitable for this population it was not piloted on this
population. Although not available at the time it was subsequently determined that this
questionnaire met the recommendations of an expert group about the design of
headaches questionnaires to be used for research purposes (Stovner et al., 2014).

Based on classification research from the low back pain field (Stanton 2012) a two part
algorithm was developed to assist with specific classification of headache being used
in this study. The algorithm was designed using the ICHD and CHISG criteria to guide
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the researchers in decision making for headache classification. Professor Jull, a world
leader in headache diagnosis and management, reviewed and approved the algorithm
before testing. Trials of the algorithm were encouraging with very good agreement
between the two raters with consensus reached on 21 out of 24 headache
classifications. There was a moderate test retest reliability of the questionnaire across
a six week interval.

To determine prevalence and characteristics of headaches for research purposes it is
imperative that validated and reliable tools are available. This includes both a
questionnaire to gather information about history and characteristics to enable accurate
classification as well as a reliable algorithm to guide clinical reasoning for
classification against the ICHD (Liebert et al., 2013; Stovner et al., 2014; Zito et al.,
2006). In this pilot study the algorithm was required to distinguish between CGH, MH
and TTH. Unlike some previous studies TTH was not classified as being an absence
of symptoms of MH (Kuritzky et al, 1999). The algorithm allowed for a classification
of OH, a headache type that would not meet the characteristics of CGH, MH or TTH,
but one that might be particularly important to consider in the mental health population
given the potential medication side effects and the influence of the psychiatric
condition. OH covers a range of headaches and no attempt was made to further classify
this headache type. Understanding that some headache types that are not CGH, MH or
TTH could be potentially serious medical conditions such as brain tumours or
cardiovascular accidents, care was taken to review the characteristics to ensure no
action was required to assure the safety of the participant.

The first step towards developing the algorithm was to reference the ICHD and the
CHISG to identify characteristics that differentiate headache types. This process
emphasised the similarities and cross-over between characteristics of various headache
types and highlighted the difficulties associated with classifying headaches. Examples
of similarities identified included characteristics such as the presence of neck pain in
MH or TTH (Florencio et al., 2014; Pfaffenrath et al, 2009; Sjaastad, 2008), despite
neck pain being a key characteristic of CGH (Fleming et al., 2007; Hall et al., 2008;
Hall et al., 2007). Nausea and vomiting are usually associated with MH but may also
be present in some instances of TTH or CGH (Fleming et al., 2007; Florencio et al.,
2014; Frese & Evers, 2008; Hall et al., 2008; Hall et al., 2007; Pfaffenrath et al., 2009;
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Sjaastad, 2008). These finding dictated that the algorithm should be divided into two
sections.
The first section was based on ‘classic’ presentations of CGH, MH with aura and TTH.
The ‘classic’ CGH was defined as unilateral, side locked pain originating in the neck
and precipitated by neck movement or awkward posture. The person whose symptoms
were undeniably unilateral, moderate to severe pain of a throbbing or pulsating nature,
pain that was time locked and prohibited movement or activity and was accompanied
by aura were given a classification of MH. TTH was classified when the characteristics
were mild to moderate bilateral pain which was pressing or band like and not
associated with neck pain or stiffness. When characteristics did not categorically meet
all of these criteria and classification was not straight forward the second part of the
algorithm was used. This section of the algorithm contained more detailed information
from the ICHD, the CHISG and clinical investigations about characteristics of each
headache type and guided clinical reasoning to determine the headache classifications.

Once the algorithm was ready to test for inter-rater reliability and test-retest reliability
of classification of headache type, participants were approached to complete the
questionnaire and then repeated the process six weeks later. The majority of the sample
population in the pilot study were physiotherapists and it is possible that their clinical
knowledge of expected signs and symptoms of some headache types might have biased
their responses in the questionnaire and impacted on the precision of answers given.
To reduce possible bias participants were asked to answer each question based only on
their personal experience and not their perceived diagnosis. Participants were also
known to the researcher and it was thought that her being present with them while they
completed the questionnaire may inadvertently influence some participants’ answers.
Therefore participants were given the questionnaire to complete independently without
the researcher being present. It is recognised that this is not the preferred method
(Pfaffenrath et al., 2009) as there is no opportunity to ask for clarification of questions
but it was deemed appropriate for this pilot. All participants completed the
questionnaire without any missing data.

Using the algorithm developed for this pilot study agreement between raters was
87.5% (21/24). The Kappa Measure of Agreement across all 24 responses was 0.83
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indicating very good agreement (Peat 2002). These results are similar to those reported
by Amiri et al. (2007), who found 82% agreement (9/11) with the same questionnaire.
It is possible that classification may have been facilitated by the clarity of responses
based on the fact that participants in this pilot study were mostly physiotherapists. Our
results and the results of Amiri et al., (2007) suggest that this is a reliable tool for
classifying headache although the performance may vary slightly in the schizophrenic
population.

To determine test/retest reliability a comparison was made between classifications
from the first round of responses to the questionnaires compared to classification from
the second round of responses. While six weeks was considered an appropriate gap
between questionnaires for participants to prevent recall of previous answers, a further
six weeks elapsed before raters independently classified the headaches of the repeat
questionnaire. This extended time was to minimise possible recall/bias on their part
because discussion had occurred between the raters after the initial questionnaires were
completed. It was thought they may recognise responses if enough time had not
elapsed. The Kappa Measure of Agreement (0.67) between the consensuses
classifications of initial and follow up questionnaire indicated moderate agreement
(10/12).

Many researchers do not agree with asking participants to complete headache
questionnaires independently and prefer to administer questionnaires face to face to
assist with clarification of questions (Borhani Haghighi et al., 2008; Dong et al., 2012;
Pfaffenrath et al., 2009). For convenience and a desire not to influence answers since
the pilot study participants were known to the researcher, the questionnaire was given
to them to take away and complete. It is possible that the two participants who had
quite different clinical characteristics in their second questionnaire from their first
might have had more consistency if there had been opportunity to get some clarity
around specific questions. To reduce the possibility of this occurring in the main study
it was decided to implement the suggestion of the Consultant Psychiatrist and Mental
Health Nurse and ensure that the researcher would be present while the participants
with schizophrenia or schizoaffective disorder completed the questionnaire.
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1.6

Conclusion

This pilot study succeeded in identifying a valid and reliable questionnaire tool to use
to gather clinical characteristics to guide classification of headache into CGH, MH,
TTH and OH. While identified as lengthy, the questionnaire was not too complicated
and was deemed appropriate for the main study population by experts in the mental
health field. It was decided that the researcher should be present while participants
complete their questionnaires to clarify questions for participants in order to ensure
accurate and reliable responses.

A comprehensive two part algorithm was developed to guide clinical reasoning to
enable classification of headaches based on the ICHD, the CHISG and clinical
investigations. This algorithm was proven to be reliable with excellent agreement
between reviewers classifying headaches. Test/retest agreement was good. Both
instruments were deemed suitable for the project.
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CHAPTER TWO
Introduction
This introduction focuses on the background and reasons for undertaking this crosssectional cohort study exploring the prevalence, characteristics, impact and
management of headache in people with schizophrenia and schizoaffective disorder.

2.1

Topic and purpose

It has long been identified that headache is one of the most common pains reported by
people with schizophrenia, with a prevalence rate as high as 48% (Kuritzky, Mazeh,
& Levi, 1999; Morgan et al., 2012; Watson, Chandarana, & Merskey, 1981). Research
has determined that people who experience chronic headache have a poorer quality of
life than healthy people (Leiper, Elliott, & Hannaford, 2006; Solomon, Skobieranda,
& Gragg, 1993; van Suijlekom, Lamé, Stomp-van den Berg, Kessels, & Weber, 2003;
Vinding, Zeeberg, Lyngberg, Nielsen, & Jensen, 2007). People with schizophrenia or
schizoaffective disorder have also been identified as having reduced quality of life
(Cuyún Carter, Milton, Ascher-Svanum, & Faries, 2011). It could be suggested that
people with schizophrenia or schizoaffective disorder who also experience chronic
headache may have an even poorer quality of life (Pompili et al., 2009; Smitherman &
Baskin, 2008) and that treatment directed towards alleviating headache could
importantly contribute to improving life quality. The first step in providing effective
management is identifying the cause of the problem; that is classifying the type of
headache. To date very little research has been conducted attempting to characterise
and classify the headache type suffered by people with mental illness (Dworkin, 1994;
Watson et al., 1981).

Reactions and/or responses to noxious input are diminished among people with
schizophrenia and schizoaffective disorders (Bonnot, Anderson, Cohen, Willer, &
Tordjman, 2009; Lévesque et al., 2012a; Potvin & Marchand, 2008; Wojakiewicz et
al., 2013). Despite diminished sensitivity to nociception the prevalence of reported
headache appears to be equivalent to that seen in the general population (Kuritzky et
al., 1999). While there are a number of explanations for this paradox, one possibility
is that the aetiological factors contributing to headache are present to a greater extent
in people with schizophrenia, that is, the factors which drive the headache experience
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are more marked in this population. There is evidence for this phenomenon from as
long ago as the 1950’s where multiple cases were documented of people with
schizophrenia experiencing perforated peptic ulcers, ruptured appendix and
myocardial infarction with no associated report of pain (Marchand et.al. as cited in
Dworkin 1994). These incidents suggest that early recognition of any other pain related
disorder including headache is particularly important in the schizophrenic population.

The International Headache Society (IHS) developed a classification for headaches in
the late 20th Century to provide diagnostic criteria for different types of headaches (The
Headache Classification Subcommitee of the International Headache Society, 2004).
Numerous headache types are defined by this classification system, however, the three
with the most significant burden of disease are TTH, MH (Jensen & Stovner, 2008;
Stovner et al., 2007) and CGH (van Suijlekom et al., 2003). Cervicogenic headache is
headache that originates from a disorder within the musculoskeletal structures of the
cervical spine (Sjaastad & Bovim, 1991) and is a problem that can be successfully
managed

with

physiotherapeutic

treatment

directed

towards

normalising

neuromusculoskeletal function in the cervical spine (Chaibi & Russell, 2012; Hall et
al., 2007; Zito et al., 2006). Prevalence of CGH in the general population is estimated
at about 4% (Bogduk & Govind, 2009; Sjaastad & Bakketeig, 2008b), though may be
as high as 20% in the headache population or those attending headache clinics (Evers,
2008; Fernández-de-las-Peñas, Alonso-Blanco, San-Roman, & Miangolarra-Page,
2006; Frese & Evers, 2008). No studies to date have determined the prevalence of
CGH amongst people with schizophrenia or schizoaffective disorders despite the high
reported incidence of headache in this group and the fact that they demonstrate known
risk factors for the development of cervicogenic headache such as poor posture and
poor postural control (Jull, Sterling, Falla, Treleaven, & O'Leary, 2008; Marvel,
Schwartz, & Rosse, 2004).

The purpose of this research is to determine the prevalence and characteristics of
headache, in particular possible cervicogenic headache, and the perceived impact on
aspects of quality of life of people with schizophrenia or schizoaffective disorder. It is
also to determine how people manage their headache and whether they receive
appropriate assessment and/or treatment from a health professional. This information
will help identify whether changes could be implemented to better address this
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manageable physical illness and possibly favourably effect general wellbeing. This
may include expanding the role of physiotherapy in mental health services.

2.2

Background

The link between good physical health and good mental health is widely accepted. The
role of physiotherapy in maintaining or achieving good physical health is also widely
accepted. The Australian Physiotherapy Association (APA) identifies that
physiotherapists are experts in the treatment of musculoskeletal conditions and chronic
pain, helping people with these conditions achieve better physical health (Australian
Physiotherapy Association, 2012). Physiotherapists also play a significant role in the
management of many preventable and/or chronic diseases including heart disease,
diabetes and respiratory diseases such as asthma, enabling people to achieve better
physical health outcomes (Australian Physiotherapy Association, 2008, 2009).

People with mental illness, in particular people with psychotic illnesses, have poorer
physical health than those without mental illness and increased morbidity and
mortality from preventable diseases (Coghlan, Lawrence, Holman, & Jablensky, 2001;
Griswold et al., 2008; McLennan, 1998; Morgan et al., 2012; Richardson et al., 2005;
Stubbs et al., 2014; Vancampfort et al., 2011). People with schizophrenia are generally
less physically active than the general population (Vancampfort et al, 2012; Morgan
et al., 2011). Morgan et al. (2011) determined that in Australia 66% of people with
psychosis smoke compared to the rate of 25.3% in the general population (Morgan et
al., 2012). People with inactive lifestyles who also smoke are at high risk of many
preventable diseases such as chronic pain, asthma, heart and circulatory problems and
diabetes. In Australia almost one third of people with a psychotic illness have asthma
(30.1%), over one quarter (26.8%) of people experience heart or circulatory problems
and a further 20.5% having diabetes (Morgan et al 2011). All these conditions
contribute significantly to mortality and morbidity of people with psychosis (Morgan
et al., 2011).

Reporting of chronic pain is common among people with mental illness (Gureje, 2008)
and as many as one in four people with a musculoskeletal condition report a comorbid
mental illness (Australian Institute of Health and Welfare, 2010). Chronic back, neck
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or other pain was reported by 31.8% of people in Australia with psychosis and severe
headache or migraine reported by 25.4% (Morgan et al 2011).

With the high prevalence of musculoskeletal conditions and chronic disease it might
be expected that physiotherapists would be integral to any mental healthcare team. In
Australia this is not the case. Physiotherapy is not considered a primary profession in
the Australian Mental Health Workforce and is not recognised as a discipline that has
a significant role in delivering services to mental health consumers (Health Workforce
Australia, 2013). In general physiotherapists play either no or an insignificant role in
mental health care teams (Australian Physiotherapy Association, 2011) and as a result
many people who access the mental healthcare systems are missing out on key
treatment and/or preventative health measures to address their physical wellbeing.
While these services are available through the general healthcare systems there are
challenges and barriers that make accessing these services difficult for mental health
consumers (Fagiolini, 2008). Ongoing and unmanaged poor physical health for these
people could result in a further compromise to their mental health.

The omission of physiotherapists in mental health teams suggests that directors of
mental health services are either unaware of the benefits to consumers of including
physiotherapists as part of the multidisciplinary team or overlook the impact poor
physical health has on mental health. Either way within Australia there is a need to
promote the role of physiotherapy and the benefits of employing physiotherapists
within mental healthcare.

One approach to highlight the value of physiotherapy as an integral profession in
mental healthcare is to evidence the impact of physiotherapeutic interventions to the
overall health of the person with mental illness. Research is beginning to emerge in
Europe that demonstrates the positive effects of physiotherapy on the mental and
physical wellbeing of people with schizophrenia (Vancampfort et al., 2012). Another
approach is to identify situations where people with psychotic illness are being
disadvantaged by not being able to access best practice treatment for conditions in
which physiotherapists are considered experts. One such condition is headache which
has already been identified as one of the most common pains reported by people with
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schizophrenia (Kuritzky, Mazeh, & Levi, 1999; Morgan et al., 2012; Watson,
Chandarana, & Merskey, 1981).

Physiotherapeutic intevention is considered the treatment of choice for CGH (Chaibi
& Russell, 2012; Hall et al., 2007; Zito et al., 2006). Physiotherapists are trained not
only to diagnose and treat CGH but also to differentially diagnose CGH from MH,
TTH and other headache types. Physiotherapy has also been shown to play a role in
the holistic management of the person with TTH (Fernández-de-las-Penos et al., 2006).
Physiotherapists are not experts in the management of MH but will refer clients to
health professionals who can provide best practice treatment of these headache types.
Physiotherapy is a treatment of choice to assess and if appropriate manage neck pain
and postural problems that may be present alongside MH or TTH. Without access to
physiotherapy, clients of mental health services experiencing headache are likely be
disadvataged by not receiving best practice, holistic management that will improve
their physical health which in turn could impact positively on their mental well being.

While this study was initially conceived as a vehicle to highlight just one small way in
which physiotherapists can contribute to the holistic care of people with mental illness
is was also inspired by a desire to help address the much bigger issue of headache that
has long been regarded as a problem for people with psychotic illness (Kuritzky,
Mazeh, & Levi, 1999; Morgan et al., 2012; Watson, Chandarana, & Merskey, 1981).
It was thought that a better knowledge of the prevalence and impact of headache on
this population might be useful to highlight the need for mental health workers to
address this significant physical health problem.

2.3

Potential significance

This research is significant to all the people with schizophrenia or schizoaffective
disorder who experience headache. Information that leads to a better understanding of
the nature, characteristics and impacts of these headaches will provide a basis to
determine better management and probable improvement in wellbeing. This
information could also benefit other users of mental health services.

Diminished responses to or reduced reporting of pain in this population may suggest
that the impairments driving a headache need to be severe before the person will report
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it to their health professional. No literature is currently available that examines the
characteristics of the headache experienced by this population and compares them to
the general population. If this research determines that headache characteristics are at
least the same or more severe than in the general population it will provide an argument
for better management strategies to be considered and implemented.

People with chronic headache experience a poor quality of life (Leiper et al., 2006;
Solomon et al., 1993; van Suijlekom et al., 2003; Vinding et al., 2007) as do people
with schizophrenia or schizoaffective disorder (Cuyún Carter et al., 2011). It is
possible that headache experienced by people with schizophrenia or schizoaffective
disorder may further impact negatively on quality of life. There is very little research
investigating the impact of headache on the quality of life of people with schizophrenia
or schizoaffective disorder who experience chronic headache (Pompili et al., 2009;
Smitherman & Baskin, 2008). It is important to better understand the impact headache
is having on the quality of life of a population that has already been identified with a
reduced quality of life. The results could highlight a greater need to better manage
headaches in this population.

Poor posture and impaired postural control is associated with schizophrenia and poor
posture is associated with cervicogenic headache (Marvel et al., 2004; Zito et al.,
2006). It is possible that this population may be at greater risk of developing
cervicogenic headache than the general population. Determining the characteristics of
headache and exploring prevalence of possible CGH may provide basis for further,
more detailed research into the impacts of poor posture associated with schizophrenia.

Treatment protocols and guidelines have been researched and instigated for the
management of headaches including physiotherapeutic intervention for CGH and
TTH. Within the general population people presenting to a medical practitioner with
frequent or chronic headaches are referred to the appropriate health practitioner for
treatment based on the characteristics and diagnosis of their headache. Within the
psychiatric population it would appear that screening and referrals for further
investigation of physical health issues including headache is less common than for the
general population (Griswold et al., 2008; Happell, Scott, & Platania-Phung, 2012).
Happell et al, (2012) suggested that there is a tendency for many mental health workers
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to undervalue complaints about physical illness and view their consumer only in terms
of their mental illness. The result is that these mental health workers do not act on the
reports of physical illness but dismiss them as a part of the mental illness. It was noted
that if this behaviour is repeated frequently that it may result in people eventually not
reporting the presence of a physical illness. It is unclear if this is occurring in the case
of headache amongst people with schizophrenia or schizoaffective disorder. Kuritzky
et al. (1999) suggest that people with schizophrenia do not report headache because
they do not want to bother anyone, have a fear of hospitalisation or simply do not have
anybody to complain to. It is possible that any of these reasons mean that treatable
headache, including CGH and TTH is underreported in this population. If CGH and
TTH has the same or greater prevalence in this population as in the general population
then it further strengthens the argument that physiotherapists should be included as
integral members of the mental health teams.

A screening tool for headache could help case managers identify when their client
experiences headache and when referral or follow up of reported headache is indicated.
Information about management of headache types and the role of physiotherapy could
guide them towards the most appropriate referral pathway and raise the awareness of
the value of physiotherapy in the care of this client group. This process would enable
more timely and appropriate intervention for the mental health consumer thus
preventing needless suffering and discomfort and hopefully improving both their
mental and physical wellbeing.

This research aims to identify the prevalence, characteristics and determinants of
headache amongst people with schizophrenia or schizoaffective disorder and compare
them against the general population. It will determine the impact comorbid headache
has on their quality of life and the current management of the headache. A better
understanding of these could result in better management of headache amongst this
population.
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2.4

Research Questions

1. What is the prevalence of headache amongst people with schizophrenia and
schizoaffective disorder?
2. What are the prevalence rates of specific headache types amongst people with
schizophrenia and schizoaffective disorder?
3. Are any clinical characteristics different between people with schizophrenia
and schizoaffective disorder who experience headache and those who don’t?
4. Are any clinical characteristics different between people with schizophrenia
and schizoaffective disorder who experience specific headache types?
5. Are there any perceived impacts of headaches on quality of life of people with
schizophrenia and schizoaffective disorder?
6. How are headaches managed in this population?
7. Is the management appropriate for the headache classification?
8. Is physiotherapy used as a treatment option where indicated?
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CHAPTER THREE
Review of Literature
This literature review will be presented in eight sections providing information about
headache and schizophrenia and schizoaffective disorder as described below.

3.1 Overview of headache
This section will provide information about the prevalence of headache in both the
general population and in the population of people with schizophrenia and/or
schizoaffective disorder.

3.2 Cervicogenic Headache
This section will report literature findings on the prevalence, clinical characteristics,
mechanisms behind and management of CGH.

3.3 Migraine Headache
This section will examine the prevalence, clinical characteristics, mechanisms behind
and management of MH.

3.4 Tension Type Headache
In this section literature about the prevalence, clinical characteristics, mechanisms
behind and management of TTH will be reviewed.

3.5 Overview of schizophrenia and schizoaffective disorder
This section will provide an overview of schizophrenia and schizoaffective disorder.
It will also review the literature on people with schizophrenia’s response to pain and
explore postural anomalies, both of which could have significant implications on the
presentation and characteristics of their headache experience.

3.6 Physical health of people with mental illness and role of physiotherapy
This section will provide some more information on the poor overall physical health
of people with mental illness and the insight into the role of physiotherapy in overall
management of physical health. It will also highlight the lack of physiotherapy input
into this management within this population.
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3.7 Factors that impact on quality of life
This section will provide an overview of the impact schizophrenia and/or
schizoaffective disorder has on the quality of life of an individual. It will also report
on the impact of headache on quality of life in the general population and investigate
any literature on effect of headache on quality of life of people with schizophrenia and
schizoaffective disorder.

3.8 Summary of literature review
This section will provide a summary of the above information.
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3.1

Overview of Headache

The World Health Organisation (WHO) rates headache as a common disorder of the
nervous system that is underestimated, under-recognised and under-treated (World
Health Organisation, 2012). Headache is listed as one of the 10 most disabling
conditions world-wide (Martelletti, Birbeck, et al., 2013; Martelletti, Mitsikostas, et
al., 2013; Stovner et al., 2007). Four percent (4%) of medical practitioner consultations
and 20% - 30% of referrals to neurological departments in the United Kingdom are for
headaches (Kristoffersen, Lundqvist, Aaseth, Grande, & Russell, 2013) and in
America, headache is the fourth most common presentation at emergency departments
with between 1.4 - 3.3 million visits per year (Kelley & Tepper, 2012a).

Despite this, it has been identified that up to 50% of headache sufferers do not seek
medical advice for headache and when they do many are wrongly diagnosed and
wrongly treated. The WHO (2012) identified that worldwide an average of four hours
of undergraduate medical training is dedicated to education on headache disorders. In
contrast The University of Notre Dame Australia Physiotherapy undergraduate
programme has 16 hours dedicated to assessment and management of the upper
cervical spine and cervicogenic headache alone, suggesting physiotherapists are well
prepared to be involved in the management of headache and in particular CGH (Wand,
2014). Martelletti et al. (2013) advocate for better headache health-care services and
improved training of physicians within these services to deliver more comprehensive
and accessible services to headache sufferers (Martelletti, Mitsikostas, et al., 2013).

Headaches are classified in the ICHD into primary and secondary headache. Primary
headaches are those with a vascular or muscular origin occurring in the absence of any
organic disorders while secondary headaches are attributed to other disorders such as
inflammation or injury (Cathcart, Winefield, Lushington, & Rolan, 2010; Racicki,
Gerwin, Diclaudio, Reinmann, & Donaldson, 2013). Secondary headache symptoms
either resolve or reduce following treatment of the causative disorder.

The most prevalent primary headaches found in the adult population are TTH and MH
(Cathcart et al., 2010; Fernández-de-las-Peñas et al., 2006; Fumal & Schoenen, 2008).
The most common secondary headaches include those triggered by alcohol, fever and
medication overuse (Kristoffersen et al., 2013). Cervicogenic headache is considered
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a secondary headache type with a quality of life burden similar to that of people
experiencing MH and TTH (van Suijlekom et al., 2003). While less prevalent than
TTH and MH the mechanisms behind CGH are some of the best understood (Bogduk
& Govind, 2009).

Each type of headache has a different pathogenesis and logically each respond to
treatment specifically targeted to that headache type. Incorrect diagnosis and therefore
inappropriate treatment can mean poor outcomes for the headache sufferer (Bogduk &
Govind, 2009; Hall et al., 2008; Hall et al., 2007; Li et al., 2012). To complicate
diagnosis and treatment even further some people will experience more than one
headache type (Hall et al., 2008; Stovner et al., 2014).
3.1.1 Prevalence of headache in the general population
The WHO Global Burden of Headache study identified that headache affects 47% of
the world’s population (Jensen & Stovner, 2008; Stovner et al., 2007). This figure was
calculated to be the mean value of prevalence of headaches found in numerous
headache studies conducted across North and South America, Asia and Europe
(Stovner et al., 2007). Data on prevalence in these studies was collected from
questionnaire or personal interview. The lifetime prevalence (47%) of headache was
determined to be similar to the 1 year prevalence of 46%.

There are some significant differences in prevalence of headache in recent studies. In
Brazil in 2009, during a routine home visit by health officials, face to face surveys
were conducted to determine a one year prevalence of headache in the entire
population of one town (Junior et al., 2009). The response rate was 98.4% (n=1605).
Participants were asked if they had any headache episodes in the previous twelve
months. An overall twelve month prevalence of headache of 65.4% was found with a
higher prevalence in women (69.5%) than men (60.9%) and prevalence of headache
diminishing in people over 60 years of age. A slightly higher twelve month prevalence
of 72.1% was documented by Queiroz et al. in a study undertaken 3 years earlier using
the same questionnaire (Queiroz et al., 2009). Unlike Junior et al. (2009) this survey
was not limited to one town but conducted across 27 states in Brazil with 3,848 people
participating. Recruitment and was through randomised ‘cold call’ telephone calls and
interviews were conducted over the telephone. The response rate was only 49.9%.
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Junior et al. (2009) surmise that discrepancies in headache prevalence between these
two studies may be attributed to the different response rates stemming from the two
differing recruitment methods, that of the personal home visit, face to face approach
versus the impersonal ‘cold call’ telephone approach. They suggest that in the case of
‘cold call’ telephone recruitment, people without headache were less likely to engage
thus creating a bias in the participant cohort resulting in a higher prevalence of
headache. They also suggest that cultural and ethnic differences across the different
regions of Brazil may have had an impact on prevalence of headache.
Reza et al. (2012) asked an all-female population in Hawaii if they had been ‘bothered’
by headache in the preceding two weeks and found the two-week headache prevalence
was 47% (Reza, Sievert, Rahberg, Morrison, & Brown, 2012). While it might appear
that this prevalence is in line with the WHO Global Burden of Headache study (Jensen
& Stovner, 2008; Stovner et al., 2007) for twelve month prevalence of headache no
such assumption can be made. It is known that women have a higher prevalence of
headache than men (Stovner et al., 2007) which might suggest that this two week
prevalence is in fact less than the WHO twelve month prevalence. It is not possible to
make a comparison between two week and twelve month prevalence, supporting the
need for uniformity in methodology of headache research (Stovner et al., 2014). This
study did support the theory of ethnicity contributing to variances in headache
prevalence proposed by Junior et al. (2009) identifying that there was a higher
prevalence of headache among Caucasian women (42%) compared to Chinese (30%)
and Japanese (37%).

The Norwegian Nord-Trondelag Health Studies (HUNT 2 and HUNT 3) determined
the mean 1-year prevalence of headache was 38% (Linde, Stovner, Zwart, & Hagen,
2011). Participants were asked in a mailed survey if they had ‘suffered’ from a
headache in the past year. Linde et al. (2011) hypothesised that this low prevalence
could be attributed to the number of people who responded ‘no’ to suffering from
headache, who then continued to either complete some of the headache questions about
characteristics of their headaches or record a headache in their diary. It could be
surmised that some participants did not respond ‘yes’ because although they
experienced headache they may not have felt that they actually ‘suffered’ from the
headache. If the people who responded ‘no’ to suffering from headache but went on to
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complete information about headache had been included with those responding ‘yes’
to suffering from headache the prevalence of 12 month headache would have been
more comparable to the findings of Junior et al. (2009).

Radtke and Neuhauser (2009) determined that 60.2% of Germans experienced
headache in the previous twelve months. Data was collected via telephone interview
with a 52.3% response rate comparable to that of Queiroz et al. (2009). Like the Linde
et al. (2011) study, participants in this survey were also asked if they ‘suffered’ from
headache. Unlike the Linde et al. (2011) study there was a high ‘yes’ response rate.
Although not identified by the authors it is possible that similar to the Brazilian study
by Queiroz et al. (2009) there may have been some bias in the recruitment process in
that people who experience headache may have been more likely to engage in the
telephone interview than those who do not. This study did identify that headache
created a significant burden to the individual and society with reduced quality of life,
loss of productivity and an increased use of healthcare resources (Radtke & Neuhauser,
2009). Nearly one quarter of people who reported severe headache were seen by a
physician equating to 8% of the population.

The twelve month prevalence of headache in the Italian city of Parma was found to be
42.8%, more comparable to the Burden of Headache study (Torelli et al., 2010).
Participants in this study were asked in a face to face interview ‘did you have headache
in the past year?’ It was determined in this study that most people only experience one
type of headache with the number of headaches never greater than 2. Torelli et al.
(2010) reported that this finding was in agreement with a previous 1999 study by
Schwartz et al. who identified that 80% of headache sufferers only experience one type
of headache.

Headache is a global disorder associated with a significant level of disability. While
headache is widespread throughout all continents, cultural and ethnic consideration
may account for local variations in prevalence. Methodological variations including
the recruitment process, the framing of questions about presence or absence of
headache and the interpretation of the responses used to allocate participants into
‘headache’ or ‘non-headache’ cohorts, the length and validity of questionnaires and
factors such as whether the interview is conducted face to face, over the telephone or
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by post impact on prevalence of headache cited in different studies. It also needs to be
recognised that most people who have headache only experience one type but some
people may experience two different headaches which may be problematic when
trying to estimate prevalence rates of individual headache types.

Prevalence rates for CGH, MH and TTH are of particular interest to this study. TTH
is recognised as the most prevalent of headaches and has prevalence ranging from 20%
to 70% with global 12 month prevalence of 42%. (Bezov, Ashina, Jensen, & Bendtsen,
2011; Dong et al., 2012; Fernández-de-las-Peñas et al., 2006; Queiroz et al., 2009;
Steiner, Stovner, & Birbeck, 2013; Stovner et al., 2007; World Health Organisation,
2012). The second most common form of primary headache is MH with one year
prevalence rates of between 11% -31% and the most current WHO figure of 14.7%
(Kelley & Tepper, 2012a; Noseda & Burstein, 2013; Sjaastad & Bakketeig, 2008a;
Stovner et al., 2007; World Health Organisation, 2012). One year prevalence of CGH
is between 0.17% - 4.6% and estimated to account for between 15% and 20% of all
chronic headache (Chaibi & Russell, 2012; Diener, Kaminski, Stappert, Stolke, &
Schoch, 2007; Liebert et al., 2013; Racicki et al., 2013). Each of these headache types
will be reviewed in more detail later in this literature review.
3.1.2 Prevalence of headaches in people with schizophrenia and
schizoaffective disorder
In a study exploring pain in schizophrenia, Watson et al. (1981) recognised that as long
ago as 1911, Bleuler in ‘Textbook of Psychiatry’ identified headache as the most
common pain experienced by people with schizophrenia. In their own study of 78
people with schizophrenia, Watson et al. (1981) too determined that headache was the
pain problem most commonly experienced by this population and that all people who
reported multiple pain sites included head pain as one of the sites. There is limited
description of the methodology of data collection employed in this study of 46 men
and 32 women, but it is likely that it was via face to face interview. This study was
undertaken prior to the introduction of the International Classification for Headache
(Sjaastad, Fredriksen, & Pfaffenrath, 1998) and no attempt was made to classify
headache types although it was noted that no participant described their headache pain
as tight, gripping or vice-like suggesting that TTH might have been uncommon.
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Dworkin (1994) conducted a literature review investigating pain insensitivity in people
with schizophrenia and cited previous studies stating that headache was the most
common pain reported in this population (Dworkin, 1994). No data on prevalence was
presented. In 1999 a controlled study of 108 people with schizophrenia and 100 healthy
controls was undertaken by Kuritzky et al. (1999). Using a questionnaire to gather
information in a face to face interview about headache prevalence, characteristics,
management and impact the study determined that the prevalence of headache in
people with schizophrenia was 48% while the prevalence in the control group was
41%. This study focused on MH and TTH and found the prevalence of MH in the study
group was 19.4% (21/108) and in the control group was 24% (24/100) while TTH in
the study group was 28.7% (31/108) compared to 17% (17/100) in the control group.
The study found no statistically significant differences in overall headache prevalence
or prevalence of either headache type between the sample and control group. There
was no consideration of CGH.

There are methodological factors that may have impacted on the results of this study
by Kuritzky et al. (1999). Firstly, like Linde et al. (2011), underreporting of prevalence
of headache may be attributed to the process used to determine who experienced
headache and who did not experience headache. People where asked if they were
‘subject to headache’ and if they responded ‘no’ were asked no further questions.
However, people may interpret ‘subject to headache’ in different ways and respond
differently as it is a statement open to a number of interpretations. It is possible that
people who experienced infrequent headache may have answered ‘no’, believing that
they would only be ‘subject to headache’ if headaches were frequent. Secondly,
prevalence may be affected by the gender distribution of the participants. The only
demographic questions in this study were age and socioeconomic background so it is
unknown if both males and females participated. As previously noted, females have a
higher prevalence of headache so if either very few or no females were in this study
then the prevalence could be affected (Stovner et al., 2007). There is a need for more
investigation of prevalence of headache in a cohort that can be identified as a true cross
section of people with schizophrenia to be able to provide accurate estimates on the
actual prevalence of headache in this population.
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The second Australian National Survey of Psychosis surveyed a random cross section
of people identified with psychotic illness and conducted interviews with 1,825 people
(Morgan et al., 2012). Almost one third (32%) reported chronic back, neck or other
pain and 25.4% reported frequent or severe headaches and migraine (Morgan et al.,
2012). No explanation was given as to what severe headache meant or how a diagnosis
of migraine was determined, nor was it possible to specifically identify prevalence
rates within the schizophrenic or schizoaffective disorder population. Although
interesting, this survey does not provide accurate representation of headache within
this population.

Lake et al. (2005) noted that since 1999 very little research has been conducted into
the prevalence and characteristics of headache experienced by people diagnosed with
psychiatric illnesses. It is their opinion that despite an IHS classification for headache
attributed to psychotic disorder (ICHD-2 12.1) where headache is a delusional belief;
there are in fact very few instances where headache truly is a psychotic phenomenon.
This is consistent with Watson et al. (1981) who reported that hallucinated pain was
uncommon among people with schizophrenia. Lake et al. (2005) suggest more
research is required to accurately identify both the psychiatric diagnosis and the
headache diagnosis to determine true prevalence and characteristics of headache in this
population.

Kuritzky et al. (1999) determined that 40% of the people with schizophrenia who
experienced headache had not ever reported it to a health practitioner and suggest that
this might be for fear of hospitalisation or simply because they have no-one to
complain to. In comparison Watson et al. (1981) found that 80% of people with
schizophrenia who experienced pain had reported it to a health professional. Neither,
Kuritzky et al. (1999) nor Watson et al. (1981) report on whether appropriate treatment
was implemented or if there was any follow up once the pain was reported. As
suggested by Lake et al. (2005), a headache screening tool for people attending
psychiatric clinics would be useful to help guide management and better treatment
outcomes for this group of people.

Developing a simple screening tool that identifies presence of headache is not
sufficient to guide management because different headache types manifest in response
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to different mechanisms. To develop a screening tool to help guide the user towards
the pathway to access appropriate expert assessment and management of headache
there needs to be an understanding of the mechanisms driving the particular headache
type. The following sections will focus on prevalence, characteristics, mechanisms
driving impairment and management of CGH, MH and TTH.

3.2

Cervicogenic Headache

The Cervicogenic Headache International Study Group have developed the clinical
diagnostic criteria of CGH and provided the information and detail about the condition
for the 2004 ICHD operational criteria (Chaibi & Russell, 2012). CGH is a secondary
headache that presents as unilateral pain originating in the neck, usually without side
shift and is triggered by a sustained awkward neck position or pressure over the upper
cervical joints. Symptoms can be reduced through physiotherapy involving manual
therapy and exercise.
3.2.1 Prevalence of CGH
The prevalence of cervicogenic headache in the general population varies from 0.17%
to 4.6% depending on the characteristics of the study (Knackstedt et al., 2010).
Prevalence of CGH within the headache population has been identified as between
14% - 20% (Fleming et al., 2007; Liebert et al., 2013; Zito et al., 2006). Studies have
shown that the mean age of onset of CGH is 33 years with people experiencing them
for between 7 and 17 years (Antonaci & Sjaastad, 2011; Hall et al., 2008). A significant
difference exists between hospital based studies and community based studies in the
preponderance of CGH experienced by females versus males, with females having a
higher prevalence of CGH in hospital settings. This gender difference is not apparent
in community settings (Anthony, 2000; Chaibi & Russell, 2012; Diener et al, 2007;
Sjaastad & Bakketeig, 2008b). No studies have been conducted to identify prevalence
of CGH in people with schizophrenia and schizoaffective disorder.
3.2.1 Clinical characteristics of CGH
Characteristics of CGH include unilateral, side locked headache originating from the
neck, exacerbated by neck movement and/or sustained awkward neck position and/or
external pressure over the occipital region on the side of pain. Moderate to severe pain
refers from the neck to frontal regions supplied by the trigeminal nerve (Frese,
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Schilgen, Edvinsson, Frandsen, & Evers, 2005; Vincent, 2010). There is usually
restriction in ROM of the upper cervical segments. Neck, shoulder and arm pain may
also be present. In general a forward head posture is associated with cervicogenic
headache although this has also been observed in those with migraine and tension type
headache (Jull et al., 2008).

Diagnostic anaesthetic blocks can be used to provide further diagnostic information,
(Anthony, 2000; Narouze, Casanova, & Mekhail, 2007) although as identified in the
pilot study, many people with MH and TTH also complain of neck pain (Fernándezde-las-Peñas et al., 2014). The value of diagnostic blocks for diagnosis is discussed
later.
3.2.3 Mechanisms behind CGH
Cervicogenic headache is a problem of referred pain (Bogduk & Govind, 2009).
Painful dysfunction of somatic structures within the cervical spine give rise to the
experience of head pain due to the convergence of afferent information within the
trigemino-cervico nucleus. The exact nature of somatic tissue dysfunction is not clear
and may in fact represent different processes in different individuals. However, there
is now substantial evidence that people with CGH demonstrate impairments in the
articular, muscular and proprioceptive function of the upper cervical spine (Bogduk &
Govind, 2009; Frese & Evers, 2008; Narouze et al, 2007; Vincent, 2010).

When a noxious input is generated from structures within the upper cervical spine it
may be expected that pain would be localised to this region and not manifest as
headache. However, according to Bogduk (1993) pain from the skin is the only pain
that is felt locally, relating back to a basic human instinct where survival may be
dependent on the brain receiving accurate information from external noxious stimuli
and implementing an appropriate and immediate response. When actual or potential
damage occurs to the skin the nociceptive afferent impulse is relayed to the ventral
posterior lateral (VPL) nucleus of the thalamus and then to higher centres including
the parietal lobe via the highly organised neospino-thalamic pathway. At the same time
information from non-nociceptive receptors such as touch and pressure are also
transmitted to the VPL nucleus of the thalamus via the even more organised posterior
columns. The thalamus is thus receiving two highly specific and complementary
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messages that can accurately define and localise the source of noxious input. As the
noxious stimulation is superficial it is also likely that visual information is available to
further aid localisation.

In the case of tissue other than skin, the information reaching the thalamus and cortex
about the localisation of noxious stimuli is less well defined so in many instances the
pain is often felt at a distance from the source or may be felt to radiate from the source.
This is called referred pain (van Griensven, 2005). The exact mechanism of referred
pain is not fully understood, however, the projection-convergence model is the most
widely discussed. This model proposes that messages about noxious stimuli from deep
tissues are relayed through the spino-reticular system which is less well organised than
the neospino-thalamic pathway. At the same time the brain is not receiving additional
information about touch and/or pressure to enable localisation of the noxious source.
Visual information may also be lacking. As a result of receiving less specific
information the brain cannot pinpoint the location of the source of nociceptive input.
According to Galea (2002) the brain is probably able to localise the source of
nociceptive input from deep tissue only to the level of a particular spinal segment
(Galea, 2002). Armed only with this information the individual then attempts to
localise the source of afferent traffic further based on other available information
including other sensory information, past experiences and general knowledge.

Anatomy of the innervation and neural pathways around the upper cervical segments
is essential to understanding the mechanism of headache associated with noxious
stimuli in this region. The spinal trigeminal nucleus is a column of cells that descend
through the pons and medulla where upper cervical segments combine to form the
trigemino-cervico nucleus within the posterior horn of the upper cervical cord
(Anthony, 2000). Nociceptive afferents of the trigeminal nerve and C1, C2 and C3
spinal nerves converge onto the second order neurones in the trigemino-cervical
nucleus in the upper cervical cord (See Figure 2) (Bogduk & Govind, 2009; Chaibi &
Russell, 2012; Knackstedt, Kråkenes, Bansevicius, & Russell, 2012).

With the convergence of spinal and cranial nerve afferents in the trigemino-cervical
nucleus nociception from upper cervical region can be experienced as referred pain in
the areas of sensory distribution for the cervical nerves, the occiput and auricular
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Figure 2 - Mechanism of pain referral from the cervical spine to the head.
(Reproduced from Bogduk & Govind, 2009)

regions of the head, as well as to sensory distributions of the trigeminal nerve, in
particular the ophthalmic branch which innervates the parietal, frontal and orbital
regions (Bogduk & Govind, 2009; Fleming et al., 2007). Anthony (2000) calls this a
‘cervico-trigeminal relay’ and suggests through it nociception from any structures
innervated by C1, C2 or C3 spinal nerves can be experienced as referred pain from the
neck to the frontotemporal region of the head and vice-versa (Anthony, 2000).
Fleming, Forsythe and Cook (2007) suggest that pain can arise from theatlantooccipital, median atlanto-axial, lateral atlanto-axial and C2/3 zygapophyseal joints,
C2/3 intervertebral discs, musculature of the suboccipital, upper posterior cervical and
upper paravertebral regions, the trapezius and sternocleidomastoid muscles (Anthony,
2000; Fleming et al., 2007). According to Bogduk and Govind (2009) the source of
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noxious input in 70% of cases is the C2/3 zygapophyseal joint. They claim to have
provided complete pain relief by using fluoroscopically guided diagnostic blocks of
the third occipital nerve where it crosses the C2-3 zygapophyseal joint (Bogduk &
Govind, 2009).

Identifying the primary source of noxious input is a key element in the diagnostic
criteria of the ICHD and the CHISG, listed in both as ‘confirmatory evidence by
diagnostic anaesthetic blockades’. The most accurate diagnostic anaesthetic blockade
procedure is still to be determined. In an editorial in The Spine Journal, Carragee et al.
(2007) cite many invasive diagnostic tests which have been used to diagnose CGH,
including single joint injection, tests using both provocative and anaesthetic injections
(similar to that used by Bogduk and Govind in 2009), tests comparing anaesthetics
with varying pharmacologic-range effects and tests that include placebo-controlled
injections. They maintain that none are fully validated and most studies do not meet
the British Medical Journal and the Journal of the American Medical Association
criteria for low risk of bias diagnostic studies (Carragee, 2007). The main criticisms
are the inconsistency in what might constitute a positive block and the lack of a true
gold standard against which the blocks themselves might be validated.

Physiotherapists maintain that they can diagnose CGH through examination of the
upper cervical spine thus eliminating the need for invasive testing (Zito et al, 2006).
Bogduk and Govind (2009) discount these claims saying they have not been validated,
though how they might be validated is still an unresolved issue. While Carragee et al.
(2007) do not discredit physiotherapeutic examination as a clinical test they do not
support the notion that it has high levels of accuracy (Carragee et al., 2007). There is
obviously a need for more rigorous studies to be undertaken on the physical assessment
of CGH.
Dysfunctions in the structures innervated by the ‘trigeminal relay’ are not only evident
in CGH but can be found in people with MH (Knackstedt et al., 2012; Vincent, 2010).
When exploring the differences between MH and CGH, Sjaastad and Bakketeig (2008)
determined that the restrictions in the average range of motion of the neck was
significantly greater in people with CGH with 93% of people experiencing limitations
of ≥15° compared to only 16% of people experiencing MH. Sjaastad and Bakketeig
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(2008) also found that ‘cervicogenic factors’ (CF) were more significant in people
experiencing CGH than MH. These CF included pain provocation through pressure on
the tendon insertion in the occipital area or facet joints, ipsilateral shoulder discomfort,
radicular arm pain, posterior onset of headache and unilateral pain. They determined
there was clear distinction between MH and CGH and any neck involvement in MH
was more subtle and of a different nature.

It is worth noting that Frese & Evers (Frese & Evers, 2008; Frese et al., 2005)
demonstrated there is no increase of calcitonin gene-related peptide, an indicator of
trigeminal-neurovascular activation found in MH, in people with CGH. This further
supports the theory that the trigeminal nerve involvement is via the ‘cervico-trigeminal
relay’ thus providing a biological marker that differentiates between CGH and MH
and discredits the theory that CGH and MH are on a continuum as proposed by Watson
and Drummond (2012). MH will be discussed in more detail in the next section.

Noxious input from upper cervical muscles, facet joints, and ligaments has been shown
to produce head pain (Chaibi & Russell, 2012; Knackstedt et al., 2012) but
dysfunctions in these structures does not necessarily mean presence of CGH clinically.
Dysfunction in musculoskeletal function need not be nociceptively active and not all
nociceptive activity is interpreted as pain. Vincent (2010) suggests that while
dysfunction within the cervical structures is necessary for CGH to occur the headache
response may not be triggered without an essential ‘central disposition’. While the
experience of pain is often associated with noxious input, the two are not synonymous.
For the perception of pain to emerge into consciousness, nociceptive information is
integrated with other sensory inputs and scrutinised in relation to relevant
psychological and contextual influences. The pain experience is constructed if the
individual feels that the body is under threat and that survival/recuperation is best
served by the construction of the pain experience. In the case of CGH this means
recognising noxious input from the cervical region as a threatening stimulus. This
cortical recognition will vary from one person to the next because psychological,
emotional, behavioural and physical factors all contribute to the perception of and
response to pain (Galea, 2002). A person’s previous experience with pain, their
understanding of the pain mechanism and what pain represents to them all impact on
their responses to input from cervical structures. These factors have been extensively
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explored in people with low back pain. The role psychological factors play in
experience of CGH is poorly researched and not well understood. It is also unclear
how theoretical models such as fear avoidance belief model would relate to pain in the
head.
3.2.4 Management of CGH
Both invasive procedures and non-invasive rehabilitative approaches have been
advocated for the management of CGH (Bogduk & Govind, 2009). Invasive
procedures include surgery and injection of blocking agents while non-invasive
techniques include massage, exercise, manipulation and/or mobilisations.

A review conducted by Tobin and Flitman (2009) proposed that occipital nerve block
is effective in the treatment of CGH citing the double blinded randomised controlled
trial (RCT) conducted by Naja et al. (Naja, El-Rajab, Al-Tannir, Ziade, & Tawfik,
2006). It was noted, however, that the selection criteria for participants in the Naja et
al. study was based on the 1988 ICHD criteria rather than the 2004 ICHD criteria
suggesting that some participants may not have actually had CGH but could have had
occipital neuralgia thus impacting on results. Three other studies where participants
showed some improvement post treatment were included in the review but none of
these studies were RCT’s (Tobin & Flitman, 2009). The authors identified a significant
lack of RCT’s exploring the efficacy of nerve blocks in the management of CGH.

A systematic review by Ashkenazi et al. (2010) further highlighted the lack of evidence
supporting the efficacy of peripheral nerve blocks for treatment of CGH (Ashkenazi
et al., 2010). They identified that the most common site for nerve block injection is the
greater occipital nerve. The authors pointed out once again that very few studies
evaluating the use of nerve blockades in headache management were RCT’s. They
highlighted that any studies undertaken thus far have limitations including small
patient numbers or were retrospective designs without controls (Ashkenazi et al.,
2010). While the Naja et al. (2006) study was acknowledged as a double blinded,
randomised controlled study, Ashkenazi and colleagues were critical of the use of
polypharmacy which could have confounded results. The Ashkenazi et al. (2010)
review identified a lack of uniformity and consistency across trials in the techniques
used for nerve blockade, the types of anaesthetic used, the dose and volume
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administered and the location of the injection making it difficult to compare results. It
is evident that more rigorous research needs to be undertaken to determine the efficacy
of this treatment.

In 2010 Zhou et al. conducted a retrospective evaluation of facet joint injections in a
study of 31 people following injections into C1/C2 and C2/3 facet joints using a
mixture of anaesthetic (bupivacaine) and corticosteroid (betamethasone) for treatment
of CGH (Zhou, Hud-Shakoor, Hennessey, & Ashkenazi, 2010). Data was collected
retrospectively by looking through medical charts of people who attended a medical
centre for headache. At the clinic patients had been seen for follow up 14 days after
injection and then once a month for between 3 and 24 months. The researchers found
that 90% of participants had greater than 50% relief of their headache immediately and
then for an average of 21 days following injection (Zhou et al., 2010). They
acknowledged that their study had limitations with no control group, a small sample
size and that data was collected retrospectively.

A 2015 review of studies of facet joint injections by Ng and Wang discussed only three
trials (Ng & Wang, 2015). These included the retrospective medical chart reviews by
Zhou et al. (2010), another by Narouze et al. (2007) and a prospective study by Bovim
et al. (1992) (Ng & Wang, 2015). The Narouze et al. (2007) review of 32 patients
diagnosed with CGH highlighted that there was insufficient data to support the use of
atlanto-axial joint injection for long term relief of CGH. In 1992 Bovim et al.
conducted a small prospective study on 14 females who underwent C2/C3 facet joint
injections and C2-C5 nerve blocks determining that C2 nerve block was the more
effective treatment. Based on only these three reviews Ng and Wang (2015)
determined that there is limited efficacy in the use of facet joint injections for the
management of CGH.
No RCT’s examining the efficacy of surgery in the management of CHG. could be
found. In 2009 Riina et al. conducted a retrospective analysis of 1,004 patients, 2 years
after they had undergone either an upper cervical arthrodesis or a disc arthroplasty for
CGH (Riina et al., 2009). They determined that there was improvement in headache
pain following both procedures with 64% of patients undergoing arthroplasty and 58%
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of patients undergoing arthrodesis reporting reduction in pain scores of at least one
point on a visual analogue scale.

Research on non-invasive management of CGH is more prolific and robust than for
invasive management. Fleming, Forsythe and Scott (2007) identified in a limited
retrospective review of patient charts (n=44) that participants had best outcome from
manual therapy and exercise for treatment of CGH (Fleming et al., 2007). They also
highlight the importance of including an holistic approach to patient care. A systematic
review undertaken in 2011 went one step further to suggest there is no evidence to
support the use of spinal manipulation alone as an effective treatment for CGH
(Posadzki & Ernst, 2011). Another review by Chaibi and Russell (2012) identified
physiotherapy treatment of exercises in combination with spinal manipulation as an
effective treatment for CGH although highlighted that all RCT’s considered were
based on participants who experienced only infrequent CGH and could not comment
on people with more chronic CGH (Chaibi & Russell, 2012). A more recent systematic
review by Racicki et al. (2013) of RCT’s exploring the efficacy of conservative
management of CGH proposes that a combination of mobilisation, manipulation and
exercises to strengthen the cervico-scapular mechanisms is the most effective
conservative therapy.
In 2013 Liebert et al. (2013) undertook an investigation to explore physiotherapist’s
perceptions of why some people were non-responsive to physiotherapeutic treatment
for CGH. A survey was distributed to 290 registered physiotherapists with a mean 24.4
years of experience. There was a 31% response rate (90/290). They determined that
factors associated with poor treatment outcomes were a history of severe trauma such
as motor vehicle accident and a family history of any headache type. Responses to
open ended questions provided some qualitative data suggesting that physiotherapists
also perceived psychosocial factors such as depression and anxiety contribute to nonresponsiveness.

3.3

Migraine Headache

Migraine is a primary headache and ranks seventh highest globally in the causes of
disability, being responsible for 2.9% of all years of life lost to disability (Steiner et al,
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2013). Attributed to being a common neurovascular disorder, MH is characterised by
unilateral, pulsating pain of a moderate to severe nature, lasting up to 72 hours
(Zielman et al., 2012). MH is often associated with vomiting, nausea and/or
photophobia or phonophobia
3.3.1 Prevalence of MH
Prevalence of MH varies considerably between studies and regions. Kelley and Tepper
(2012a) have identified that Europe has the highest prevalence of MH with 15%
prevalence, followed closely by North America with 13%. Africa has the lowest
prevalence of MH at 5%. According to Noseda and Burstein (2013) around 16% of the
global population experience MH while Stovner et al. (2007) found a global
prevalence of 11%. The World Health Organisation (WHO), Global Burden of Disease
Survey 2010 estimated the worldwide prevalence of MH as 14.7% (Steiner et al.,
2013). Differences in prevalence across studies can be attributed to discrepancies in
data sampling used, diagnostic criteria applied for classification, data management and
statistical analysis (Stovner et al., 2014). Guidelines are being developed by an expert
panel to try and better standardise studies exploring prevalence of headache (Stovner
et al., 2014).

Uniformly there is a higher prevalence of MH in females than males. The American
Migraine Prevalence and Prevention (AMPP) study identified the prevalence of
migraine in females to be 17.1% compared to males 5.6% (Stewart, Wood, Reed &
Lipton, 2008). Junior et al. (2012) found a difference in the prevalence of MH with
prevalence in females of 26.4% and males of 8.5%. The AMPP study also determined
that women experience greater symptomology and increased disability associated with
the MH than males (Stewart et al., 2008). No studies have been conducted to identify
prevalence of MH in people with schizophrenia and schizoaffective disorder.
3.3.2 Clinical Characteristics of MH
The two categories of MH considered in this study are Migraine without Aura and
Migraine with Aura. Migraine without aura has some characteristics similar to both
CGH and TTH. Pain is usually unilateral, as is the case in CGH, but studies have
identified that this is in only about 60% of cases with pain in the remaining 40% being
bilateral, similar to the distribution for TTH. To complicate classification, the location
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of the pain varies between individuals and in some instances even varies between
attacks experienced by the same person (Hussain, Stiles, & Oshinsky, 2010). Pain
characteristics, however, are different from CGH and TTH as pain is pulsating or
throbbing, is usually more severe and generally of a shorter, relatively fixed duration.
MH pain is aggravated by general physical activities such as climbing stairs,
something not associated with other headache types. Nausea, photophobia,
phonophobia, heightened sensitivity to smell, cognitive, emotional and motor
disturbances are also more commonly present with MH (Hall et al., 2008; Noseda &
Burstein, 2013).

About one third of MH are preceded by an aura which commonly presents as flickering
lights or spots in the field of vision, numbness or pins and needles before the onset of
pain. These symptoms are fully reversible within 60 minutes (Hall et al., 2008) and if
aura symptoms do not subside in that time they may be an indicator of more serious
medical conditions. The presence of an aura is a strong indicator of a MH.

Comorbid neck pain has been observed in people with MH but variations in headache
classification, data sampling and data collection across different studies means that
there is no consensus on the prevalence. With neck pain being a dominant feature of
the unilateral CGH it can be challenging when trying to differentiate between CGH
and MH. An example of this challenge can be found in Calhoun et al. (2010) who
made a differentiation between CGH and MH by classifying those participants
presenting with a cervical mechanical precipitation to their headache or with reduced
cervical range of motion as CGH (Calhoun et al., 2010). As previously discussed
presence of dysfunction in the cervical spine does not necessarily mean a diagnosis of
CGH and it is possible that people were wrongly classified (Vincent, 2010). Calhoun
et al. (2020) did however include people in the MH cohort who experienced neck pain
(without a mechanical precipitation) that radiated forward so it is possible that these
people were indeed experiencing CGH as pain starting in the neck is a defining feature
of CGH (Frese & Evers, 2008; Sjaastad, 2008; Sjaastad & Bakketeig, 2008a). Some
studies on MH do not consider or do not recognise CGH as a possible differential
diagnosis while others view CGH as being on the continuum of MH (Ashina et al.,
2014; Fernández-de-las-Peñas et al., 2006; Florencio et al., 2014; Watson, 2012).
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3.3.3 Mechanisms behind MH
Migraine headache is often considered an inherited condition with many people
experiencing MH having a first degree relative who also experience MH (Ashina &
Bendsten 2013). Pain is not believed to be related to tissue damage or any detectable
pathology but can be triggered by environmental factors such as fatigue, lack of sleep,
certain foods, smoke, hunger, menstrual cycle and even bright light (Landy, Rice, &
Lobo, 2004).

It is thought that the causative mechanism in migraine is an altered excitability in the
brain in response to these environmental triggers activating the trigemino-vascular
system (Hall et al., 2008; Noseda & Burstein, 2013). Theories have been proposed
about the possible over excitability (dysexitability) of different cortical areas and
Cosentino et al. reported findings that supported cortical hyper-responsivity as an
explanation for susceptibility to migraine (Cosentino et al., 2014).

A phenomenon called cortical spreading depression (CSD) occurs spontaneously once
a critical threshold of neurochemical changes has occurred in the brainstem in response
to the environmental stimuli and prior to the onset of headache. During CSD neural
activity across the cortex diminishes as does the cortical blood flow and this is thought
to trigger visual aura and other prodome associated with MH (Kelley & Tepper,
2012a). Following CSD dural blood flow increases and the vessels dilate. At this stage
meningeal nociceptors are activated releasing calcitonin gene-related peptide and other
neuropeptides which in turn trigger further vasodilation and an inflammatory reaction.

Innervation of the meninges and intracranial vasculature originates in the trigeminal
ganglion and passes along the trigeminal nerve with additional innervation arising
from the neurons in the upper cervical dorsal root ganglion (Noseda & Burstein, 2013).
Activation of nociceptors in the dura mater, meningeal vessels, intracranial segments
of V, IX and X cranial nerves as well as intracranial segments of the basilar, vertebral
and carotid arteries, trigger signals which are transmitted to the spinal trigeminal
nucleus in the medulla and the dorsal horn of the upper cervical spine. Similar to CGH
headache pain experienced in MH is referred through the trigeminal nerve pathways,
predominately the ophthalmic branch but to a lesser extent the maxillary and
mandibular branches too (Noseda & Burstein, 2013). It has been noticed that that once

54

a MH has begun, neuroplastic changes may alter the response profile of nociceptive
neurons such that pain may continue without further noxious stimuli (Landy et al.,
2004).
3.3.4 Management of MH
MH is associated with a significantly decreased quality of life so it is no surprise that
people experiencing MH would ideally like a treatment that provides long lasting and
complete pain relief, without side effects (Kelley & Tepper, 2012b; Zielman et al.,
2012). Medication is the first choice of treatment for most migraine sufferers (Wells
et al., 2014). The European Headache Federation identifies two steps in management
of MH


Step One - symptomatic therapy



Step Two - specific therapy

It is advised that Step Two should not be considered unless Step One has been tried
three times without success (World Health Organisation, 2012).

Symptomatic therapy includes administration of medication to target the symptoms of
migraine including simple analgesics, non-steroidal anti-inflammatory drugs
(NSAIDs) and antiemetic medication. Pain killers such as paracetamol and
acetylsalicylic acid are taken to relive headache pain. NSAIDs such as ibuprofen and
naproxen act to reduce the inflammatory responses associated with migraine and
therefore reduce the activation of nociceptors and subsequently pain. Use of
antiemetic’s can reduce the symptoms of nausea and vomiting.
A systematic review by Kelley and Tepper (2012a) noted that over half of people
suffering from MH use ‘over the counter’ analgesics such as paracetamol and
acetylsalicylic acid to treat their headache. A Cochrane Review of the efficacy of
paracetamol in the management of MH highlighted that paracetamol is superior to
placebo in reducing pain from moderate or severe to mild or no pain in 2 hours (Derry
& Moore, 2013). There is not enough data to determine its efficacy beyond 2 hours
(Derry & Moore, 2013) resulting in the WHO guidelines for symptomatic therapy
advising that paracetamol has limited efficacy in the management of MH. Another
Cochrane Review identified that 1,000mg of effervescent acetylsalicylic acid is more
effective in the management of MH providing a 2 hour pain free response similar to
Sumatriptan (a specific therapy which will be discussed later), however, there were no
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studies to provide data for 24 hour relief so the longer term benefits are unknown
(Kirthi, Derry, & Moore, 2013).
Ibuprofen is an ‘over the counter’ NSAID used to manage MH. The Cochrane Review
described Ibuprofen as an effective medication in the management of MH providing
significant pain relief to half of the people who take it (Rabbie, Derry, & Moore, 2013).
It was noted, however, that very few people experienced complete pain relief. Another
NSAID used in the management of MH is Naproxen. The Cochrane Review
investigating the efficacy of Naproxen for treatment of MH identified that the
medication was better than a placebo but is not clinically useful being effective in less
than 1 in 5 people (Law, Derry, & Moore, 2013). Kelly and Tepper’s Systematic
Review (2012c) identified that intramuscular or intravenous Ketoprofen provides
temporary relief of MH symptoms, however, this requires the person to present
themselves to a medical practitioner to receive treatment.
WHO guidelines for Step One are


use soluble analgaesics



take early in the attack



use antiemetic medication as required



rectal administration of medications may be preferable if vomiting is present.

When Step One has been implemented three times and is not successful in managing
the MH then Step Two, specific therapy of either triptans or ergotamines should be
instigated. The WHO recommends that triptans should be offered as a first option of
treatment. Triptans act to constrict blood vessels and inhibit the release of the
vasodilator calcitonin gene-related peptide responsible for further vasodilation.
Triptans also inhibit the release of anti-inflammatory peptides in the meninges which
subsequently reduces pain. Ergotamine acts similarly to triptans but also block
activation of the trigeminal nucleus caudalis reducing headache (Kelley & Tepper,
2012a).

The two most common triptans are Sumatriptan and Rizatriptan. Sumatriptan was the
first marketed and is used extensively world-wide (Derry, Derry & Moore 2014). An
overview of four Cochrane reviews of Sumatriptan indicates it provides fast acting
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pain relief and in the case of subcutaneous administration can provide relief within 2
hours (Derry, Derry, & Moore, 2014; Kelley & Tepper, 2012a). The WHO suggest
that up to 40% of people who initially respond to triptans have their symptoms return
within 48 hours at which time a second dose may be administered (WHO 2012).
Subcutaneous administration provides more rapid response but comes with increased
adverse effects which include chest pressure, neck tightness, limb heaviness, tingling,
dizziness and flushes and its use is only recommended with caution.

The WHO (2012) recommends that triptans should not be used more than 10
days/month. Triptans have very varied efficacy on individuals and in many instances
patients may need to try several before finding the most effective one for them. It has
been identified that triptans are more effective when taken during the mild phase of
the headache.

Dihydroergotamine (DHE) provides slower but longer lasting relief than Sumatriptan.
Unfortunately there are side effects of which nausea is the most common, followed by
diarrhoea, abdominal cramps, vasoconstriction and leg pain (Kelley & Tepper, 2012a).
The WHO (2012) found that while ergotamines has a longer duration of action which
can provide longer relief of symptoms than Sumatriptan, in many instances this also
results in poor tolerability in the long term.

WHO guidelines for Step Two are


use of triptans first



do not use triptans for more than 10 days/month



begin with only one tablet and administration of a second tablet is not
recommended if non responsive to the first



triptans are more effective if administered while headache is mild

Landy et al. (2011) noted that when treatment for MH is instigated within the first hour
of the episode that the MH lasts a significantly shorter time than when treatment is
commenced more than an hour after symptoms manifest (Landy, Runken, Bell, Higbie
& Haskins, 2011). This finding is consistent with the WHO recommendations. Not
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having medication available was the most common response for not taking medication
within the hour (Landy et al, 2011).

When MH manifests more than two days a month, and acute therapy as described
above does not prevent this, prophylactic medication should be considered (WHO
2012). Zielman et al. (2012) found that only 18% of people who met the criteria for
prophylactic treatment referred to neurologists in The Netherlands where actually
taking prophylactic medication. There exists significant variation between countries in
the number of people taking prophylactic treatment for MH, although is it recognised
that the number of people taking prophylactic medication is much lower than the
number of people who actually meet the criteria for prophylactic treatment (Zielman
et al., 2012). It is not known if this is because people are not prescribed the medication
or if they chose not to take it. It appears that anti-emetic medication is also underused.

Two medications recognised by the WHO as effective prophylactic medication for MH
are the mood stabiliser sodium valproate, a medication used extensively in the
management of schizoaffective disorder and the antidepressant drug amitriptyline used
in the management of depression associated with schizoaffective disorder or
schizophrenia. It may be possible that people taking these medications for their mental
illness are inadvertently receiving prophylactic medication for MH thus impacting on
the prevalence of MH manifesting in this population.

Non pharmaceutical treatment may be considered by people experiencing MH either
in isolation or in combination with pharmacological based treatments. A systematic
review of RCT’s exploring the efficacy of spinal manipulation in the management of
MH has identified a serious lack of reliable research that will either support or refute
this form of treatment for MH (Fernández-de-las-Peñas et al, 2006). Neck pain,
however, is often experienced by people with MH and is seen as a confounder that
may affect treatment choice (Ashina et al., 2014; Florencio et al., 2014).

Other non-pharmacological treatments and/or preventative measures considered in the
US Headache Consortium guidelines (Wells et al., 2014) include relaxation training
and cognitive behavioural therapy (CBT). These conservative therapies have evidence
to support their use in the preventative management of MH based on evidence from
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39 controlled trials (Wells et al., 2014). Although there is no evidence to support the
efficacy of meditation and yoga about half of Americans who experience MH report
using them to assist with management (Wells et al, 2014). A more recent technique
considered is mindfulness training which has been shown to assist in management of
chronic pain. Despite some positive trends from a recent small RCT pilot study there
is no evidence to support the use of mindfulness an effective treatment for MH (Wells
et al., 2014).

3.4

Tension Type Headache

TTH is considered one of the most prevalent primary headaches yet the
pathophysiology behind the headache is less well understood than MH and CGH
(Cathcart et al., 2010; Jensen, 2003). Unlike all other headache types, diagnosis of
TTH relies entirely on clinical symptoms and is often diagnosed by the absence of
features of other headache types (Fumal & Schoenen, 2008). ICHD characteristics
include band like bilateral, pressing or tightening pain of a mild to moderate intensity.
3.4.1 Prevalence of TTH
Tension Type headache has been identified as the most prevalent headache (Li et al.,
2012; Queiroz et al., 2009) with a global point prevalence estimated at 20% (Steiner
et al., 2013) and a 12 month prevalence of 42% (World Health Organisation, 2012).
Prevalence of TTH is higher in women than men and tends to decrease with age in
both genders (Fumal & Schoenen, 2008), although one study by Queiroz et al. (2009)
determined prevalence was higher in men with a higher education.

Kuritzky et al. (1999) determined the prevalence of TTH amongst people with
schizophrenia to be 28.7% using the criteria that all headaches not fitting the definition
for MH were classified as TTH. This cannot be an accurate figure of TTH but simply
a figure of all headaches that were not MH. No other studies have explored the
prevalence of TTH in this population.
3.4.2 Clinical characteristics of TTH
Characteristics of TTH include bilateral mild to moderate pain most frequently in the
frontal region but also experienced in the parietal and occipital regions (Li et al., 2012).
Headache may last from 30 minutes to up to seven days (The Headache Classification
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Subcommitee of the International Headache Society, 2004). TTH has sometimes been
called a ‘featureless headache’ being simply an experience of pain predominately
described as pressing or tight (Fumal & Schoenen, 2008). The presence of neck pain
has been associated with TTH and in one limited cross-sectional study a prevalence of
88% neck pain in TTH was found with a strong correlation between frequency of neck
pain and TTH (Ashina et al., 2014).
3.4.3 Mechanisms behind TTH
Independent reviews investigating the pathophysiology of TTH undertaken by Fumal
and Schoenen in 2008 and Cathcart et al. in 2009 produced similar findings. Both
described studies that identified an increase in muscle activity in pericranial muscles
of people who experience TTH. This increase in muscle activity was not shown to
have an association to the presence or intensity of headache, suggesting it might be an
epiphenomenon (Fumal & Schoenen, 2008; Cathcart et al., 2009).

Fumal & Schoenen (2008) also reported on a series of blinded controlled studies that
indicated there is an increased number of active and latent myofascial ‘trigger-points’
in the head, neck and shoulders of people who experience TTH (Fumal & Schoenen,
2008). It was considered possible that continued activation of these hypersensitive
areas within pericranial and cervical muscles could lead to sensitisation of the
nociceptors in the spinal trigeminal nucleus. More recently Bezov et al. (2011)
reviewed literature on the pathophysiology of TTH and hypothesised that frequent
nociceptive input from ‘trigger points’ within pericranial muscles induces sensitisation
of the sensory afferents and second order neurones in the trigeminal nucleus. They
propose it is plausible to conceive that if this process is not stopped through
prophylactic measures then neuroplastic changes within the central nervous system
could lead to a maladaptive sensitivity state and the precipitation of chronic TTH.
However, in 2014 Quintner, Bove and Cohen undertook a review of literature about
‘trigger points’ and surmised that the concept of ‘trigger points’ is an invention with
no specific scientific basis to support it (Quintner, Bove, & Cohen, 2014). They cited
a lack of diagnostic certainty to support the concept of ‘trigger points’ with limited
inter-rater reliability of physical examination findings. They also cited a lack of
recognised pathogenesis to explain ‘trigger points’ with a deficiency of unique specific
tissue biochemistry and EMG or imagery findings. The authors did suggest that a
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plausible hypothesis is emerging with new insight into the neurobiology of nociception
and pain that should better explain the phenomena currently attributed to the ‘trigger
point’ concept.

Both the review by Fumal and Schoenen (2008) and that by Cathcart et al (2009)
reported the findings of an investigation using electrical stimulation into pain
sensitivity in people with chronic TTH. This study found that there is a generalised
increase in pain sensitivity in this population suggesting a central nervous system
abnormality in processing pain. Both reviews also referred to a study published by
Schmidt-Wilke in 2008 that found that people who experience chronic TTH have
decreased cortical grey matter density in particular the pons, anterior cingulate cortex,
insular cortex, temporal lobe, orbito-frontal cortex and the hippocampus. They
hypothesise that this reduction in tissue density suggests supra-spinal sensitisation as
a result of constant activation of these pain related areas.

Based on these reviews the authors hypothesised that TTH is the result of pain elicited
by peripheral mechanisms such as overloaded pericranial muscles combined with
sensitisation of nociceptors in the spinal trigeminal neurones and abnormal pain
processing in the CNS, possibly as a response to stress. It is accepted that physical and
emotional stress, increased nociception from pericranial muscles, lack of sleep and
fatigue are common triggers for TTH (Cathcart et al., 2010; Fumal & Schoenen, 2008;
Li et al., 2012).
3.4.4 Management of TTH
The majority of people who experience TTH do not consult a doctor, rather treat
themselves with ‘over the counter’ medication resulting in many people with more
frequent TTH overusing medications and developing associated medication overuse
headaches (Fumal & Schoenen, 2008; Li et al., 2012). The European Headache
Federation has indicated that pharmacological intervention is appropriate for the acute
care management of people who experience infrequent TTH episodes but has limited
scope in the management of chronic TTH (World Health Organisation, 2012). ‘Over
the counter’ analgesic medications such as paracetamol, ibuprofen and acetylsalicylic
acid are effective for relief of pain, however, caution is advised because if TTH
becomes frequent and this treatment regime continues there is a risk of developing
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medication overuse headache. If TTH presents on more than 2 days per week
prophylactic treatment is recommended.
Verhagen et al. (2010) undertook a systematic review of 41 RCT’s that provided
evidence that paracetamol and ibuprofen are both effective for short term pain relief
in the case of episodic TTH. Another systematic review by Moore et al. (2014)
provided the same result (Moore, Derry, Wiffen, Straube, & Bendtsen, 2014). An
earlier study by Steiner, Lang and Voelker (2003) demonstrated in a double blinded,
placebo controlled trial of 638 people that there was no difference between taking
acetylsalicylic acid or paracetamol for the management of TTH and that both were
effective in the management of episodic TTH (Steiner, Lange, & Voelker, 2003).
In 2006 Fernández-de-las-Penos et al. undertook a systematic review of RCT’s
examining the efficacy of spinal manipulation in the management of TTH, CGH and
MH. They reviewed 3 papers relating to TTH and noted that in general the
methodological quality was low indicating a need for more rigorous research.
Physiotherapy was found to play a role in the holistic management of the person with
TTH by providing ergonomic and postural education combined with muscle
strengthening exercises to reduce stresses on the myofascial tissues involved in the
generation of the headache. Physiotherapy can also be effective in managing neck pain
that may be present in conjunction with TTH. As identified by Fernández-de-las-Penos
et al. (2006) more robust research would need to be undertaken to determine if these
physiotherapeutic measures impact on the frequency and intensity of TTH.

There is consensus that initial treatment of infrequent episodic TTH is the use of simple
‘over the counter’ analgesics, but when headache becomes frequent and the trigger for
headache cannot be avoided then prophylactic measures should be implemented to
avoid the development of medication overuse headaches. After reviewing 44 clinical
trials on prophylactic pharmacological intervention Verhagen et al. (2010) found that
preventative medications for TTH are either no more effective than a placebo or there
was conflicting or limited evidence to support their effectiveness. If prophylactic
pharmacological intervention is not effective then a more multidisciplinary approach
may be required for best results. The review by Verhagen et al. (2010) examined
another 44 RCT’s exploring the effectiveness of CBT and another 12 trials exploring
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physiotherapy as preventative measures for TTH. No conclusions could be drawn as
there were either inconsistent results or trials did not have adequate power to
demonstrate a significance for the use of the specific intervention (Verhagen et al.,
2010). The WHO Global Campaign to Reduce the Burden of Headache Worldwide
recommends some self-management strategies of relaxation, exercise, seeking help for
stress management and seeking help for depression if identified as a problem (World
Health Organisation, 2012).

Ashina and Bendsten (2013) have reviewed systematic and Cochrane reviews on nonpharmaceutical management of TTH including behavioural treatments, spinal
manipulation and physiotherapy and acupuncture (Ashina & Bendsten, 2013). They
found the following


Cognitive Behavioural Therapy is effective in the management of TTH



People taking antidepressants and receiving non pharmaceutical treatment for
stress management had a 50% decrease in the number of TTH experienced



A combination of physical therapy and exercise provides reduced frequency
and intensity of TTH



Acupuncture was not found to be superior to physical therapy

‘Over the counter’ medications such as paracetamol, acetylsalicylic acid and ibuprofen
are recognised as effective form of management of infrequent episodic TTH (Fumal
& Schoenen, 2008; Li et al., 2012; Moore et al., 2014; Steiner et al., 2003; Verhagen
et al., 2010; World Health Organisation, 2012). In the case of frequent TTH these
medications must be used with care to prevent the development of medication overuse
headache (Fumal & Schoenen, 2008; World Health Organisation, 2012). There is some
evidence to support the use of a combination of CBT and physiotherapeutic
interventions as preventative measures for more frequent episodic or chronic TTH
(Ashina & Bendsten, 2013; Verhagen et al., 2010; World Health Organisation, 2012).

3.5

Overview of Schizophrenia and schizoaffective disorder

Schizophrenia is considered one the most debilitating mental illnesses having been
identified worldwide as the fifth leading cause of disability in people aged between 15
- 44 years (Sawa & Snyder, 2002; Vancampfort et al., 2012). Schizophrenia symptoms
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include positive symptoms of psychotic episodes such as delusions, hallucinations and
bizarre thoughts and negative symptoms such as apathy, social withdrawal and
flattened affect (Kuswanto, Teh, Lee, & Sim, 2012; Sawa & Snyder, 2002).
Schizoaffective disorder has features of both schizophrenia and mood disorders and
can be classed as manic or depressive depending on the symptoms that are present.
Prognosis is better for people with schizoaffective disorder than it is for people with
schizophrenia (Essali, Al-Haj Haasan, Li, & Rathbone, 2009; Jäger, Bottlender,
Strauss, & Möller, 2004).
3.5.1 Prevalence of schizophrenia and schizoaffective disorder
Schizophrenia is a disease that affects 0.4 - 1.4% of the population (Carter, 2012;
Castle & Buckley, 2011; Vancampfort et al., 2012). Symptoms usually first appear in
young adults with males making up nearly 60% of the patient population (McGrath,
Saha, Chant, & Welham, 2008). To date there have been no large scale studies to
determine the prevalence of schizoaffective disorder but according to Malhi et al.
(Malhi, Green, Fagiolini, Peselow, & Kumari, 2008) prevalence has been estimated to
be between 0.5% and 0.8% in the general population. The onset of thirty percent of
cases is before age 25 and a further 30% between age 25 and 35 and occurs more
frequently in females (Abrams, Rojas, & Arciniegas, 2008).

In the 2010 Australian National Survey of people living with a psychotic illness, 47%
of people with a psychotic illness had a diagnosis of schizophrenia and 16.1% a
diagnosis of schizoaffective disorder (Morgan et al, 2011). Nearly 65% of people with
a psychotic diagnosis in Australia develop this illness between the ages of 25 and 34
years of age (Morgan et al., 2012).
3.5.2 Clinical Characteristics of schizophrenia and schizoaffective
disorder
Emil Kraepelin was the first person to describe ‘dementia praecox’ or schizophrenia
as we now call the illness. This condition is characterised by positive symptoms,
negative symptoms and/or stereotypical behaviours that are evident for a period of at
least one month in conjunction with a noted decline in function over a 6 month period.
Positive and negative symptoms and cognitive deficits alter the person’s sense of
reality which in turn may affect personal, social and occupational functioning. Positive
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symptoms include psychoses such as delusions, hallucinations, bizarre thoughts,
suspicion and disorganised speech and behaviour. Negative symptoms are
characterised by poor motivation, apathy, flattened affect and social withdrawal.
Kraepelin clearly identified a decline in cognitive function through his use of the word
‘dementia’ to describe what he was witnessing in patients. The cognitive deficits
include attention, memory and executive functions (Kuswanto et al., 2012).

WHO ICD-10 identifies that schizoaffective disorder has symptoms of both
schizophrenia and mood disorders which are present at the same time or within a few
days of each other. The patient’s symptoms do not meet the specific criteria for either
schizophrenia or depressive/manic episode. To be diagnosed with schizoaffective
disorder a person must experience a major depressive episode for at least two weeks
or a manic episode for one week either concurrently or within a few days of
experiencing positive symptoms of schizophrenia. Two of the following must be
present for more than two weeks – delusions, hallucinations, disorganised speech,
disorganised behaviour or negative symptoms (Malhi et al., 2008). Schizoaffective
disorder will be defined as bipolar schizoaffective disorder if mania is part of the
presentation or depressive schizoaffective disorder if depression is the only mood
disorder observed.
3.5.3 Mechanism behind schizophrenia and schizoaffective disorder
Schizophrenia is a complex condition in which the pathophysiology is still not clearly
understood. It is believed that schizophrenia develops in response to specific stressors
in vulnerable people. Stressors can be either biological factors such as infections or
substance abuse and/or environmental such as death and trauma (Castle & Buckley,
2011).

Genetics are believed to contribute to a predisposition or vulnerability of an individual
to develop schizophrenia. (Arnedo et al., 2014; Castle & Buckley, 2011; Lowry, 2014).
Research is being undertaken to better understand the role of genetics in the
development of the illness. In recent years attempts have been made to find a
‘schizophrenia gene’ without success and the complex nature of the genetic links
suggest that there may not be such a gene but rather a series of gene-gene interactions
(Arnedo et al., 2014). Castle and Buckley (2011) tabled a ‘gradient of genetic risk for
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schizophrenia’ which evaluates the risk of developing schizophrenia based on the
proximity of the genetic relationship to a person who has a diagnosis of schizophrenia.
Table 4 presents information on the chances of developing schizophrenia based on this
genetic link.

Table 4 - Chances of developing schizophrenia
Relationship

Chance of developing schizophrenia

General population

1%

Sibling with schizophrenia

8%

One parent with schizophrenia

12%

Fraternal twin with schizophrenia

14%

Both parents with schizophrenia

39%

Monozygotic twin with schizophrenia

47%

Castle and Buckley (2011) identified that early life environmental factors contribute
to vulnerability of developing schizophrenia but emphasise that in isolation these are
not the cause of the development of schizophrenia. These factors include, but are not
limited to, maternal infection, maternal anaemia or malnutrition, maternal Vitamin D
deficiency, birth complications and maternal stress during pregnancy.

Karlsgodt et al. (2012) propose a more specific neurodevelopmental hypothesis where
brain lesion caused by a combination of genetic and environmental factors interferes
with the normal growth and development in the brain resulting in schizophrenia
(Karlsgodt, Ellman, Sun, Mittal, & Cannon, 2012). The theory recognises three
specific elements
1. Conception - genetic make-up
2. Early development - pre and peri-natal brain development which may be
influenced by environmental factors identified above such as maternal
infection and other obstetric complications
3. Later development - late adolescent and young adult stresses resulting in the
structural changes to grey and white matter noted previously. Studies are
currently being undertaken in an attempt to better understand the role of stress
in the onset of psychosis (Mondelli & Pariante, 2012).

66

This complex interaction is explained in Figure 3.
Figure 3 – Neurodevelopmental model of schizophrenia

Reproduced from Karlsgodt, K., Ellman, L., Sun, D., Mittal, V & Cannon, T.
(2012). The neurodevelopmental hypothesis of schizophrenia. In A. David, S.
Kapur & P. McGuffin (Eds), Schizophrenia: The Final Frontier - A Festschrift for
Robin M. Murray (p4.). East Sussex: Psychology Press

While the mechanisms behind the development of schizophrenia are still not fully
understood there is an understanding of the structural changes within the brain of a
person with schizophrenia. A systematic review of brain MRI anatomy of people with
schizophrenia by McCarley et al. (1999) and a review of Diffusion Tensor Imaging
studies by Kuswanto et al. (2012) have found enlarged lateral ventricles, enlarged third
ventricle, reduced overall grey matter and widespread cortical and cerebellar atrophy.
There is also noted volume reduction of the inferior prefrontal cortex and the
amygdala, hippocampus and parahippocampal gyrus particularly on the left side
(Kuswanto et al., 2012; McCarley et al., 1999).
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Along with structural changes within the brain, an increase in dopamine D2 receptors
has long been associated with schizophrenia (Madras, 2013). With the development of
imaging technology (SPECT) it has now been determined that there is an increase in
presynaptic dopamine D2 receptors as well as the previously identified increased
levels in response to a ‘challenge’ (Howes, 2012). A new theory of the involvement of
dopamine in schizophrenia as the final common pathway for schizophrenia has been
proposed by Howes (2012). He suggests that multiple ‘hits’ on risk factors described
above lead to increased dopamine levels and in particular presynaptic dopamine
dysregulation through abnormalities with the function and regulation of dopamine cell
bodies in the midbrain. It is unknown if there is dysregulation in other neurons within
the midbrain or if they are limited to the dopaminergic cell bodies.

Malhi et al. (2008) highlight the dearth of studies into biological mechanism associated
with schizoaffective disorder although some have shown enlarged ventricles, reduced
white matter and asymmetry of the parahippocampal gyrus as well as an increased in
dopamine D2 receptors. They also have been shown to have striatal regional
abnormalities similar to those seen in people with bipolar affective disorder.
3.5.4 Management of schizophrenia and schizoaffective disorder
The main treatment of antipsychotic medication aims to reduce symptoms of
schizophrenia and maintain and improve patient functioning and quality of life.
Neuroleptic medication reduces positive symptoms of the illness through blocking of
the dopamine D2 receptors unfortunately with neurological side effects mimicking
Parkinson’s disease (Sawa & Snyder, 2002). Atypical neuroleptics have been
developed that target serotonin receptors to a greater extent than dopamine D2
receptors and do not have these Parkinsonian side effects. These drugs have been
shown to be effective in reducing both positive and negative symptoms of
schizophrenia; however, these drugs have adverse metabolic side effects including
weight gain.

Schizoaffective disorder is usually treated with a combination of antipsychotic
medication and mood stabilisers but there is a lack of evidence to support that this is
the optimum treatment for the condition (Murru et al., 2011). The systematic review
undertaken by Murru et al. (2011) highlights this lack of research with only one
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antipsychotic medication having been tested in a placebo controlled trial and no
placebo controlled trials of mood stabilisers. Murru et al. (2011) noted that the basis
for prescribing these medications for the treatment of schizoaffective disorder was
from extrapolation of data from trials of these drugs in other populations such as
bipolar disorder or schizophrenia. They cautioned this practice and proposed the need
for more specific, robust RCT’s exploring the efficacy of these medications for the
management of schizoaffective disorder.

Many people with schizophrenia and schizoaffective disorder are non-adherent to their
treatment regime and non-compliance of medication is thought to be the biggest factor
contributing to relapse (Carter, 2012; Lammers, Zehm, & Williams, 2013). Depot
injections have been identified as a safe and effective way of ensuring compliance
(Olivares et al., 2009; Sim et al., 2004). Some studies have associated the use of depot
with males and people who have aggressive behaviour (Sim et al., 2004) while other
have identified depot users as people more likely to have alcohol or substance abuse,
higher involvement with police and more frequent hospitalisation (Ascher-Svanum,
Peng, Faries, Montgomery, & Haddad, 2009; Rubio et al., 2006). For many users,
however, the convenience of not having to remember to take medication is appealing
and they voluntarily choose to receive their medication in depot form (Sim et al.,
2004).
3.5.5 Pain and schizophrenia
Early pioneers in the study of schizophrenia, Kraepelin and Bleuler noted that people
with schizophrenia have a reduced sensitivity to nociception (Potvin & Marchand,
2008). In 1982 Fishbain warned about the importance of clinicians exploring pain
reported by people with psychoses to prevent misdiagnosis of medical conditions and
even death (Fishbain, 1982). A review of literature relating to pain experienced by
people with schizophrenia and psychoses conducted by Singh et al. (2006) uncovered
that many people experiencing psychosis fail to respond to noxious input from life
threatening conditions such as myocardial infarction, ruptured appendix and
perforated bowels (Singh, Giles, & Nasrallah, 2006).

A study by Atik et al. (2007) explored the differences in pain threshold, pain tolerance
and pain endurance between people with schizophrenia, bipolar affective disorder and
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controls (Atik, Konuk, Akay, Ozturk, & Erdogan, 2007). The study used the cold
pressor test (immersing the hand in iced water) on the non-dominant hand and recorded
when the cold began to hurt (pain threshold), when participants removed their hand
(pain tolerance), their pain score out of 10 using a visual analogue scale at the point
where they removed the hand (pain magnitude) and then the time that elapsed before
pain resolved (pain endurance time). They determined there was no statistical
difference between time to pain threshold between the group with schizophrenia
(mean=144.4sec) and the control group (mean=112.5sec) and measured pain
magnitude (schizophrenia mean=6.85/10 and control group mean=6.94/10). It was
determined, however, that people with schizophrenia had higher pain tolerance
(mean=199.4sec) in that they could leave their hand in the cold for longer than the
control group (mean=137.5sec) before pain forced them to remove it. In what appears
to be a contradiction people with schizophrenia had longer pain endurance times
(mean=56.4 sec) than the control group (mean=25.0 sec). It was suggested that this
discrepancy existed because report of pain resolution was based on subjective
evaluation and delay in reporting could be attributed to affective abnormalities.
However, no consideration was given to the fact that having left their hand in the iced
water for longer periods of time other physiological changes associated with prolonged
cold might have meant it could have taken longer for pain to resolve after emersion.

In 2008 Potvin and Marchand conducted a meta-analysis of twelve studies conducted
between 1966 and 2007comparing experimental pain responses in people with
schizophrenia to healthy controls (Potvin & Marchand, 2008). Six studies related to
thermal stimulation of pain with two using the cold-pressor test, five studies related to
electrical stimulation and one study used mechanical stimulation through pressure on
the deltoid, tibia and finger to stimulate pain. They determined that people with
schizophrenia had a diminished sensitivity to experimentally induced pain from
electrical and thermal stimulation. An important aspect of their report was that this
diminished sensitivity was present in people taking medication as well as those not
taking medication suggesting antipsychotic medication alone cannot be responsible for
diminished pain sensitivity in people with schizophrenia. Hooley and Delgado
evaluated pain responses in relatives of people with schizophrenia using finger
pressure algometer (Hooley & Delgado, 2001). They determined that relatives of a
person with schizophrenia had a higher threshold to pressure pain than people who did
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not have a relative with schizophrenia. This could suggest a genetic predisposition to
hypoalgesia amongst people with schizophrenia.

A systematic review of literature by Bonnot et al. (2009) focused on differences
between behavioural responses to pain and physiological responses to pain. Fiftyseven articles were reviewed under the following sub headings


Case reports of people with schizophrenia who reported no pain in known
painful medical conditions



Clinical and epidemiological studies where a high prevalence of people with
schizophrenia experiencing headaches was noted



Experimental studies with varied results, some showing higher pain threshold
in people with schizophrenia and others not showing this phenomenon.



Previously reviewed articles.

A decrease in behavioural responses to pain was found which was attributed to
cognitive impairments (Bonnot et al., 2009). Bonnot et al. (2009) and Potvin and
Marchand (2008) suggest that poor communication and cognitive impairments as well
as negative symptoms such as blunted responses experienced by this population group
could contribute to altered pain expression. They hypothesise that noxious stimuli will
still provoke a pain response but the expression of the pain response may be blunted.
The research evaluated in these two reviews focused on cutaneous pain and not deep
tissue sensitivity which is more likely to be associated with medical conditions and
musculoskeletal dysfunction.

A more recent study not included in the above systematic reviews examined responses
of people with schizophrenia to both acute and prolonged painful stimuli elicited by
transcutaneous electrical stimulations of the sural nerve (Lévesque et al., 2012). They
determined that people with schizophrenia have a unique response to noxious input
with increased sensitivity to acute nociception and decreased sensitivity to prolonged
nociception when compared to a control group of people with no family history of
schizophrenic spectrum disorders. The fact that participants had different responses to
different types of noxious input might suggest that communication and blunted
responses are not the limiting factors to pain expression. There is some consistency
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between this study and that of Atik et al. (2007) mentioned above who found that
people with schizophrenia have higher pain endurance and tolerance.

Engels et al. (2014) conducted a systematic review on fourteen studies on clinical pain
in schizophrenia reflecting that responses to nociception induced in experimental
conditions are very different from those of clinical pain experienced in daily life
(Engels et al., 2014). Clinical pain included surgical pain, chronic pain and pain
experienced in daily life. It appeared that prevalence and intensity of pain associated
with medical causes is lower in people with schizophrenia than controls. When pain
was not related to a medical cause both prevalence and intensity were the same as
healthy people. Possible explanations were presented for the lower prevalence and
intensity of medical related pain and these include


Not actually reporting the pain for fear of hospitalisation or to avoid being a
burden



Diminished processing of motivational-affective aspects of pain due to
dysfunction in the frontal lobe. The person may feel pain but not exhibit pain
behaviour



Decline in cognitive functioning



Use of antipsychotic medication.

The question of whether lower prevalence and intensity of medically caused pain is a
result of being less sensitive to nociception or having a blunted response to pain was
not resolved. A possible explanation, not suggested by the authors, is that medical pain
could be more prolonged whereas experimental pain may be more acute and as
identified by Lévesque et al., (2012) there appears to be a reduced sensitivity to
prolonged pain in people of this population.

According to Wojakiewicz et al. (2013) people with schizophrenia not only have a
reduced response to their own pain but also that they have difficulty recognising when
other people are in pain (Wojakiewicz et al., 2013). The hypothesis for this study was
that response to pain is both physiological and emotional. Wojakiewicz et al. (2013)
evaluated the emotional aspects of pain recognition by comparing responses to facial
expressions, videos of pain sequences and a situational pain questionnaire. They
compared responses of 29 people with schizophrenia against 27 controls matched on
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age, gender and IQ. They found differences that suggest people with schizophrenia
lack an ability to recognise basic emotions from facial expressions and are not able to
differentiate between imaginative painful and non-painful situations and have an
altered ability to recognise pain and pain behaviours.

Regardless of the underlying mechanism it is acknowledged that people with
schizophrenia do have a diminished response to noxious input especially in the chronic
stages of their illness (Bonnot et al., 2009; Engels et al., 2014; Guieu, Samuélian, &
Coulouvrat, 1994; Potvin & Marchand, 2008). All researchers agree that more research
into the responses of people with schizophrenia to noxious stimuli is required.

The concept that people with schizophrenia experience reduced pain responses but
have a high incidence of pain and a prevalence of headache the same if not greater than
the general population raises questions about the nature and characteristics of the
headaches that they may experience. Are the headaches different or are the
impairments driving the conditions more severe than the general population in order
to provoke a response? If this is the case then it is important that headache can be
identified and treated in a timely manner.
3.5.6 Posture and schizophrenia
As already noted a forward head posture has been associated with headache and in
particular cervicogenic headache. Poor trunk stability and diminished postural control
can be a factor in forward head posture (Beinert & Taube, 2013). There is evidence
that people with schizophrenia have structural abnormalities of their cerebellar vermis
a neural structure that plays an important role in maintaining postural control
(Nopoulos, Ceilley, Gailis, & Andreasen, 1999). Using MRI it has been determined
that the proportional relationship between volumes of grey and white matter in the
cerebellar vermis region of people with schizophrenia is different compared to a
healthy control group (Lawyer, Nesvag, Varnas, Okugawa, & Agartz, 2009).
Diminished postural control and balance has been observed in people with
schizophrenia and are often referred to as neurological soft signs (Ho, Mola, &
Andreasen, 2004; Marvel et al., 2004; Picard, Amado, Mouchet-Mages, Olié, & Krebs,
2008; Varambally, Venkatasubramanian, & Gangadhar, 2012; Varambally,
Venkatasubramanian, Thirthalli, Janakiramaiah, & Gangadhar, 2006).

73

In an experiment comparing postural sway in people with schizophrenia to healthy
individuals the people with schizophrenia demonstrated more sway in the anteriorposterior plane which was even more pronounced when feet were together and arms
raised (Marvel et al., 2004). In this study it was suggested that medication could be a
potential confounder. Ho et al. (2004) compared cerebellar signs of 155 neuroleptic
naïve people with schizophrenia against 155 healthy volunteers of similar age and
gender. The tests included finger-nose, rapid alternating pronation-supination, heelknee-shin, muscle tone, Rhomberg and tandem gait tests. It was determined that about
one fifth of the study group (neuroleptic naïve) displayed positive cerebellar sign,
particularly in gait and stance indicating that neuroleptic medication cannot be totally
responsible for positive cerebellar signs. A possible limitation to this study was that
examiners were not blinded to participant’s diagnosis. These findings of Ho et al.
(2004) were reproduced in a later study by Varambally et al. (2006) in a cohort
screened for comorbid alcohol abuse or dependence. People with known alcohol
dependence were excluded from the study thus eliminating the possibility of alcohol
abuse as a reason for cerebellar abnormalities.

Reviewing clinical, cognitive and functional literature on the role of cerebellum in
schizophrenia, Picard et al. (2008) found nothing to refute the concept of cerebellar
involvement in schizophrenia resulting in anomalies in postural control and
equilibrium (Picard et al., 2008). A later review of current literature also supports the
belief that cerebellar signs are part of the syndrome of schizophrenia and determined
that their presence may have some link to poorer prognosis (Varambally et al., 2012).

3.6

Managing the physical health of people with mental illness and

role of Physiotherapy
There is a strong connection between physical wellbeing and good mental health.
Good mental health is fundamental to the wellbeing of individuals, families and
communities (Department of Health and Aging, 2009). Good health is a result of a
complex interaction of biological, psychological, social, environmental and economic
factors. When any of these factors are compromised so is the health of the individual.
It is widely accepted that people with mental health disorders have poorer physical
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health than the general population with higher levels of mortality and morbidity from
physical illness (Coghlan et al., 2001; Happell et al., 2012; McLennan, 1998;
Richardson et al., 2005).

The importance of maintaining good physical health of mental health clients is
recognized in the Australian National Mental Health Policy (2008). Australian mental
health teams are comprised of psychiatrists, psychologists, mental health nurses, social
workers, occupational therapists and Aboriginal and Torres Strait Islander mental
health workers (National Mental Health Policy, 2008). Unfortunately it has been
identified that people working in mental health often discount physical complaints as
side effects of medication or a psychotic event and do not investigate further often
resulting in poor outcomes for the client (Cuyún Carter et al., 2011; Happell et al.,
2012).

In order to access holistic health care all mental health consumers are encouraged to
visit a general practitioner (GP), someone who is responsible for their overall
management including physical health issues. Unfortunately Morgan et al. (2011)
reported that only 35.5% of people with psychotic illness who visited their GP had a
general health examination. This was not a surprising finding when most GP visits
(65.4%) lasted between 10 and 19 minutes allowing very limited time to address both
mental and physical health issues (Morgan et al., 2011).

It would appear that mental health consumers are not getting adequate access to health
practitioners who can evaluate and manage their physical health issues. Many papers
recommend that better assessment and diagnosis of physical complaints of people with
schizophrenia and schizoaffective type disorders is necessary (Connaughton, Patman,
& Pardoe, 2013; Fagiolini, 2008; Galletly et al., 2012; Jeste, 1996; Morgan et al.,
2012). Within the general healthcare system, physiotherapists play significant roles in
the assessment, treatment and ongoing management of many of the more common
physical health issues experienced by people with schizophrenia or schizoaffective
disorder (Australian Physiotherapy Association, 2011, 2012). These include chronic
back, neck or other pain (Galletly & Murray, 2009; Gureje, 2008; Morgan et al., 2012;
The Chartered Society of Physiotherapy, 2008), cardiovascular disease, ischaemic
heart disease, hypertension, diabetes, respiratory disease (Fagiolini, 2008; Morgan et
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al., 2012; Richardson et al., 2005), and illnesses associated with obesity (Morgan et
al., 2012). Given that the National Mental Health Policy (2008) advocates for good
holistic health of mental health consumers it could be argued that physiotherapists
should be included as integral members of mental health teams.

Physiotherapeutic interventions of aerobic exercise, muscle strengthening and
relaxation have been shown to have positive effects on psychiatric symptoms,
psychological distress and anxiety of people with schizophrenia as well as improving
health related quality of life (Gorczynski & Faulkner, 2010; Vancampfort et al., 2012).
A limited systematic review of the effects of physical exercise in schizophrenia (n=3
articles) has determined that exercise can lead to an increase in hippocampal volume,
increased cardio-respiratory fitness and has been associated with an increase in cortical
thickening in the left hemisphere (Vancampfort et al., 2014). It is becoming evident
that physiotherapy has a bigger role to play in the holistic management of people with
schizophrenia and schizoaffective disorder than just addressing their physical health,
further strengthening the argument to include them as a profession within mental
health workforce.

3.7

Factors affecting quality of life

Quality of life (QOL) is no longer measured by the presence or absence of disease and
survival but covers a more holistic view of the person (Magnusson, Riess, & Becker,
2012). Most quality of life questionnaires explore a person’s perceptions of their
physical and social functioning, their psychological status and disability attributed to
disease related symptoms (Magnusson et al., 2012; Manhalter, Bozsik, Palásti,
Csépány, & Ertsey, 2012).
3.7.1 Impact of headache on quality of life
The WHO identified in the document ‘Lifting the Burden’ (2012) that many people
‘belittle’ the impact headache can have on a person. It is often overlooked by medical
health professionals because almost every one experiences headache from time to time
and is not usually a life threatening illness (Stovner et al., 2007; Stovner, Zwart,
Hagen, Terwindt, & Pascual, 2006). Headache has been recognised as one of the
world’s top 10 causes of disability, is among the top 3 most prevalent diseases globally
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and has been identified as the top neurological cause of years lived with disability
(Martelletti, Mitsikostas, et al., 2013; Martelletti, Birbeck, et al., 2013).
The presence of headache impacts on a person’s function and quality of life. Solomon
and colleagues (Solomon et al., 1993) undertook a study of 208 people attending a
headache clinic using the Medical Outcomes Study Short Form Health Survey (SF-36)
to determine the impacts chronic headache has on quality of life. People with
headaches recorded significantly worse scores for physical, social and role functioning
components and had worse mental health than people with chronic diseases such as
arthritis and diabetes. The reduced quality of life results were comparable to those of
people who had experienced myocardial infarction.

A Dutch study was undertaken in 2003 using the SF-36 to explore the health related
quality of life of 118 people attending a headache clinic who had either CGH, TTH or
MH diagnosed by neurologists against the ICHD (van Suijlekom et al., 2003). They
found that people experiencing CGH had a quality of life burden greater than the
normal population but similar to that of people experiencing MH without aura and
TTH (van Suijlekom et al., 2003). The 2007 study by Vinding and colleagues
examining the impact of headache in a Danish Headache centre population found
people experiencing frequent headaches also made greater use of the healthcare
system, had more time off work and were less effective when at work than the general
population (Vinding et al., 2007). The need for early intervention was highlighted to
reduce the burden and improve quality of life.

Wiendels et al conducted a population based survey exploring prevalence and risk
factors of chronic frequent headaches (Wiendels et al., 2006). This postal survey was
sent to 21,440 people who were registered with a GP in two regions of The
Netherlands. There was a response rate of 76% (n=16,232). Researchers wanted to
minimise selective responses so it was not identified that headache was their primary
focus. They found that fifty percent of people experiencing chronic frequent headaches
had significant comorbidities and reported moderate disability. The most prevalent
comorbidities were gastrointestinal and musculoskeletal conditions including arthritis,
back pain, neck pain and fibromyalgia. The majority of people attending headache

77

clinics also had comorbid mental health issues the most common of which were
depression and anxiety disorder.

In a qualitative study exploring the experiences and perceptions of people with
headache it was found that presence of headache had negative effects on work, family
life, social activities and mood (Leiper et al., 2006). A significant worry for headache
sufferers was the cause of the headache and it was identified that there was a desire for
investigations to determine the cause to rule out sinister origins. There is nothing to
suggest this is any different for people with schizophrenia or schizoaffective disorder.
3.7.2 Impact of schizophrenia and schizoaffective disorder on quality of
life
People with schizophrenia and schizoaffective disorder are known to have poor quality
of life and global functioning (Morgan et al, 2011). Worldwide, schizophrenia has
been found to be the fifth leading cause of disability (Vancampfort et al., 2012). A
study conducted over a three year period by Cuyún Carter et al. (2011) found that only
10% of people with a diagnosis of schizophrenia had good QOL outcomes including
an improved quality of life, increased daily activities and global functioning. This
agrees with the Australian Government Report, People Living with Psychotic Illness,
2010 (Morgan et al, 2011) which determined that 90% of people in Australia with
psychotic illness report deterioration in their occupational and social functioning after
their diagnosis (Morgan et al, 2011). Two thirds of people were identified as having a
severe dysfunction in their ability to socialise and about one third were severely
impaired in their ability to look after themselves and undertake basic activities of daily
living.

Ritsner, Lisker and Grinshpoon (2014) highlight that poor quality of life in people with
schizophrenia and schizoaffective disorder is linked to presence of depressive
symptoms, side effects of antipsychotic medication and emotional distress (Ritsner,
Lisker, & Grinshpoon, 2014). In their study Ritsner et al., (2014) only focused on
psychological features that may contribute to emotional stress and overlooked impacts
of physical factors such as pain (Ritsner et al., 2014).
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3.7.3 Impact of headache on quality of life of people with mental illness
Presence of a psychiatric comorbidity is known to complicate the management of
headache (Bera, Khandelwal, Sood, & Goyal, 2014). Verri et al. (1998) identified the
most common comorbidity of people who experience chronic daily headaches were
anxiety and mood disorders (Verri et al., 1998). A more recent study determined that
the most common psychiatric comorbidity associated with headache is depression with
Bera et al. (2014) finding depressive symptoms present in 37.5% of people
experiencing MH and 30% of those with TTH compared to 10% in a headache free
control group. The study examined the QOL of people experiencing different headache
types but no comparisons were made in the QOL between those with depression and
those without depression.

People experiencing headaches with a comorbid psychiatric condition incur increased
medical costs, a higher headache related disability and a reduced quality of life
(Smitherman & Baskin, 2008; Wang & Juang, 2002). Pompili et al. (2009) found that
a psychiatric disorder among people with headaches decreased quality of life, resulted
in poorer prognosis and response to treatment and resulted in an increased chronicity
of the disease (Pompili et al., 2009). The presence of migraine or chronic non migraine
headaches increased the risk of developing depression. The study found
pharmaceutical intervention targeting mental health comorbidities improved mental
health but did not impact on headache number or intensity. No physiotherapeutic
assessment or intervention was considered.
It is already known that management of physical complaints of people with mental
illness is poorer than the general population (Coghlan et al., 2001; Fagiolini, 2008;
Morgan et al., 2012) and it could be suggested that people with schizophrenia and
schizoaffective disorder are not receiving assessment and treatment for their headaches
equivalent to the general population. Already considered a burden on the healthcare
systems the addition of headaches on a person with schizophrenia or schizoaffective
disorder could compound this.

3.8

Summary of literature review

Headache is recognised as one of the top ten disabling conditions worldwide yet up to
50% of headache sufferers in the general population do not seek medical advice.
Prevalence of headache amongst people with schizophrenia has been determined at
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48% which is comparable to that of the general population. Headache is reported to be
the most common pain experienced by people with psychotic illness. People with
mental illness have poorer physical health than the general population and for many
reasons do not receive appropriate care. It is suggested that fewer people with
schizophrenia or schizoaffective disorder report the presence of headache to their
health professional which would also suggest that they do not receive appropriate
assessment and treatment.

Headache of particular interest to physiotherapists is CGH. The prevalence of
cervicogenic headache is about 4% in the general population and roughly 15-20% of
patients suffering from ongoing headache. No studies have been undertaken to
determine if this is the same for people with schizophrenia or schizoaffective disorder.
Physiotherapy plays an important role in the management of CGH.
TTH and MH are also of interest to physiotherapists. Physiotherapy plays a role in the
management of TTH and although not a key treatment for MH, physiotherapy has a
role to play when comorbid neck pain exists. Physiotherapists are able to differentially
diagnose between CGH, TTH and possible MH and refer people to appropriate health
professionals for the management of MH. Prevalence of TTH is 42% and MH 14.7%
in the general population. Only one study has looked at the prevalence of TTH and
MH in people with schizophrenia but this study did not use the ICHD to classify TTH
and it is unknown how MH was classified. More research is needed to determine the
prevalence of these headache types in people with psychotic illness.

Schizophrenia and schizoaffective disorder affects about 1% of the population. These
disorders are associated with a diminished response to pain which could have
significant implications on the presentation and characteristics of their headache
experience. The cerebellum vermis is involved with postural control and can be
impaired in people with schizophrenia. Poor posture can be a contributing factor to
headache and in particular CGH. It could be possible that people with schizophrenia
who already have poor postural control may be more at risk of developing headache
than the general population.

The literature has identified that the general physical health of people with mental
illness is poorer than the general population. Despite recognition of the relationship of
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one to the other there is increased mortality and morbidity from preventable diseases
and ailment in this population. There is a need for better assessment and diagnosis of
physical complaints of people with schizophrenia and schizoaffective disorder.
Physiotherapy plays an important role in the management of chronic pain,
musculoskeletal conditions, cardiovascular, neurological and metabolic conditions and
it could be argued that they should be more involved in the holistic management of
mental health clients to address both the physical and mental wellbeing of people with
mental illness

It has been noted that chronic or regular headache reduces quality of life with particular
impact on physical, social and role functioning. People with schizophrenia experience
reduced quality of life in relation to global functioning. It could be suggested that the
presence of headache could further reduce an already poor quality of life of the person
with schizophrenia or schizoaffective disorder. There are very few studies
investigating the impact on quality of life of people with schizophrenia and
schizoaffective disorder who experience headache.

The purpose of this research is to determine the prevalence and characteristics of
headache, in particular possible CGH, and the perceived impact on aspects of quality
of life of people with schizophrenia or schizoaffective disorder. It is also to determine
how people manage their headache and whether they receive assessment and/or
treatment from a health professional. This information will help identify whether
changes could be implemented to better address this manageable physical illness and
possibly favourably effect general wellbeing. This may include expanding the role of
physiotherapy in mental health services.
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CHAPTER FOUR
Design and Methodology
4.1

Study Design

A cross-sectional observational cohort study was undertaken surveying patients
attending the Fremantle Mental Health Services (Alma Street). Ethical approval was
provided through the Human Research Ethics Committee of both The University of
Notre Dame Australia (HREC Ref 012113F) and the South Metropolitan Area Health
Service (HREC Ref 12/390). All participants provided informed consent and all
procedures adhered to the declaration of Helsinki.

Based on a headache prevalence of 48% (Kuritzky et al., 1999) with a 95% certainty
it was estimated that 97 participants would be required to provide a level of absolute
precision for our estimate of the prevalence to be within 10% of the population
prevalence. It was decided to oversample by 3 for a final recruitment target of 100
participants.
4.1.2 Participants
One hundred participants with a medically confirmed diagnosis of schizophrenia or
schizoaffective disorder were recruited from a cross section of people attending the
Fremantle Hospital Mental Health service between 2nd July and 28th November 2013.
Recruitment occurred in the outpatient depot clinic in July and the open wards at the
Fremantle Hospital Mental Health complex between August and November.

Participants were not selected according whether they experienced headache or not
rather they were selected using the following criteria.

Inclusion criteria
People who


Had a confirmed psychiatric diagnosis of schizophrenia or schizoaffective
disorder



Were over 18 year of age
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Were consumers of Fremantle Hospital Mental Health Services in either an
inpatient open ward or as an outpatient



Were deemed stable in their recovery process so that a researcher asking
questions about clinical characteristics and headache would not potentially
jeopardise their recovery progress

Exclusion Criteria
People who


Had a history of psychosis but the psychiatric diagnosis was not yet verified



Were in the secure wards



Were deemed cognitively impaired by their case manager/nurse to the extent
they would not be able to complete the questionnaire



Were in critical time of their recovery which could potentially be destabilised
by attending an interview about headache



Were assessed as a potential safety risk to the researcher by nurse or case
manager

The first cluster of recruitment of outpatient participants was via the facility’s twice
weekly depot clinic. The majority of clients attending the depot clinic have a diagnosis
of schizophrenia or schizoaffective disorder which has been confirmed by a
psychiatrist. Posters in the waiting room and depot injection treatment room advertised
the project. The depot nurses invited everyone attending the clinic over the month of
July 2013 who met the selection criteria to participate in the study. Those agreeable
were introduced to the principal researcher and invited to complete a questionnaire.
Recruitment saturation was achieved after one month, with all eligible attendees
having been approached regarding participation by this time.

The second cluster for recruitment of inpatient participants was via the open wards at
the Fremantle Hospital Mental Health Complex from August to November 2013. The
Fremantle Mental Health Services have five inpatient wards comprised of two secure
wards and two open wards on the main campus as well as a ‘step up/step down’ ward
in a facility within short walking distance of the hospital. In the ‘step up/step down’
ward patients are monitored by medical staff while transitioning towards discharge or
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avoiding admission into the hospital proper. They remain overnight in this facility but
during the day are responsible for their own activities of daily living and are
encouraged to return to daily activities such as working and socialising. Patients in the
two secure wards did not meet selection criteria due to the acuity of their illness. The
nurse manager on the three open wards initially alerted the researcher as to which
inpatients had a diagnosis of schizophrenia or schizoaffective disorder. Discussion
with the nurse manager or the patient’s ward nurse manager identified those who met
the selection criteria and these people were approached by the researcher to participate
in the study.

4.2

Procedure

Once an outpatient was identified by the depot nurse as a suitable candidate, and
following their injection, they were introduced to the researcher in a private interview
room. The researcher explained the purpose of the project to them as well as the
research process. If still interested participants were given the opportunity to read the
plain language statement (PLS) and sign a consent form prior to completing the
questionnaire. In the inpatient setting once possible participants were identified the
nurse case manager introduced the researcher to them and once again the researcher
went through an explanation of the purpose and process of the study. If the patient was
still interested a private area was found on the ward and the participant was offered a
copy of the PLS to read prior to gaining written informed consent.

Based on previous research (Kuritzky et al., 1999; Pfaffenrath et al., 2009), the
researcher’s personal experience of working with this client group and on the advice
of experts consulted during the pilot study, the researcher offered the first seven
outpatient participants the option of either independently completing the questionnaire
in her presence or have her ask the questions and fill in the form. All seven people
specifically requested that the researcher ask the questions and so for consistency all
subsequent participants were not offered that option (Stovner et al., 2014).

This method proved to be essential as some participants needed clarification of
questions and prompting as to what was being asked. When some participants
appeared to be losing interest the researcher could speed up the interview. This
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facilitated both participation in the study and participant’s attention to questions and
task.
4.2.1 Demographics and Clinical characteristics
Questions to capture demographics of age and gender to enable comparisons to normal
population studies were included (Stovner et al., 2014). Previous headache
questionnaires had identified comorbidities and medication as variables to consider
and questions about these were included along with data about inpatient/ outpatient
status.

To evaluate the impact of chronicity of mental illness a question was initially included
asking the participant how long ago they had been diagnosed with schizophrenia or
schizoaffective disorder. This question was removed from the questionnaire in
accordance with one ethics committee’s recommendation. This information was then
determined from the case notes. It should be noted that the majority of clients
volunteered this information without being asked and referral to the notes was not
always necessary.

Body Mass Index (BMI) was considered a possible variable impacting on presence of
headache. To determine BMI, participants were asked to give their height and weight
a method that has been found to be reliable in other studies (Queiroz et al., 2009).
Participants who were unsure of their height or weight were measured in the clinic or
on the ward.
4.2.2 Headache characteristics
It was acknowledged that there is a low participation rate of people with schizophrenia
and schizoaffective disorder in psychiatric research with a participation rate in
interviews of between 53% and 85% (Haapea, 2007). When compared to a depressed
population, people with schizophrenia are less willing to participate in questionnaires
(Schäfer et al., 2011). Bearing this in mind important aspects of the data collection
process were to collect all the necessary data in a timely manner, not overwhelm
participants with too many questions and exclude irrelevant questions in order to limit
losing participants (Stovner et al., 2014). The pilot questionnaire formed the basis of
the study to collect data about the prevalence and characteristics of headaches. In both
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inpatient and outpatient settings if a person identified more than one headache type
they were initially asked to complete the questionnaire on their most worrying
headache and only when this was finished were they invited to complete a second
questionnaire on the other headache.
4.2.3 Headache impact
Recurrent headache is known to impact on a person’s quality of life and general health
so one additional feature of this study was to determine the impact headache had on
the quality of life of the participants (van Suijlekom et al., 2003). Questionnaires
evaluating Quality of Life for people with schizophrenia and schizoaffective disorder
can be lengthy. In order to collect data in a timely manner and to try and prevent
participants from losing interest during the interview only selected questions from the
SF-36 were included in the questionnaire. These were to gauge the perceived effects
recurrent headache have on role-physical, social functioning and bodily pain.
Questionnaires evaluating impact of headache on QOL must be specific enough to be
sure they are capturing only impacts from the headache and not from other physical
and psychological factors (Stovner et al., 2014). It was suggested that people with
schizophrenia and schizoaffective disorder may consider the impairment to their
functional role more important than actually considering what may be causing it and
have difficulty answering the question (Picard et al., 2008). However, as suggested by
Magnusson et al. (2012) including a qualifying phrase about headache allowed for
better interpretation of the questions. The researcher found that by asking all the
questions she was able to emphasise to participants that these QOL questions related
only to impairments from headache not from their mental illness.

There has been mixed views on the validity of the SF-36 to evaluate quality of life of
people with schizophrenia and other severe mental illnesses (Papaioannou, Brazier, &
Parry, 2011). Leese et al. (2008) determined that people with schizophrenia were just
as able to use the SF-36 as the general population, however, highlighted the importance
that participants correctly interpret the questions providing further evidence for the
researcher to present the questionnaire in person (Leese et al., 2008).

86

4.2.4 Headache Classification
The algorithm described in the pilot study was used to assist with the classification of
headaches. A copy of the questionnaire and algorithm can be found in the Appendix 1
and Appendix 2.

4.3

Data Analysis

4.3.1 Preparing and processing data
Each participant was allocated an individual identification number (ID) from 1-100.
People who experienced more than one type of headache and completed two
questionnaires were allocated a second ID for the second questionnaire starting from
101. A variable coding table was developed to list all the variables in the questionnaire
and assign each a numerical code. All data were double entered and screened for errors.
Analysis was undertaken using IBM SPSS statistics version 22. Continuous variables
were screened for normality of distribution using Kolmogorov-Smirnov test and the
influence of outliers was investigated using the 5% Trimmed Mean.

Monthly Index of Medical Speciality (MIMS) searches were conducted on all
medication to determine how they should be rated in relation to impacting on
possibility of developing headache. All participants were taking antipsychotic
medication due to the nature of their illness. Medications were divided into groups of


antipsychotic medication only,



all other mental health medication that did not include antipsychotics,



all other medication that did not include any for mental health conditions.

The groups were further divided into two subgroups


headache as a common or very common side effect



headache as an uncommon or rare side effect

In every instance the highest rating of headache side effect of any of the drugs being
taken by that participant was considered. So for example if a person was taking an
antipsychotic medication which rated headache as a rare side effect but was taking
another mental health medication such as venlafaxine which has a common side effect
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of headache then when considering if the person was taking medication with headache
as a common or rare side effect the rating was ‘common’.
4.3.2 Analysing data
Descriptive statistics were used to describe participant’s demographic, general health
and psychiatric clinical characteristics. Where possible the clinical and demographic
characteristics were compared to normative data.

The 12-month prevalence rate for headache was calculated for the whole sample. A
series of univariate logistic regressions were conducted to determine if there were any
demographic or clinical characteristics that impacted on the likelihood of participants
reporting headache. Headache was the dependent variable and explanatory variables
explored were gender, age, inpatient/outpatient status, BMI, length of illness,
medication with headache as side effect and diabetes. A Pearson product-moment
correlation was conducted to determine if there was a linear relationship between
reported pain from headache and chronicity of mental illness.

Two researchers independently screened each headache questionnaire and classified
each individual’s headache as MH, TTH, CGH or OH. The responses of the two raters
were then compared and inter-rater agreement was assessed using the Kappa Measure
of Agreement. Any disagreements between the raters headache classifications were
discussed and a consensus reached on the most appropriate classification for that
person. In situations where a consensus could not be reached a third review would be
asked to review the questionnaire and a majority decision would be made. Prevalence
rates for each of the headache types were also calculated. Within the population who
experienced headache the proportion of participants experiencing each headache type
was calculated.

To explore the likelihood of any demographic and/or clinical characteristics impacting
on participants experiencing specific headache types a series of logistic regression
analyses were undertaken, one within the whole sample and then another within the
headache only population. For example when investigating the influence of clinical
and demographic factors on the presence of MH, the whole sample was dichotomised
into migraine or not migraine such that the non-migraine cohort contained some
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headache free participants as well as headache patients who suffered from nonmigrainous headache. Univariate logistic regression analyses were performed in this
way for each headache type using the whole sample with the dependent variable of
presence or absence of specific headache type. Explanatory variables explored were
gender, age, inpatient/outpatient status, BMI, length of illness, medication with
headache as side effect and diabetes. This process was repeated for each specific
headache type as well as OH. To model the combined influence of significant
explanatory variables on headache status a multivariate logistic regression was
conducted using explanatory variables identified in the univariate logistic regression
with p<0.2. No multivariate logistic regression was conducted is no variable recorded
p<0.2.

Then to further explore the influence of demographic general health and psychiatric
clinical characteristics on specific headache status the same series of univariate logistic
regressions using the headache only population, meaning no headache free participants
were included in the sample. A multivariate logistic regression was also conducted
using the same parameters as described for the whole population.

Correlations were used to explore the impact of headache on quality of life. If data was
normally distributed a Pearson correlation was used or if data was not normal a
Spearman’s correlation was undertaken to determine if there was a relationship
between quality of life scores (QOL) for Bodily Pain, Social Functioning, Role
Physical and length of headache (LOH), frequency of headache (FOH) and pain
(VAS). One way group analysis of variance (ANOVA) for parametric data or a
Kruskal-Wallis Test for non-parametric data was used to explore if a specific headache
type impacted on quality of life scores (QOL) for BP, SF and RP.

Themes of management strategies for headache were identified and ranked in order of
prevalence.
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CHAPTER FIVE
Results
5.1

Participation

Across the five months of recruitment 148 people met selection criteria and were
approached regarding participation. There was a 68% participation rate with 48/148
people (32%) declining to participate. The final cohort consisted of 100 people with a
diagnosis of schizophrenia or schizoaffective disorder confirmed by a psychiatrist. All
subjects completed most aspects of the questionnaire – there was minimal missing data
and specifics of missing data are detailed below. A flow chart detailing the recruitment
process can be found in Figure 4.

During the recruitment period 85 people who met selection criteria attended the
outpatient depot clinic and were invited to participate. Fifty five people (55/85) agreed
to participate making a participation rate of 65% in this setting. Participation rate for
males was 63% (31/49) and 67% (24/36) for females. The main reasons given to
decline participation included


I’m not interested (n=13)



No reason given (n=4)



I’m in a hurry (n = 4)



I would but I don’t want to sign a consent form (n=3)



My children are in the waiting room (n=2)



I don’t want to (n=2)



I have just completed a medical appointment and am not feeling good (n=1)



I’m too tired (n=1)

During the inpatient recruitment phase 63 people met selection criteria and 45 people
agreed to participate giving a participation rate of 71% in this setting. The participation
rate for males was 80% (35/44) and 53% (10/19) for females. Main reasons given to
decline participation included


I’m not interested (n=12)



I would but I don’t want to sign a consent form (n=4)



I want to go to sleep (n=2)
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Figure 4 - Flow chart of recruitment rate in inpatient and outpatient settings
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Outpatients
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5.2

Outpatients who
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Inpatients who
consented

n=55

n=45

Demographics

Sixty six percent of participants were male (66/100) and 34% were females (34/100).
Participation rate for males was 71% (66/93) and 61.8% for females (34/55).
Recruitment of males was distributed reasonably evenly between inpatient (53%,
35/66) and outpatient settings (47%, 31/66). In contrast, of the 34 women recruited,
71% were from the outpatient setting (24/34) with only 29% recruited from the
inpatient setting (10/34). Figure 5 shows the distribution of males to females in both
approached and participated groups.
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Figure 5 – People approached and participated by setting and gender
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Age ranged from 19 years to 60 years with a mean age of 38.8 years (SD=10.39 years).
As can be seen in Figure 6 there was a slight skew to the left with scores clustered
around the lower ages.

92

Figure 6 – Age distribution of participants

Figure 7 shows that BMI ranged from 16.8 to 55.5 with a mean score of 29.4
(SD=6.62). A normal BMI range is from 20-25, the overweight range is 25-30 and
over 30 is deemed obese. The mean score for this sample population is therefore at the
upper end of the overweight range. When compared to previous studies of a similar
population the distribution of BMI is comparable, however, there is quite a discrepancy
between BMI distribution in these two samples and the general population as indicated
in Figure 8 (Morgan et. al., 2012).
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Figure 7 – BMI distribution of participants

Figure 8 – Comparisons of BMI in the general population, people living with
psychotic illness population and the sample population.
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Based on results of People living with psychotic illness 2010, Australian Government.
The length of time a person had been diagnosed with their psychotic illness ranged
from 6 months to 50 years with a mean of 14.5 years (SD=9.2 years). It is evident from
Figure 9 that more people access the mental health services in the early stages of their
illness. The age on onset of mental illness ranged from self-reported 6 years of age to
51 years of age with 62% of participants having developed their illness before age 25.

Figure 9 - Length of time since diagnosis of mental illness

Medications were grouped according to antipsychotic medication, other mental
health medications and all other medications. All patients were on antipsychotic
medication due to the nature of their illness, 53/100 participants were taking other
mental health medication including mood stabilisers and antidepressants and 39/100
participants were taking other medication for conditions amongst which were
diabetes, high blood pressure and high cholesterol. Two thirds (66/99) of people
were taking some form of medication with headache as a common or very common
side effect.
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Diabetes was the most common co-morbidity identified with 15% (15/100) people
reporting this condition. Only 3/100 people identified co-morbid musculoskeletal
problems.

5.3

Headache characteristics

The prevalence of headache within the last twelve months was 57% (57/100).
Prevalence rates by gender were very similar with 58% (38/66) of males and 56%
(19/34) of females reporting headache in the last 12 months.

Within the headache population 23% (13/57) experienced a headache on the day of
interview and 68.5% (39/57) had experienced a headache in the last month. The
majority of participants who experienced headache only reported having one type of
headache (81%, 46/57). Of those people who did experience more than one type of
headache (11/57) only one person completed a second questionnaire. Participants had
started experiencing headaches from as recently as 5 months ago to as long as 50 years
ago with a median value for length of time experiencing headaches of 20 years
(IQR=5.5-24.5 years). Participants started getting headaches from as young as 6 years
of age through to 58 years of age with a median age of 19 years (IQR=13-31.3 years).
Four participants were missing data for this part of the questionnaire as they reported
finding it too hard to remember when they first started experiencing headache.
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Figure 10 - Length of time participants have been experiencing headaches

Table 5 records how frequently people experienced headache. Sixty percent of people
only experienced a headache once a month or less. Twelve percent (7/57) people
experienced headache daily with a further 18% (10/57) experiencing headache at least
weekly.

Table 5 - Frequency of headaches
Frequency

Percentage of headache sufferers

Daily

12% (7/57)

3-4/week

3.5% (2/57)

1-2/week

14% (8/57)

1/fortnight

10.5% (6/57)

1/month

31% (18/57)

Less than once a month

29% (16/57)
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Headaches were reported to last from as short a time as 10 seconds to being continuous
with no relief. Figure 11 highlights that this distribution is not normal with a significant
skew toward headaches of shorter duration times. When people with continuous
headache are excluded the median value for length of headache time was 3 hours
(IQR=1– 8 hours).
Figure 11 – Length of time headache lasts in hours
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Analysis of the intensity of headache pain using the 0-10 Visual Analogue Scale
(VAS) showed (Figure 12) that average headache pain intensity ranged from 0.5/10 to
10/10 with a mean of 5.8 (SD=2.1). A negative skewness value (-0.35) indicates a
clustering of scores to the higher end of the scale. All participants completed this
section of the questionnaire including the person who completed two questionnaire
giving a total of 58 responses. Forty one percent (24/58) reported having neck pain or
stiffness at the time of their headache.
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Figure 12 – Average headache pain intensity scores

5.4

Relationship between clinical characteristics and headache

Males made up 67% (38/57) of people experiencing headache. Within both the male
and female population there was a 58% and 56% prevalence respectively of
participants who experienced headache (male 38/66, female 19/34). The univariate
logistic regression found no significant association between gender and headache
(p=.87) with an odds ratio of 1.07, 95% CI [0.47–2.47].

The mean age of people experiencing headache was 37.7 years (SD=9.4 years) and
40.2 years (SD=11.5 years) for people who did not experience headache. There was
no significant relationship between age and presence of headache (p=.25) with an odds
ratio of 0.99, 95% CI [0.94-1.02].

Within the headache population 53% were inpatients (30/57) and 47% (27/57) were
outpatients. Inpatient/outpatient status did not impact significantly on presence of
headache (p=.08) with an odds ratio of 2.07, 95% CI [0.92-4.68].
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There was no significant relationship between length of time from diagnosis of mental
illness and presence of headache (p=.61). The odds ratio for length of illness is 0.99,
95% CI [0.95-1.03]) suggesting no significant link between chronicity of
schizophrenia or schizoaffective disorder and headache.

Those participants experiencing headache had a mean BMI of 29.67 (SD=7.4)
compared to those not experiencing headache M=28.96 (SD=5.48). BMI did not have
a significant impact on headache status (p=.58) with an odds ratio of 1.02, 95% CI
[0.96-1.08].

All medications listed by participants were examined to determine the impact
medication usage might have on headache status. Figure 13 shows the number of
people taking medications with headache as either a common or rare side effect. It is
apparent that almost two thirds of participants (66/99) were taking some form of
medication that lists headache as a common or very common side effect. One person
had missing data about their medications and was not included in this or any
subsequent medication calculations. This person did not experience headache. Within
the headache only population these figures were almost the same 64% (37/57) taking
any medication with side effect of headache.
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Figure 13 – Medication with headache as side effect
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Taking medication with headache as a common or very common side effect was not
significantly related to headache status (p=.89). The odds ratio was 0.94 with 95% CI
[0.40-2.19] suggesting no difference between taking medication with headache as a
common side effect or medication with headache as a rare side effect.

Diabetes was the most commonly occurring comorbid health problem, though only
10% of headaches sufferers reported having diabetes. Diabetes did not impact on
presence of headache (p=.15) with an odds ratio of 0.44 and 95% CI [0.14-1.37].
A multivariate logistic regression was performed to model the combined explanatory
power on potentially significant variables. Variables with p<.2 from the univariate
analysis were considered as explanatory factors in the multivariate analysis. The
variables included were inpatient/outpatient status and diabetes. This model was not
statistically significant X²(2,n=100)=5.36,p=.07 indicating the model had difficulty
distinguishing between those who had headache and those who didn’t. This model
explained between 5.2% (Cox and Snell R square) and 7.0% (Nagelkerke R square) of
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variance in headache and classified 60% of cases correctly. As can be seen in Table 6
neither variable had a unique significant influence on headache.

Table 6 - Logistic Regression predicting likelihood of headache
95% CI for
B

Inpatient/

S.E

Wald

df

p

Odds
Ratio

odds ratio
Lower

Upper

.76

.42

3.21

1

.07

2.13

0.93

4.86

-.86

.58

2.15

1

.14

.43

0.14

1.33

outpatient
Diabetes

To evaluate the strength of the relationship between pain and chronicity of
schizophrenia or schizoaffective disorder, a Pearson product-moment correlation was
performed using headache pain intensity and length of illness. There was no
significant relationship between pain intensity and length of illness detected (r=.098,
p=.465).

5.5

Headache classification

Using the algorithm developed in the pilot study two physiotherapists independently
classified all the headaches into migraine (MH), tension type (TTH), cervicogenic
(CGH) and other (OH) headache. There was agreement on 47 out of 58 questionnaires.
One rater classified 20/58 headache as MH, 17/58 as TTH, 5/58 as CHG. and 16/58 as
OH while the other rater identified 15/58 as MH, 20/58 as TTH, 5/58 as CHG. and
18/58 as OH. The Kappa Measure of Agreement value was 0.74, 95% CI[0.59-0.88]
with significance of p<0.0005 indicating good agreement according to Peat (2002).
Following this the physiotherapists met together and discussed and reached agreement
on all participants without needing to refer to a third person.

Classification of headache determined OH to be the most common type of headache
experienced followed by MH and TTH. As expected CGH was the least prevalent.
Prevalence rates are listed in Table 7.
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Table 7 – Prevalence of headache by classification
Headache type

Total Sample Population

Headache population only

Migraine

17.8%

31.0%

TTH

15.8%

27.6%

CGH

4.85%

8.6%

Other

18.8%

32.8%

5.6

Relationship between clinical characteristics and specific

headache types
5.6.1 – Cervicogenic Headache
The age of people experiencing CGH ranged from 37 years to 59 years with a mean
age of 47.2 years (SD=8.3 years). Gender was evenly divided with 2 females and 3
males. Two people were inpatients and 3 were outpatients. The mean BMI was 27
(SD=6.6) with a range from 21.2 to 38. People with CGH had been diagnosed with a
mental illness from as recently as 2 years ago to as long as 23 years ago with a mean
of 16 years (SD=8.3 years). The age range of onset of headache was from 13 years of
age to 58 years of age with a mean of 37 years of age (SD=14.5 years). Three of the 5
people experiencing CGH were taking medications that listed headache as a common
or very common side effect. No people experiencing CGH had a history of diabetes.

As can be seen in Table 8 none of the variables age, gender, BMI, LOI, diabetes or
medication had statistically significant impact on presence of CGH. No multivariate
logistic regression was performed as age was the only variable that had a p<.2.
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Table 8 Univariate models for explanatory variables for CGH in the total
population
Variable

95% CI

Odds

P value

Ratio

Lower

Upper

Inpatient Outpatient

.82

.81

.13

5.05

Age

.08

1.08

.99

1.19

Gender

.77

.76

.12

4.79

LOI

.71

1.02

.93

1.12

BMI

.41

.93

.79

1.10

Medication

.75

.74

.12

4.65

Diabetes

1.0

.00

.00

Within the headache only population age impacted significantly on CGH (p=.03) with
an odds ratio of 1.14, 95% CI [1.01–1.29]. This suggests that there is relationship with
age and CGH (Table 9). This is consistent with the clinical characteristics of CGH in
the general population.

Table 9 Univariate models for explanatory variables for CGH in the headache
only population
Variable

95% CI

Odds

P value

Ratio

Lower

Upper

Inpatient Outpatient

.53

.55

.09

3.58

Age

.03

1.14

1.01

1.29

Gender

.79

.77

.12

5.04

LOI

.66

1.02

.93

1.12

BMI

.40

.93

.79

1.10

Medication

.81

.79

.12

5.19

Diabetes

1.0

.00

.00

A univariate logistic regression using the variable aged² in the headache only
population was also conducted to determine if the relationship between CGH and age
followed a linear progression (Table 10). The impact of aged² on CGH was also
significant p=.03 indicating that the association of age and CGH is not linear meaning
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that while age impacts on presence of CGH there is not a direct association with each
year of aging.

Table 10 - Logistic Regression predicting likelihood of CGH by age in headache
only population.
95% CI for
B

Total
population

S.E

Wald

df

p

Odds
Ratio

odds ratio
Lower Upper

Age

.081

.046

3.095

1

.08

1.084

.991

1.187

Age

.135

.062

4.707

1

.03

1.144

1.013

1.293

Age²

.001

.001

5.010

1

.03

1.001

1.000

1.003

Headache
only
population

5.6.2 – Migraine Headache
Thirteen males and 5 females experienced MH with inpatient/outpatient status evenly
spread with 9 in each setting. The mean age of people with MH was 24.8 years (SD=6.7
years) and ranged from 24 years to 57 years. BMI of people with MH ranged from
21.5 to 55.5 with a mean BMI of 29.8 (SD=8.0). The most recent diagnosis of mental
illness was 1 year previously with the longest being 27 year earlier. Mean time from
diagnosis was 11.4 years (SD=7.5 years). The youngest age that anyone with MH
started experiencing their headache was 6 years old and the oldest was 36 years. The
average age of onset of MH was 19 years (SD=9.0 years) with average age of onset
for males 19.4 years (SD=9.3 years) and 18.2 years (SD-10.1 years) for females.
Fifteen of the people experiencing MH were taking medication that listed headache as
a common or very common side effect. Thirty three percent (6/18) of the migraine
population reported neck pain or stiffness when they have a headache. Three people
(3/18) reported the comorbidity of diabetes.

The logistic regression results presented first are based on the total population. Table
11 summarises the information from univariate logistic regression models exploring
the impact of the explanatory variables of age, gender, BMI, LOI, medication and
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diabetes on MH within the total sample population. Taking medication with headache
as a common or very common side effect was significant (p=.05) within the total
population.

Table 11 - Univariate models for explanatory variables for MH in the total
population
Variable

95% CI

Odds

P value

Ratio

Lower

Upper

Inpatient Outpatient

.64

1.28

.46

3.55

Age

.08

.95

.90

1.01

Gender

.54

1.42

.46

4.39

LOI

.12

.95

.89

1.01

BMI

.79

1.01

.94

1.09

Medication

.05

4.56

.98

21.30

Diabetes

.83

1.17

.29

4.65

A multivariate logistic regression was performed using variables with p<.2 to
determine the combined effect they might have on the presence of headache (Table
12). The variables included were age (p=.08), LOI (p=.12) and medication (p=.05).
This model was statistically significant X²(2,n=99)=7.694,p=.05 indicating the model
could distinguish between those who had MH and those who didn’t. The model
classified 82.8% of cases correctly and could explain between 7.5% (Cox & Snell R
square) and 12.5% (Nagelkerke R Square) of the variance in MH. Within this model
no variable had a statistically significant impact on presence of MH.
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Table 12 - Logistic Regression predicting likelihood of MH by medication, age
and LOI in total population.
95% CI for odds
B

S.E

Wald

df

p

Odds

ratio

Ratio

Lower

Upper

Medication

-1.520

.794

3.662

1

.06

4.57

.964

21.684

Age

-.034

.037

.881

1

.35

.966

.899

1.038

LOI

-.019

.042

.205

1

.65

.981

.903

1.066

Amongst the headache only population the univariate logistic regression model found
the impact of medication with headache as a common side effect was statistically
significant (p=.03) with an odds ratio of 6.14, 95% CI [1.24-30.44]. This indicated that
people experiencing headache who are taking medication with headache as a common
or very common side effect are 6.14 times more likely to experience MH. None of the
other variables age, gender, BMI, LOI and diabetes had statistically significant impact
on presence of MH (Table 13).

Table 13 Univariate models for explanatory variables for MH in the headache
only population
Variable

95% CI

Odds

P value

Ratio

Lower

Upper

Inpatient Outpatient

.72

.82

.27

2.49

Age

.13

.95

.89

1.01

Gender

.47

1.56

.46

5.25

LOI

.13

.95

.88

1.02

BMI

.96

1.00

.93

1.08

Medication

.03

6.14

1.24

30.44

Diabetes

.30

2.47

.45

13.63

A multivariate logistic regression was conducted exploring the impact of age, LOI and
medication on MH within the headache only population (Table 14). The logistic
regression model was statistically significant (X²(1,N=57)=9.797,p=.02). It could
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explain between 15.8% (Cox & Snell R square) and 22.4% (Nagelkerke R Square) of
the variance in MH and correctly classify 61.4% of cases. Within this model
medication remained statistically significant (p=.02) with and odds ratio of 7.47, 95%
CI [1.39-40.02] indicating that a person taking medication with headache as a common
or very common side effect was 7.47 times more likely to experience MH.
Table 14 – Multivariate logistic regression for impact of medication, age and LOI
on MH within the headache only population
95% CI for odds
B

S.E

Wald

df

p

Odds
Ratio

ratio
Lower

Upper

Medication

-2.011

.856

5.512

1

.02

7.468

1.394

40.016

Age

-.049

.044

1.273

1

.26

.952

.874

1.037

LOI

-.020

.044

.200

1

.66

.981

.900

1.068

5.6.3 – Tension Type Headache
People experiencing TTH ranged in age from 23 years to 51 years (Mean=50 years,
SD=8.4 years). Of the 6 females and 10 males classified with TTH, 5 were inpatients
and 11 were outpatients. BMI of this group ranged from 18 to 38.7 with a mean BMI
of 29 (SD=5.8). The length of time since diagnosed with mental illness ranged from
as recently as 2 years to 21 years with a mean time of 13.7 years since diagnosis
(SD=5.4 years). People with TTH started experiencing them from as young as 10 years
old to as old as 35 years old with a mean age of onset of headache 19 years (SD=8.1
years). A large proportion of the participants with TTH (11/16) were taking medication
that listed headache as a common or very common side effect. One quarter (4/16) of
people with TTH had neck pain or stiffness at the time of their headache. No people
experiencing TTH reported a history of diabetes.

Univariate logistic regressions were conducted on the total population using the
explanatory variables of age, gender, BMI, LOI, diabetes and medication. No one
variable had a statistically significant impact on the presence of TTH within this
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population. (Table 15) No multivariate logistic regression was conducted as no
variables had a p<.2.

Table 15 Univariate models for explanatory variables for TTH in the total
population
Variable

95% CI

Odds

P value

Ratio

Lower

Upper

Inpatient Outpatient

.23

.50

.16

1.56

Age

.60

.99

.94

1.04

Gender

.75

.83

.28

2.53

LOI

.69

.99

.93

1.05

BMI

.81

.99

.91

1.08

Medication

.85

1.12

.35

3.54

Diabetes

.99

.00

.00

The univariate logistic regression models exploring the impact of these variables on
TTH within the headache only population determined that inpatient/outpatient status
was the only variable that was statistically significant (p=.04) (Table 16). The odds
ratio of 0.28, (95% CI [0.08-0.95]) being less than 1, indicates that as an inpatient the
odds of headache being TTH was 0.28 less likely.

Table 16 Univariate models for explanatory variables for TTH in the headache
only population
Variable

95% CI

Odds

P value

Ratio

Lower

Upper

Inpatient Outpatient

.04

.28

.08

.95

Age

.96

1.00

.94

1.06

Gender

.77

.83

.25

2.77

LOI

.77

.99

.93

4.06

BMI

.68

.98

.90

1.07

Medication

.71

1.27

.37

4.36

Diabetes

1.0

.00

.00
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5.6.4 – Other Headache
Demographics of the group of people experiencing other headaches were 12 males and
7 females ranging in age from 19 years to 56 years with a mean age of 38 years
(SD=11.3 years). Fifteen of this group were inpatients with only 4 in the outpatient
setting. The mean BMI of this group was 30.8 (SD=8.3) with a range from 17 through
to 54. This group of people had the largest distribution of length of illness ranging
from 6 months since diagnosis to 50 years with a mean length of time from diagnosis
of schizophrenia or schizoaffective disorder of 16.9 years (SD=12.7 years). There was
also a large variation in age of onset of headaches from as young as 6 years old to 48
years old with a mean age of 14.5 years (SD=6.8 years). Less than half of the people
experiencing OH were taking medication which listed headache as a common or very
common side effect (9/19). Almost half (9/19) of people experiencing OH reported
feeling neck pain or stiffness when they had a headache. Three people in this cohort
reported having diabetes.

The impact of age, gender, inpatient/outpatient status, BMI. LOI, medication and
diabetes on OH amongst the whole population was explored using univariate logistic
regressions. Two variables were statistically significant (Table 17). With a p<.01 and
an odds ratio of 5.76, 95% CI [1.74-19.07] the chances of developing OH is 5.76 times
more likely as an inpatient. Taking medication with headache as a common or very
common side effect was also significant (p=.03) with an odds ratio of 0.32, 95% CI
[0.11-0.90] meaning a person taking this medication was 0.32 times less likely to
experience OH. The odds ratio for a person taking medication that does not have
headache as a side effect is 3.15, 95% CI [1.11-8.99] means that a person taking
medication without headache as a side effect is actually 3.15 times more likely to
experience OH.
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Table 17 - Univariate models for explanatory variables for OH in the total
population
Variable

95% CI

Odds

P value

Ratio

Lower

Upper

Inpatient Outpatient

.00

5.76

1.74

19.07

Age

.83

.99

.95

1.05

Gender

.95

1.04

.35

3.06

LOI

.28

1.03

.98

1.08

BMI

.26

1.04

.97

1.12

Medication

.03

.32

.11

.90

Diabetes

.83

1.16

.29

4.65

A multivariate logistic regression exploring the impact of inpatient/outpatient status
and medication on OH was undertaken to explore how they impacted on OH in
combination with each other (Table 18). This model was statistically significant
(X²(1,N=99)=14.095,p=.001) being able to explain between 13.3% (Cox and Snell R
square) and 21.7% (Nagelkerke R square) of the OH variance and classify 81.8% of
cases correctly. Within the total population an inpatient (p=.01) is 5.85 (95% CI [1.7119.98]) times more likely to experience OH and a person taking medication with
headache as a common or very common side effect (p=.04) is 0.30 (95% CI [0.100.92]) times less likely to experience OH. The odds ratio for a person taking
medication that does not have headache as a side effect is 3.32, 95% CI [1.09-10.09]
means that a person taking this medication is 3.3 times more likely to experience OH.
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Table 18 - Logistic Regression predicting likelihood of OH by medication and
inpatient/outpatient status in total population.
95% CI for odds
B

S.E

Wald

df

p

Odds

ratio

Ratio

Lower

Upper

Medication

1.199

.568

4.453

1

.04

.302

.099

.918

Patient

1.766

.627

7.941

1

.01

5.849

1.712

19.982

Within the headache only population the univariate logistic regression model found
only two variables to have a statistically significant impact on OH (Table 19). Once
again inpatient status had a statistically significant impact on OH (p=.01) and when
considered within the headache only population the odds ratio of 5.39 (95% CI [1.5119.28]) indicates that as an inpatient the odds of headache being OH was 5.39 more
likely. Taking medication with headache as a common or very common side effect
(p=.01) meant a person in the headache only population was 0.23 (95% CI [0.07-0.77])
times less likely to experience OH. Once again when looking at medication where
headache is not a side effect the odds ratio is 4.43, 95% CI [1.36-14.40] meaning that
a person taking medication that does not have a side effect of headache is 4.4 times
more likely to experience OH.

Table 19 Univariate models for explanatory variables for OH in the headache
only population
Variable

95% CI

Odds

P value

Ratio

Lower

Upper

Inpatient Outpatient

.01

5.39

1.51

19.28

Age

.88

1.01

.95

1.07

Gender

.79

.86

.27

2.70

LOI

.14

1.05

.99

1.12

BMI

.48

1.03

.96

1.11

Medication

.01

.23

.07

.77

Diabetes

.35

2.25

.41

12.38
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A multivariate logistic regression was also undertaken in the headache only population
exploring the impact of inpatient/outpatient status and medication on OH as can be
seen in Table 20. This model was statistically significant (X²(1,N=57)=12.395,p=.002)
being able to explain between 19.5%% (Cox and Snell R square) and 27.1%
(Nagelkerke R square) of the OH variance and classify 71.9% of cases correctly.
Within the total population an inpatient (p=.02) is 4.8 times more likely to experience
OH (95% CI [1.27-18.27]) and a person taking medication where headache is a
common or very common side effect (p=.03) is 0.24 times less likely to experience
OH (95% CI [0.07-0.85]). Similarly to previous examples the person taking
medication that does not have a side effect of headache is more likely to experience
OH (OR=4.11, 95% CI [1.18-14.37]).

Table 20 - Logistic Regression predicting likelihood of OH by medication and
inpatient/outpatient status in headache only population.
95% CI for odds
B

S.E

Wald

df

p

Odds
Ratio

ratio
Lower

Upper

Medication

1.413

.639

4.896

1

.03

.243

.070

.851

Patient

1.571

.681

5.324

1

.02

4.811

1.267

18.269

5.5

Hospital admission

Only seven people (12%, 7/58) associated headache with being admitted to hospital
suggesting that unlike previous studies this is not a reason for people to fail to report
the existence of headache. The following table (Table 21) indicates the headache types
experienced by these people.
Table 21 – Association to hospital admission based on headache classification
MH
Number

2/18

TTH
3/16

CGH
0/5
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OH
2/19

5.6

Quality of Life

Quality of Life relating to Bodily Pain (BP), Role Physical (RP) and Social
Functioning (SF) of the 36 people who had experienced headache in the previous four
weeks and completed the questionnaire were scored used the RAND 36 Item Health
Survey 1.0 scoring system (Ware & Sherbourne, 1992).
5.6.1 Impact of headache on QOL
The scoring system used in the RAND 36-Item Health Survey is designed to deliver a
score between 0 and 100. The closer the score is to 100 the less impact there is on
QOL. Analysis of each of the individual SF-36 items showed normality as did the
category of calculated BP scores with a mean of 60.8 (SD=19.98). The categories SF
and RP calculated scores were not normally distributed with the median for SF=75
(IQR 50-100) and the median for RP=50 (IQR 0-100). The high and low scores of all
headache types are represented in Figure 14. The mean scores for BP and median score
for SF are above 50 suggesting less impact on functioning from headache while the
median score for RP is 50 suggetsing moderate impact.

Figure 14 - High/low and mean/median scores of BP, SF and RP
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QOL variable
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A Pearson correlation was undertaken to determine if there was any correlations
between quality of life scores (QOL) for BP and length of headache (LOH), frequency
of headache (FOH) and pain (VAS). Spearman correlations were undertaken to
determine if there was any relationship with QOL scores for SF, RP and length of
headache (LOH), frequency of headache (FOH) and pain (VAS). Frequency of
headache was the only factor that had a statistically significant correlation to QOL.
There was a medium correlation between FOH and SF (ρ=-.44, n=56, p=.00), BP (r=.41, n=56, p=.00) and RP (ρ=-.32, n=56, p=.01). The more frequent the headache the
more impact on SF, BP and RP.
5.6.2 Impact of specific headache on QOL
Comparing the mean score for BP and the median scores for SF and RP against each
headache type it is clear to see that CGH and OH scored significantly worse on all
three measures but in particular, along with OH, on role physical (Figure 15).

Figure 15 - Mean score for BP, and median score for SF and RP of each headache
classification
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OH

Tests were conducted to determine if there were any relationships between quality of
life scores for BP, SF, RP and headache classification. A one way between groups
analysis of variance was conducted to explore if any headache type of MH, TTH, CGH
or OH impacted on BP. There is no significant relationship between bodily pain scores
and any specific headache classification F(3,32)=.21, p=.89. A non-parametric
Kruskal-Wallis test was conducted to explore if any headache type impacted on SF.
No significant differences were found x²(3, n=36) =3.43, p=.33. A non-parametric
Kruskal-Wallis test was also conducted to explore if any headache type impacted on
RP. Once again no significant differences were found x²(5, n=36) =9.07, p=.11.

FOH was shown to have an impact on QOL within the headache population of the
sample. However, there was no significant connection between QOL scores and any
specific headache classification suggesting frequency of headache rather than the type
of headache has more impact on QOL for the individual with schizophrenia and
schizoaffective disorder who experiences headache.

5.7

Management

Table 22 provides a summary techniques used by participants to relieve their
headaches. The table is presented in order of most common to least common.
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Table 22 – Management of Headache
Strategies used to manage Headache

Number

Medication

47

Sleep

40

Massage

12

Heat or Ice

7

Drink of water

6

Relaxation

5

Physical activity and stretching

4

Neck exercises

3

Cannabis or other drugs

3

Pressure points on thumb or head

3

Alcohol

2

Chiropractic

2

Unknown

2

Correct posture

1

Eat

1

Depot

1

Eighty nine percent (16/18) of people experiencing MH took medication to relieve
their headache and 78% (14/18) used sleep. The most common management for TTH
was also medication with 75% (12/16) using medication for relief of symptoms. Sleep
was also the second most prevalent form of treatment for TTH with 56% (9/16) of
participants sleeping to relieve headache. No people used relaxation as a form of
treatment and only 12.5% (2/16) people used massage.

No person experiencing headache reported receiving assessment or treatment from a
physiotherapist. One person experiencing CGH attended chiropractic for their
headache and another used pressure on the head. One person used massage while 4/5
took medication. No-one undertook neck exercises. Medication (79%, n=15/19) and
sleep (74%, n= 14/19) were also the most common treatments used by people who
experienced OH to relieve the symptoms.
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CHAPTER SIX
Discussion of findings
6.1

Summary of results

The aims of this study were to determine the prevalence, characteristics, management
and impact of headache in people with schizophrenia and schizoaffective disorder.
One hundred and forty eight eligible patients from the Fremantle Hospital, Mental
Health Services with a diagnosis of schizophrenia or schizoaffective disorder were
invited to an interview to complete a questionnaire about headache. Forty-eight people
declined to participate, leaving a sample of 100 ranging from 19 years to 60 years of
age. Fifty-five people were recruited from the outpatient depot clinic and forty-five
from the inpatient wards.

Sixty six of the participants were male and the mean age of all participants was 38.8
years. The BMI of participants ranged between underweight (16.8) and morbidly obese
(55.5) with a mean BMI of 29.5. Participants had been diagnosed with either
schizophrenia or schizoaffective disorder for between 5 months and 50 years with the
mean length of illness being 14.6 years. All participants were on antipsychotic
medication, 53 were taking other mental health medication and 39 were taking
medication for other physical medical conditions. Sixty six people were taking some
medication that had headache as a common side effect. The most common comorbid
physical illness was diabetes with 15/100 people reporting the condition. Forty-one
percent (24/58) of headache sufferers also experienced neck pain or stiffness.

The twelve month prevalence of headache in this population was 57% with 81% of
these people only experiencing one type of headache. People had been experiencing
headache from between 5 months and 50 years with a median time of 20 years. Some
participants were as young as 6 years old when they started experiencing headache.
Only 7 of the 57 people who experienced headache reported having them on a daily
basis. Headaches lasted from 10 seconds through to continuous with the median time
being 3 hours. The average reported intensity of pain associated with headache was
5.8/10.
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Gender, age, inpatient/outpatient status, length of mental illness, BMI, medication type
or diabetes did not impact on presence of headache. There was no correlation between
chronicity of illness and intensity of pain associated with headache.

Twelve month prevalence of CGH was 4.9%, MH was 17.8%, TTH was 15.8% and
OH was 18.8%. Age was shown to impact on CGH within the headache only
population in a non-linear fashion. Within the headache only population people taking
medication with headache as a side effect were up to 7 times more likely to develop
MH. People who are inpatients have up to 4.8 times more likelihood of developing OH
and those taking medication with headache as a common or very common side effect
are nearly 0.25 less likely to develop an OH.

The frequency of headache impacted on quality of life with more frequent headaches
impacting moderately on social function, bodily pain and role physical. There was no
correlation between headache type and QOL suggesting frequency of headache is a
bigger factor in impact on QOL than type of headache.
Participants reported utilising a wide variety of strategies to manage their headache,
often in combinations. The most common strategies reported were medication, sleep
and massage. No participants reported seeking advice or treatment from a
physiotherapist to help manage their headache. This includes participants who
experience CGH, though one of these participants was receiving spinal manipulation
from a chiropractor.

6.2

Participants and recruitment

The 100 people recruited represented a good cross section of the Australian population
of people diagnosed with schizophrenia and schizoaffective disorder with
demographic and clinical characteristics comparable to those of the participants in the
Australian Government survey ‘People living with psychotic illness 2010’ (Morgan et
al., 2011). This finding supports that the recruitment process of using consecutive
sampling in two clusters, one in the inpatient setting and the other in the outpatient
depot clinic, was appropriate and captured a true representation of people with these
illnesses.
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Non-participation is a common occurrence in research involving people with
schizophrenia and schizo-affective disorder (Haapea et al., 2007). Haapea et al. (2007)
report participation rates varying between 53% and 85% which suggests that the 67%
response rate in this study is appropriate for this demographic. Schafer et al. (2011)
determined that the more unwell the person with schizophrenia the less likely they are
to engage in research, however, this was not the case in this study. The participation
rate was higher in the inpatient setting (71%) where people are deemed more acutely
unwell than the in the outpatient setting (65%) (Schäfer et al., 2011). Within both
populations the most common reasons for non-participation were internally driven
reasons such as lack of interest, not wanting to sign a consent form or being too tired.
Within the outpatient population there were other more pragmatic reasons for nonparticipation that could have affected the response rate, such as being in a hurry to
attend another appointment, having children waiting for them or feeling unwell after
just completing a difficult medical appointment with their psychiatrist. These
externally driven reasons for non-participation may have influenced the different
response rate between inpatient and outpatient settings or this anomaly may simply
exist because in the inpatient setting there was more opportunity for the interviewer to
spend time with the potential participant to better inform them about the research.
Being better informed might have made people more inclined to engage in the research
resulting in an improved participation rate in this population.

A Finish study by Haapea et al. (2007) determined that men were less likely to engage
in psychiatric research, a finding not supported by this study. Within the inpatient
setting 80% of men meeting the selection criteria who were approached agreed to
participate in the study while only 53% of women agreed to participate. In the
outpatient setting participation rate was more equitable with 63% for males and 67%
for females approached agreeing to participate. If it is considered that people with
schizophrenia who are more severely ill are less likely to participate in questionnaires
(Schäfer et al., 2011) then it would be expected that there would be a higher refusal
rate amongst inpatients. This gender discrepancy in participation rate in the inpatient
setting could indicate that that women inpatients were more unwell than the men.
There is no way to measure this possibility.
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A fear of compromising privacy or concerns that information might be made available
to a third party were reasons identified by Schafer et al. (2011) for non-participation
of people within this population (Schäfer et al., 2011). Prior to starting this project
these concerns were also considered as potential problems and possible barriers for
participation. However, these fears were possibly over stated as in the outpatient
population the main reasons given for non-participation were lack of interest/not
wanting to participate (12/30) or simply for no reason (4/30). Only 3/30 (10%) refusals
in the outpatient setting was because that person did not want to sign a consent form.
In the inpatient setting the main reason given for non-participation was also lack of
interest/not wanting to participate (12/18) but 4/18 people in the inpatient setting
(22.2%) refused because they did not want to sign a consent form. Fears around
privacy may have influenced these potential participants because initially they had
given verbal consent to participate but once the researcher asked them to sign the
consent form they refused, citing that they did not want to sign a written consent form
and withdrew from the study. Participants were not pressured to say why they would
not sign the consent form so it cannot be known what their reasons were for refusal.
Privacy could have been an issue for them but it is also possible that people who were
voluntary patients may have feared that they were being tricked into signing something
to make them involuntary patients. There is also the possibility that they may have had
paranoid tendencies or as described by Schafer et al. (2011) been concerned that
information might be passed onto a third party. There is no easy solution to the problem
of people refusing to sign consent forms as this is an essential component of ethical
research, though greater time might need to be dedicated to allaying fears of invasion
of privacy when recruiting people with mental health problems.
6.2.1 Demographics of the sample population
The prevalence of psychotic illness in Australia has been determined to be 60% in
males and 40% in females (Morgan et al., 2011). In their systematic review of
incidence, prevalence and mortality of schizophrenia, McGrath et al. (2008) also
determined a prevalence of 60% males (McGrath et al., 2008). The male (66%) and
female (34%) participation rates in this study are comparable with both studies
indicating a good gender representation of people with schizophrenia in the sample
population.
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In contrast, however, a review of the literature on schizoaffective disorder by Abrams
et al. (2008) identified that schizoaffective disorder is more common amongst women
with a prevalence of around 66%. Based on this, the higher male prevalence in the
sample population suggests that it might not be a good representation of people with
schizoaffective disorder. It could be surmised that more participants had a diagnosis
of schizophrenia than schizoaffective disorder. While a diagnosis of schizophrenia or
schizoaffective disorder was an inclusion criterion the diagnosis of each participant
was not recorded so it was not possible to explore the male/female prevalence in each
individual disorder.

This concept of a higher representation of people with schizophrenia than
schizoaffective disorder within the sample cohort is also supported by the findings of
Perala et al. (2007). In their study of 8,082 people in Finland they found a lifetime
prevalence of schizophrenia to be 0.87%, more than double the 0.32% for
schizoaffective disorder (Perälä et al., 2007). Although their study was limited to
people over 30 years of age Perala et al. (2007) identified that their prevalence findings
agreed with other studies that had also determined prevalence of schizoaffective
disorder to be around half of that for schizophrenia (Perala et al., 2007). Knowing that
the prevalence of schizophrenia is higher than that for schizoaffective disorder and
considering that there were more males than females in the sample population it is
reasonable to assume that more people had the diagnosis of schizophrenia.
The mean age of people surveyed in the Australian Government survey ‘People living
with psychotic illness 2010’ was 39 years with ages ranging from 18 year to 64 years.
These figures are comparative to this headache study where participants’ ages ranged
from 19 year to 60 years with a mean age of 39 years. Symptoms of schizophrenia and
schizoaffective disorder usually appear in young adults with onset of the majority of
cases before 25 years of age (Abrams et al., 2008; McGrath et al., 2008; Morgan et al.,
2012). In our sample 62% of participants developed their illness before age 25
consistent with the literature further supporting that the study recruited a good
representative sample of people with psychotic illness.

Obesity is a characteristic commonly observed in people with psychotic illness, partly
as an unwanted side effect of psychotropic medication and partly due to lifestyle
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factors associated with negative symptoms such as sedentary lifestyle (McGrath et al.,
2008; Vancampfort et al., 2011). Within the general population 34% of people are
considered overweight with a further 21% obese (Morgan et al 2011). Within this
sample population 31% of people were identified as overweight with a further 43%
considered obese, a finding more consistent with the psychotic population in the
Morgan et al. (2011) study where 28% of people had BMI in the overweight range and
45% in the obese range. Both the Morgan et al. (2011) study and this headache study
reveal a worrying trend for people with psychotic illness with about three quarters of
people being overweight or obese as opposed to 55% in the general population. These
results support the perception of poor management of physical health among this
demographic.

One consequence of increased BMI is diabetes yet despite almost 75% of the sample
population being overweight or obese only 15% (15/100) of participants were
identified as having diabetes. Presence of diabetes was determined either by selfreporting and/or if diabetic medications were listed in the medication chart. In the 2010
Australian study population of people with psychotic illness both self-reporting and a
more accurate fasting blood triglyceride level was used to identify if a person had
diabetes (Morgan et al, 2011). A slightly higher incidence of 20.5% of people having
diabetes could be attributed to the different methods used to determine presence of
diabetes. It is possible that some people in the Australian national study may have been
unaware that they had diabetes and would not have reported it until they received
results of the blood tests measuring fasting blood triglyceride level taken during the
study. If fasting triglyceride levels had also been tested in this headache study sample
population a higher prevalence of diabetes may have been found. This is, however,
only supposition. The sample population still reported a higher prevalence of diabetes
than the 6.2% found in the general population (Morgan et al, 2011).

6.3

Prevalence of headache

The prevalence of headache in people with schizophrenia or schizoaffective disorder
within the previous 12 months was calculated as 57%. As explained previously there
has been little research into the prevalence of headache within the schizophrenic
population and none in the schizoaffective disorder population (Lake, 3rd et al., 2006;
Lake et al., 2005). In 1999 Kuritzky et al. asked 108 outpatients with a diagnosis of
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‘chronic’ schizophrenia (diagnosis for more than 2 years) whether they had ever
experienced headache and determined a lifetime prevalence of 48%. A control group
of 100 people without schizophrenia returned a headache prevalence of 41%. These
findings are a little inconsistent with the findings of our headache survey. This may be
due to the narrower age range employed by Kuritzky et al. (28-60 years) although this
is unlikely as our study did not find any correlation to age and presence of headache.

It is possible that the discrepancy in prevalence could be due to the phrasing of the
question regarding presence of headache. In the Kuritzky et al. (1999) study
participants were asked if they were ‘subject to headache’ and if the person responded
‘no’, no further questioning was undertaken. It is possible that people who experienced
infrequent headaches may not have thought being ‘subject to headache’ applied to
them associating this term to people with more regular headaches. In the current study
many people initially stated that they did not get headaches but subsequently answered
‘yes’ to having a headache in the last 12 months. In order to determine accurate
prevalence the wording of the question is important (Stovner et al., 2014). Stovner et
al. (2014) have created guidelines for headache research which include guidance about
framing this initial question. If all future research follows these guidelines it will be
easier to compare prevalence between populations.

A recent study by Guveli et al., (Guveli et al., 2014) in Turkey found a prevalence of
38.6% headache amongst people with schizophrenia, however their control group also
had a low prevalence of headache (37.1%.) compared to the general population. It
appears that this study did not look at 12 month prevalence rather considered
participants who declared a headache at the time of interview or in the past.
Discrepancies in prevalence have also been attributed to cultural differences in
participants and methodological differences across studies (Junior et al., 2009; Linde
et al., 2011; Radtke & Neuhauser, 2009). Junior et al. (2009) attributed the high
prevalence of headache in Brazil (65.4%) to cultural differences but cultural
background was not explored in this survey so how much of an impact culture had on
prevalence of headache in this population is not known. It is possible that cultural
factors may have also contributed to the low prevalence of headache in both the
schizophrenic population and the control group in the Guvelli study (Guveli et al.,
2014).
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When compared to the general population a 57% one year prevalence of headache is
slightly higher than 46% determined by the WHO Global Burden of Headache (Jensen
& Stovner, 2008; Stovner et al., 2007). The willingness or not of people with
schizophrenia or schizoaffective disorder to participate in research studies may have
impacted on this figure. It has been observed that people in this demographic may be
more willing to participate in research if they believe there is a relevance to their own
lives (Schäfer et al., 2011). It is therefore possible that some people who don’t
experience headache could not see any relevance of this research to themselves
personally and therefore declined to participate thus increasing the final prevalence
rate of headache. This may well have been the case for those participants who declined
because they were ‘not interested’. It cannot be known if this trend is also the same for
all headache research but it is reasonable to interpret that the prevalence of headache
in this population is higher than in the general public.

6.4

Clinical characteristics and headache

This section will examine and compare the clinical characteristics of people with
schizophrenia and schizoaffective disorder who experience headache to those who do
not experience headache and to the general population.
6.4.1 Gender and headache
The gender distribution in this study was 2:1 males to females. Headache prevalence
within genders population was the same for both males and females. This finding is
incongruent with those of the general population where the prevalence of headache is
higher in women than men. A review by Stovner et al. (2007) determined that both
globally and within each of the continents of Africa, Asia, Australia, Europe, North
America and South America the prevalence of headache in the general population is
greater in women than men. There is no data on prevalence of headache by gender for
people with schizophrenia and schizoaffective disorder to compare against so it is
unknown if the findings of this headache study are truly representative of that
population. More research is required to determine if it is a true reflection or an
aberration.
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6.4.2 Age and Headache
This study identified that age did not have a significant impact on the presence of
headache. Junior et al. (2009) and Stovner et al. (2006) have identified that the
prevalence of headache diminishes when a person is over 60 years of age but as there
were no participants over 60 in this study it was not possible to determine if this is the
case amongst people with schizophrenia or schizoaffective disorder. Further studies
would need to be undertaken to explore if there were any changes in headache
prevalence in the older adult population with schizophrenia or schizoaffective
disorder. It may be worth noting that life expectancy of people with schizophrenia is
20% less than the normal population (Paton, Esop, Young, & Taylor, 2004) impacting
on the number of people with the disorder over 60 available for surveying.
6.4.3 Age of onset of headache
The majority of people in this study had been experiencing headache prior to their
psychiatric diagnosis. Fifty one percent (29/57) of headache sufferers developed
headache before or at age 20 years. This finding is consistent with the argument made
by Lake et al. (2005) and Watson et al (1981) that most headaches are not a result of
psychosis rather are a comorbid physical illness which should be treated as such.
However, it doesn’t rule out the possibility of headache as a trigger or early indicator
of mental illness, an issue that will be explored later in the discussion.
6.4.4 Chronicity of illness and headache
Kuritzky et al. (1999) and others have suggested that people with schizophrenia and
schizoaffective disorder have a diminished response to pain or a reduced sensitivity
which is more pronounced in the chronic phase of the illness (Bonnot et al., 2009;
Engels et al., 2014; Guieu et al., 1994; Potvin & Marchand, 2008). Therefore, it might
be expected that more chronic participants, that is those with a less recent diagnosis of
mental illness, would report headache less frequently than those with a shorter history
of schizophrenia or schizoaffective disorder, particularly as we found age not to be a
factor. This was not the case. Our data showed that length of illness did not impact on
presence of headache. not the case. Our data showed that length of illness did not
impact on presence of headache. A recent systematic review by Stubbs et al. (2014)
also determined no significant difference in the prevalence of clinical pain, including
headache, between people with schizophrenia and a control group of people of similar
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age and gender without a diagnosis of schizophrenia (Stubbs et al., 2014). The lack of
evidence to support that headache pain responses diminish with chronicity could
indicate that in order to elicit pain and for people in the chronic phase of their mental
illness to report the presence of headache the symptoms and/or impairments driving
the headache must be more severe. Unfortunately this is a very complex concept and
not one that can be easily tested. Stubbs et al.,. (2014) also suggest that more research
is required to determine if this phenomenon is due to an under-reporting of pain or if
people with schizophrenia have a higher pain threshold and therefore the impairments
driving the pain experience are more severe.
6.4.5 Medication and headache
All participants were taking anti-psychotic medication, many were taking other mental
health medication and a large number were also on medication for comorbid physical
health conditions. As already mentioned 66/99 people were taking some form of
medication that listed headache as a common or very common side effect and 59 of
these 66 people were taking antipsychotic medication where headache was a
recognised side effect. Taking medications which list headache as a common or very
common side effect did not have an impact on the presence of headache suggesting
that the presence of headache should not automatically be attributed to the side effects
of medication. The argument that headache in this population is related to medication
is not founded and many people could be missing out on appropriate assessment and
treatment of their headache if this false assumption is made. This is slightly different
for some specific headache groups and will be discussed more in later sections.
6.4.6 Inpatient/outpatient status, BMI, diabetes and headache
Inpatient/outpatient status does not relate to chronicity of illness, rather reflects the
current acuity of illness or relapse. Inpatients represent those people who have an
exacerbation of positive or negative symptoms possibly due to stress, relapse or noncompliance of medication. It could be considered feasible that the extra stresses
associated with an exacerbation could potentially be a trigger for headache. However,
inpatient/outpatient status was not found to have an impact on presence of headache.
There is nothing to support the concept that stresses associated with exacerbations
and/or the inpatient environment impact on prevalence of headache. This will be
discussed further when specific headache types are considered.
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Jensen and Stovner (2008) have suggested a link between obesity and headache. With
the mean BMI of this population being only slightly below obese (29.4, SD=6.62) it
could be expected that a large number of this population would experience headache
and may be one reason why the prevalence rate in our sample is higher than the general
population. However, we did not find an association between BMI and headache, for
both headache in general and for each of the different headache types. Diabetes was
identified as the most prevalent comorbidity, although it should be noted that only 10%
of people who experienced headache also had a diagnosis of diabetes. In 2003, Warren
et al. identified headache as a symptom of hyperglycaemia but no relationship was
found between diabetes and headache (Warren et al., 2003).
6.4.7 Summary of clinical characteristics and headache
It is evident that no clinical characteristics included in this study have a significant
impact on the presence of headache, however it is of interest to note that unlike the
general population there was not a higher prevalence of headache in females. There is
a lack of evidence to support that either medication or the stresses associated with
hospitalisation have an impact on the presence of general headache within this
population.

6.5

Prevalence of specific headache types

This section will examine and compare prevalence and characteristics of CGH, MH,
TTH and OH of people with schizophrenia and schizoaffective disorder to the general
population. Within this study group, prevalence of CGH was 4.9%, MH was 17.8%,
TTH was 15.8% and OH was 18.8%. Within the headache only population of this study
group prevalence of CGH was 8.6%, MH was 31%, TTH was 27.6% and OH was
32.8%.

Eleven people (19% of headache sufferers) reported more than 1 headache type but
only 1 person completed two questionnaires. This is consistent with findings from
Torelli et al. (2010) who reported that 80% of headache sufferers in the general
population experienced only 1 type of headache. The reason only 1 person completed
two questionnaires is that once one questionnaire was completed the other 10 people
considered it too onerous a task to complete a second questionnaire. Everyone who
reported more than one headache type was asked to complete the first questionnaire
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on their most troublesome headache. There is no data to determine what the
classification was of the second headache.
6.5.1 Prevalence of specific headache types in schizophrenia
The only study to date that has attempted to classify headache amongst people with
schizophrenia was that of Kuritzky et al. (1999). That study classified all headaches
into only two types MH and TTH. MH was classified against the ICHD (1988 version)
but all headaches that were not MH were classed into either chronic TTH or episodic
TTH with what appears to be no reference to the ICHD. Classification for MH was
based on responses to questions on location, intensity, precipitating events before
during and after the headache but it is not known if an algorithm was used to guide
classification and there was no reference to the validity or reliability of their
classification process. There was no consideration of either CGH or any other
headache type.

The 19.4% prevalence of MH in the Kuritzky et al. (1999) study is comparable to the
17.8% of our study. Given the very diverse method of classification for TTH in both
studies it is not surprising that there was a big difference in the prevalence of TTH.
Kuritzky et al. (1999) had prevalence for TTH of 28.7%, significantly higher than our
15.8% determined by using the ICHD guidelines. Variations in the classification
process clearly contributed to this discrepancy, however, both are still quite low
compared to the general population prevalence of 42%.
6.5.2 Prevalence of specific headache types in the general population
The data on prevalence of various headache types by the WHO Lifting the Burden and
other studies highlights some similarities and some diversity when compared to the
prevalence of the same headaches types in this study (Chaibi & Russell, 2012; Diener
et al., 2007; Dong et al., 2012; Fernández-de-las-Peñas et al., 2006; Knackstedt et al.,
2010; Noseda & Burstein, 2013; Stovner et al., 2007; van der Feltz-Cornelis, Biemans,
& Timmer, 2012). The 5% prevalence of CGH in our study was comparable to that the
4.6% determined by Knackstedt et al. (2010) in the general population. Painful
dysfunction of somatic structures in the cervical spine drives the experience of CGH
and can be triggered by sustained awkward neck postures, neck movement or pressure
over the occiput (Bogduk and Govind, 2009). The musculoskeletal dysfunctions
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associated with CGH have been linked to poor posture, muscle dysfunction, restricted
range of movement, age and previous trauma but no links to schizophrenia or
schizoaffective disorder have been reported in the literature (Huber, Lisinski &
Polowcyk, 2013; Jull et al., 2007; Zito et al, 2006; Fernández-de-las-Penos et al.,
2006).

Prevalence of MH (17.8%) within the sample population is higher than the 11% for
the general population found by Stovner et al. (2007) but closer to the WHO figure of
14.7% (Steiner et al. 2013) and 16% of Noseda and Burstein (2013). It would be
expected that prevalence of MH is similar in both populations as MH is considered to
be an inherited condition (Robbins, Grosberg & Lipton, 2013) with pain attributed to
altered excitability in the brain in response to common environmental triggers such as
fatigue, lack of sleep, certain foods, smoke, hunger, menstrual cycle and even light
activating the trigemino-vascular system (Noseda & Burstein, 2013; Landy, Lobo &
Rice, 2004). We are unaware of any data linking this brain dysfunction and that
associated with schizophrenia and schizoaffective disorder, and the equal prevalence
rates for MH between the general population and the schizophrenic population might
support this lack of relationship. However, as is outlined below the data on gender
distribution and age of onset suggests that this relationship might be one worthy of
further investigation.

The mechanisms behind TTH are less clear but it is accepted that physical and
emotional stress, lack of sleep and fatigue are common triggers (Cathcart et al., 2010;
Fumal & Schoenen, 2008; Li et al., 2012). These triggers are associated with lifestyle
factors in both the general population and people with schizophrenia and
schizoaffective disorder. It is therefore surprising to find the prevalence of TTH was
significantly lower at 15.8% in the sample population compared to the WHO of twelve
month prevalence of 42% for the general population (WHO, 2012). However, knowing
that there are disparities around classification of TTH, with it often being classified as
an absence of MH or CGH, if the prevalence of TTH and OH in this study were
combined the overall prevalence of 34.6% is closer to the WHO prevalence for TTH.

130

6.6

Clinical characteristics and specific headache types

The following pages will examine and compare the clinical characteristics of specific
headache types experienced by people with schizophrenia and schizoaffective disorder
to the general population.
6.6.1 Clinical characteristics and CGH
The prevalence of CGH among the general population and people with schizophrenia
and schizoaffective disorder is the same. Although poor posture resulting from
cerebellar changes associated with schizophrenia was previously considered a possible
mechanism to precipitate CGH the finding of similar prevalence between the sample
population and the general population seems to confirm that increased postural
anomalies do not equate to an increased prevalence of CGH (Ho et al., 2004; Picard et
al., 2008; Varambally et al., 2012). There is always the possibility that poor posture
may contribute to CGH but be mitigated by the decreased pain sensitivity experienced
by people with schizophrenia. This concept requires further investigation (Bonnot et
al., 2009).

CGH is a headache usually experienced later in life. Five people with schizophrenia
and schizoaffective disorder had headaches classified as CGH with a mean age of onset
of headache at 37 years of age. This is consistent with the general population mean age
of onset of 33 years found in the literature (Antonaci & Sjaastad, 2011; Hall et al.,
2008). Our data also demonstrated a relationship between age and CGH which was not
linear. Though we are not aware if this relationship has been explored in the CGH
population, there is clear evidence of a non-linear relationship between age and neck
pain in the general population (Skillgate, Magnusson, Lundberg & Hallqvist, 2012).
These findings of similar prevalence and association with age support the notion that
the sample population has characteristics of CGH consistent with the general
population and the mechanisms driving the condition are the same.

No other clinical characteristics, gender, medications, inpatient/outpatient status,
length of illness and BMI impacted on the presence of CGH. The fact that we found
no relationship between markers of the length and severity of mental illness and CGH
strengthens the idea that CGH exists as a discrete health problem in this population
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and should not be dismissed as simply part of the clinical condition of schizophrenia.
Consideration should be given to appropriate management of CGH in this population.
6.6.2 Clinical characteristics and MH
The higher prevalence of MH found in males with schizophrenia and schizoaffective
disorder compared to the general population is notable because amongst the general
population female gender is usually a strong predictor of MH (Stovner, 2006). Buse et
al. (2013) report the prevalence of MH as determined by the American Migraine
Prevalence and Prevention (AMPP) study to be 17% in females compared to 5.6% in
males (Buse et al., 2013).This is a marked difference to the results in this sample
population where of the total population 13% of men (13/100) experienced MH and
only 5% of women (5/100). It must be remembered that there was a 2:1 ratio of males
to females in the sample population and this will have had some impact on the
prevalence by gender, however, the prevalence within each gender was similar with
19.7% (13/66) of the men and 14.7% (5/34) of the women experiencing MH and so
unlike the general population gender did not have a statistically significant impact on
MH.

The most common age of onset of MH is between 10 and 30 years of age (Jensen &
Stovner, 2008) with a median age of about 24 years (Asuni et al., 2010). The study
undertaken by Asuni et al. (2010) also explored age of onset of MH without aura in a
population of people attending a headache centre and determined the mean age of onset
of headache of that population to be 16 years (Asuni et al., 2010). The authors attribute
this younger age of onset in headache clinic population to the presumption that people
attending the headache clinic would have more severe symptoms of headache which
could include earlier onset. A mean age of onset of MH without aura of 17.7 years in
our study population is more consistent with that of people attending a headache clinic
(Asuni et al., 2010) than that of the general clinical population (Jensen & Stovner,
2008). This similarity might suggest that MH headaches experienced by people with
schizophrenia and schizoaffective disorder are more severe than those experienced by
the general population and more comparable to people attending headache clinics.

In 2008, Stewart et al. undertook a population based study that did not differentiate
between MH without aura and MH with aura (Stewart, Wood, Reed, Roy, & Lipton,
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2008). They surveyed 163,186 people aged over 12 years and looked at age of onset
within each gender. They determined that 1.2% of men with MH had an age of onset
younger than 10 years and 5.4% before age of 20 years (Stewart et al., 2008) much
lower than the 17% and 50% in the sample population. Similarly with females, in the
sample population 20% of women had an age of onset before 10 years and 60% before
age of 20 compared to 2.3% and 17.3% in the general population (Stewart et al, 2008).
The high prevalence of childhood MH amongst people with schizophrenia and
schizoaffective disorder is worth further investigation in larger samples. If the same
prevalence is found further studies would need to be undertaken to explore the
relationship between early onset MH and psychotic illness. Is early onset MH another
possible predictor of developing schizophrenia or schizoaffective disorder? Is there a
possible mechanistic link between the two conditions?

The similarity with age of onset of MH is the only characteristic that appears to be
shared between people with schizophrenia and schizoaffective disorder and people
attending a headache clinic. The length of time that headache lasts is significantly
longer in the headache clinic population and the frequency of headaches is also
significantly higher (Asuni et al. 2010). Within the sample population 83% (10/12) of
people experiencing MH without aura reported a headache lasting less than 24 hours
many more than the 28% in the headache clinic population suggesting the headache
symptoms may be less severe in people with schizophrenia and schizoaffective
disorder than in people attending a headache clinic. Similarly only 43% (6/14) of
people in the sample population experienced MH without aura more than twice a
month compared to 75% of people in the headache clinic population. In an example of
non-uniformity between studies while Asuni et al. (2010) looked at frequency of
headache in terms of more or less than 2/month, Buse et al. (2013) looked at frequency
in terms of more or less than once/month. When compared to the general population
the frequency of MH was similar in the sample population. Buse et al. (2013)
determined that 65.5% of females and 74.4% of males in the general population
experienced MH more than once a month and within the sample population 72.2%
(13/18) people experienced MH more than once a month. So while the age of onset of
migraine is comparable to people attending a headache clinic, characteristics related
to length of headache appear less severe and frequency is more aligned to the findings
in the general population.
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It could also be hypothesised that people taking the mood stabiliser sodium valproate
or the antidepressant drug amitriptyline, two medications recognised by the WHO as
effective prophylactic medication for MH, are inadvertently receiving prophylactic
treatment and contributing to the decreased frequency and duration. However, our data
suggest against this as none of the MH patients were taking amitriptyline and only one
migraineur was taking sodium valproate and they reported experiencing headache,
twice a month suggesting the sodium valproate was not an effective prophylactic
treatment for their MH.
Another possible explanation for the differences in length or frequency of headache
between the headache clinic population and the sample population could be linked to
diminished pain responses in the people with schizophrenia as previously identified by
many authors (Bonnot et al., 2009; Engels et al., 2014; Guieu et al., 1994; Levesque et
al., 2012; Potvin & Marchand, 2008). Diminished pain responses have been linked
with chronicity (length of time experienced the psychotic illness) so it might be that as
children, before the symptoms of schizophrenia or schizoaffective disorder develop,
the pain response is more akin to the general population but with increasing age, as
pain responses diminish, the clinical characteristics of MH may become less noticeable
with a reduction in frequency and duration. It is not possible to evaluate this theory
from this study as there was no exploration of how MH had changed in the individual
over time. Perhaps this phenomenon of shorter duration and lower frequency of
headache is related to the responses to pain described by Levesque et al. (2012) where
people with schizophrenia have a reduced response to prolonged pain or to the findings
of Engels et al. (2014) where people with schizophrenia or schizoaffective disorder
have diminished responses to medical pain? More investigation is required and the
question still remains at to whether MH is an example of the impairments driving the
headache needing to be more severe than the general population in order to provoke a
response?

No clinical characteristics significantly impacted on the presence of MH within the
total sample population. However, within the headache only population, medication
with headache as a common or very common side effect did have a statistically
significant impact on the presence of MH. If a person was experiencing headache and
taking medication with headache as a side effect then it was 6 times more likely that
the headache they were experiencing was MH. As already discussed most people
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started experiencing MH at an age prior to being diagnosed with schizophrenia or
schizoaffective disorder and therefore before they started taking this medication so
more research is needed to determine if the nature of MH changed after starting on
medication. Ideally a medical review of medications should be conducted to determine
which of their medications are contributing to the problem or if it is a combination of
medications.

Obesity has been linked to MH so it might be reasonable to assume that with such a
high number of overweight and obese people that BMI would have an impact on MH
(Verrotti, Di Fonzo, Penta, Agostinelli, & Parisi, 2014). In this population of people
experiencing MH the average BMI was 29.7 (SD=8.0) and it was determined that
contrary to literature BMI did not have an impact on MH.
6.6.3 Clinical characteristics and TTH
The lower prevalence of TTH in this population (15.8%) compared to the general
population (42%) could be explained by the classification algorithm used. In this study
TTH was classified against a set of characteristics identified in the ICHD classification
unlike many other studies where TTH is assigned because characteristics of the
headache do not fit MH or CGH (Fumal & Schoenen, 2008; Kuritzky et al., 1999).
This could have resulted in lower than expected prevalence of TTH. As already noted
if all headaches that were not MH and CGH were included in the classification of TTH
then prevalence would have been recorded as 34.6%.

The finding by Ashina et al, (2014) that there is 50% reduction in TTH if taking
antidepressant medication could be another explanation for the low prevalence in this
population. About one quarter (26/100) of participants were taking antidepressant
medication and of these only 5 people were experiencing TTH meaning that the
majority of participants taking antidepressants were not experiencing TTH. Further
investigation needs to be undertaken to evaluate if there is a causative relationship of
medication leading to the discrepancy in prevalence of TTH between the general
population and people with schizophrenia and schizoaffective disorder.

With the main triggers for TTH being emotional and physical stress, fatigue and lack
of sleep it could be anticipated that inpatients, people with exacerbations of their
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illness, in a known stressful environment would have a higher prevalence of TTH
(Cathcart et al., 2010; Fumal and Schoenen, 2008; Li et al., 2012). This is not the case
with inpatient/outpatient status not impacting on TTH. Indeed no one variable had a
statistically significant impact on TTH in the total cohort. Within the headache only
population being an inpatient, while statistically significant, meant a person was
actually 0.28 times less likely to experience TTH.

Once again the association between pain responses and presence of headache need to
be explored. It is hypothesised that TTH is the result of pain elicited by prolonged
overloading on pericranial muscles combined with sensitisation of nociceptors in the
spinal trigeminal neurones and abnormal pain processing in the CNS (Cathcart et al.,
2010; Fumal & Schoenen, 2008; Li et al., 2012; Jensen, 2003). Engels et al. (2014)
noted that the prevalence and intensity of responses to nociception from clinical pain
experienced in daily life was diminished in people with schizophrenia. They
hypothesised that this lower prevalence and intensity of medical related pain could be
attributed to abnormal processing of motivational-affective aspects of pain due to
dysfunction in the frontal lobe, in other words the person may feel pain but not exhibit
pain behaviour. Levesque et al. (2012) identified that people with schizophrenia have
a reduced response specifically to prolonged pain. It is possible that in the case of TTH
the person with schizophrenia and schizoaffective disorder may still experience
prolonged overloading on pericranial muscles in response to stressors provoking
sensitisation of nociceptors in the spinal trigeminal neurones but somehow the
abnormal pain processing in the CNS evident in people with TTH is altered resulting
in lack of translation of nociception to headache which in turn translates to a lower
prevalence. If this is the case then further investigation is needed to determine if the
impairments driving TTH are more severe than the general population in order to
provoke a response from the person with schizophrenia or schizoaffective disorder.
6.6.4 Clinical characteristics and OH
The classification of OH was assigned if presenting characteristics were not consistent
with those of MH, TTH or CGH as identified against the algorithm. This resulted in
quite a high prevalence of this headache type. There are no studies against which to
make a comparison of prevalence as OH is not any one specific headache type based
on specific characteristics, rather all headaches that are not CGH, MH or TTH.
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More people experienced OH on the day of interview than MH or TTH with 36.8%
(7/19) of people reporting OH compared to 1/18 (5.5%) for MH and 2/16 (12.5%) for
TTH. In the case of CGH 3/5 (60%) of people were complaining of headache at
interview. The small number of people experiencing CGH makes it difficult to
compare with the other headache types. This phenomenon of many people
experiencing OH on the day of interview was not evident when looking back over the
previous 4 weeks where almost 2/3 of people experiencing MH, TTH and OH had
experienced a headache. Once again CGH was slightly higher (80%) but again small
numbers make comparison more difficult. This high prevalence of OH on the day of
interview may be linked to inpatient status and will be explored further in the following
paragraphs.

Both inpatient/outpatient status and the taking of medication with headache as a side
effect impacted significantly on the presence of OH with an inpatient being over 5
times more likely to experience OH. As previously stated the number of people
experiencing an OH on the day of interview was 7/19. Five of these people (5/7,
71.4%) were inpatients. Similarly, thirteen people or 68.4% of people experiencing
OH reported having had headache in the previous 4 weeks with ten (10/13, 76.9%) of
these people being inpatients. Data was not collected on admission dates to the
inpatient setting so it is unknown how long participants had been in hospital prior to
interview and more importantly if OH has been experienced only since admission or
if people were experiencing them prior to admission. The following discussion will
explore some factors that may contribute to presence of OH within the inpatient
setting.

When a person is an inpatient it is quite possible that they are trialling new prescribed
medication and if this medication has a common or very common side effect of
headache it is also quite reasonable to assume that the headache can be attributed to
this medication. However, we found this not to be the case because a person is 4.5
times more likely to experience MH if they are taking medication where headache is
not a common or very common side effect. Medication with headache as a side effect
is clearly not the cause of headache.
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If medication is not the cause of headache in this population then there must be other
reasons why a person is experiencing OH while an inpatient in hospital. Some possible
causes could include a reduced caffeine intake (Torelli et al., 2009), effects of either
nicotine increase and passive smoking (Aamodt, 2006), lack of exercise (Varkey,
Hagen, Zwart, & Linde, 2008), reduced fluid intake (Spigt et al., 2005), cannabis
withdrawal (Hesse & Thylstrup, 2013), sleep disturbances (Lateef et al., 2011), side
effects of electroconvulsive therapy (ECT) (Drew, King, & Callahan, 2005) and other
possible unknown factors.
Excessive intake of caffeine has negative effects on a person’s health both physical
and mental, especially people with bipolar affective disorders (Rizkallah et al., 2011).
People with schizophrenia are known to have an elevated level of caffeine
consumption, in some instances up to 7 times higher than that of the general population
(Thompson, Pennay, Zimmermann, Cox, & Lubman, 2014). Within the psychiatric
hospital setting tea and instant coffee are available to patients only during morning and
afternoon tea and at meal times. This limited access may contribute to a reduction in
the intake of caffeine compared to when at home. Many people with schizophrenia and
schizoaffective disorder also drink quite a lot of carbonated soft drink (Roick et al.,
2007; Amani, 2007). According to the Mayo Clinic most of these drinks contain
caffeine. These drinks are not available on the wards and although obtainable in the
hospital must be purchased from areas outside the wards. Any person on restricted
leave cannot access these areas of the hospital, any people who are experiencing
significant negative symptoms may not be motivated to access them and people
without any cash are not in a position to purchase them. So on admission to hospital it
is possible that many people will experience a reduction in their tea or coffee intake
and/or a sharp reduction in the amount of soft drink they consume meaning that their
caffeine intake may be diminished possibly resulting in symptoms of headache as
identified by Torelli et al. (2009). More research should be conducted to determine if
caffeine reduction is a cause for OH in this population and if it is, education can be
provided around the harm of too much caffeine and counselling provided to assist with
reduction strategies.

People with psychotic mental illness have a high prevalence of cigarette smoking with
2/3’s of people on average smoking 21 cigarettes a day (Morgan et al., 2012). At the
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time of this study smoking was banned in hospitals in Western Australia with the
exception of psychiatric hospitals and units. Until smoking bans were implemented
there was a high rate of smoking in the units including both patients and staff (Wye et
al., 2010). People being admitted to an inpatient setting may well have increased their
nicotine intake because it was an accepted pastime to help alleviate boredom. Smoking
was only permitted in outdoor areas but because these were not large areas it would
have been difficult for non-smokers to avoid passive smoking. Headache is frequently
a side effect of an increase in nicotine and of passive smoking and may contribute to
the high rate of OH in inpatients (Aamodt, 2006). It would be good to reassess both
the prevalence of nicotine use and rate of OH now that smoking is banned in the
inpatient settings to determine if this is a factor associated with headache.
Physiotherapists have long been involved in facilitating smoking cessation
programmes and would be a very useful resource in any mental health setting.

It has already been identified that people with schizophrenia and schizoaffective
disorder have reduced physical activity (Morgan et al., 2012; Vancampfort et al.,
2012). Although not a given, some people may have been admitted to hospital for
exacerbation of negative symptoms of schizophrenia or schizoaffective disorder or be
experiencing comorbid depression. Side effects in both instances could be a reduction
in physical activity. Further investigation should be undertaken to determine if this is
indeed the case and if reduction of physical activity does contribute to the prevalence
of OH in this population in this setting. Physiotherapists are experts in the
implementation of exercise programmes especially where comorbidities exist and are
a valuable asset to any mental health facility (Australian Physiotherapy Association,
2011; Vancampfort et al., 2012).

Reduced fluid intake is a trigger for headache (Spigt et al., 2005). One third (5/15) of
inpatients experiencing OH reported drinking water to relieve their headache
suggesting that they were becoming dehydrated and their headache was related to this.
Further investigations would need to be undertaken to determine why people in the
inpatient setting might become dehydrated as water is readily available. It is possble
that people with an increase in negative symptoms are drinking less if they are lacking
motivation to get up and get themselves a drink. Other factors that could have an
influence a reduced fluid intake and dehydration are if prior to admission the person
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was used to consuming soft drinks which are no longer freely accessible or the person
is commenced on medication with dehydration as a side effect. More research needs
to be undertaken to determine the reason behind headaches from dehydration in the
inpatient setting.

The use of cannibis and illicit drugs is high in people with psychotic illness in
Australia. According to Morgan et al. (2010) 63% of males and 42% of females with
psychotic illness record a lifetime history of illicit drug abuse much higher than the
12% for males and 6% for females in the general population. Street drugs are known
to increase the risk of experiencing psychosis in people with schizophrenia and
schizoaffective disorder (Castle & Buckley, 2011) which in turn can lead to
hospitalisation. People being admitted to the inpatient facilities due to increases use of
cannibis could well be experiencing headache as a withdrawal symptom. In this study
only 3 people reported using cannabis to relieve their headache but none of these
people were inpatients suggesting that cannibis withdrawal within the inpatient setting
may not have been a factor contributing to pesence of OH.

Within general medical and general surgical wards the night-time lighting has been
identified as a problem contributing to patients not getting adequate sleep (Bernhofer
et al., 2014). It is unknown whether this is a similar problem in this mental health
setting, however if it is then lack of sleep could contribute to the high prevalence of
OH amongst inpatients (Lateef et al., 2010). Quality of sleep was not evaluated in this
study, however, it would be useful to find out how many inpatients experience
headache because of sleep distrubances. If it was discovered to be the case then further
investigation could be undertaken to determine the cause for lack of sleep and steps
could then be taken to make the inpatient environment more condusive to sleep.

ECT is a modality used mainly for the treatment of depression but is also used for the
management of other psychiatric conditions that do not reposnd to psychotropic
medication (Drew et al., 2005; Tharyan & Adams, 2005; Read & Bentall, 2010). It is
not known how many people in this study, if any, were undergoing ECT and therefore
we were not able to determine if ECT was a factor associated with OH in this
population.
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6.6.5 Summary of clinical characteristics and specific headache type
Age of onset of CGH is consistent with literature from the general population and no
other clinical characteristics were identified that impacted on the prevalence of this
headache type. It can be assumed that clinical characteristics of CGH are the same as
in the general population and should be treated as such. This includes referral to
physiotherapy.

The high prevalence of MH amongst males and the high prevalence of early age of
onset of MH are worth exploring further. Within the sample population no variables,
including gender, impacted on presence of MH. It is worth noting that if a person
experiencing headache is taking medication with headache as a common or very
common side effect then MH should be considered a possibility with a need for further
investigation and/or referral to a neurologist.

It is interesting to note that no clinical characteristics were linked to TTH suggesting
that when TTH is present it is not related to the mental illness and should be treated
appropriately following guidelines for TTH management. More research is required to
determine if the low prevalence of TTH is related to diminished pain responses.

Inpatient status had a significant impact on presence of OH but medication with
headache as a common or very common side effect, while significant was not the cause
with people on these medications less likely to experience OH. Further investigation
to determine the underlying causes for these headaches is recommended.

These findings reinforce the concept that headaches in this population are driven by
the same mechanisms as in the general population and are not simply a side effect of
schizophrenia or schizoaffective disorder. Importantly headaches are not usually
related to medication. This highlights the importance of thoroughly assessing people
with schizophrenia when they complain of headache. It is important to determine the
precise headache type in order to initiate appropriate management strategies.

6.7

Impact of headache on quality of life

The literature identifies a poor quality of life for people with schizophrenia and
schizoaffective disorder (Cuyún Carter et al., 2011; Vancampfort et al., 2012). People
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who experience headache and have a comorbid mental health issue are also known to
have a reduced quality of life (Smitherman & Baskin, 2008; Wang & Juang, 2002). Is
it possible to assume that people with schizophrenia and schizoaffective disorder who
also experience headache may have an even further reduced QOL.

This project did not set out to evaluate the QOL of all participants rather to explore
how headache impacts on the QOL of people of this demographic. As a result no
comparisons can be made between QOL of those who experienced headache and those
who did not experience headache. Recall questionnaires about QOL were used so
participants were only invited to complete the QOL section if they identified that they
had experienced a headache in the preceding four weeks, in line with the SF-36
recommendations (Ware & Sherbourne, 1992). Thirty six people completed this
section meaning that 63% of the people experiencing headache in the previous 12
months (36/57) and over 1/3 of all participants had experienced a headache in the last
month.

It has already been detailed that only three sections of the SF-36 were explored in this
study. These were Bodily Pain (BP), Social Functioning (SF) and Role Physical (RP).
It is known that people with schizophrenia and schizoaffective disorder have decreased
social functioning (Cuyún Carter et al., 2011; Morgan et al., 2012; Ritsner et al., 2014)
as do people with headache. It was hypothesised that headache could further decrease
the social functioning of the individual with scihzophrenia or schizoaffective disorder.
Studies exploring the impact of headache on QOL have also identified bodily pain and
role physical as other key areas of functioning that are reduced (Leiper et al., 2006;
Solomon et al., 1993; Stovner et al., 2007; Stovner et al., 2006) which is why these
were included in this study. It is acknowledged that using the whole SF-36
questionnaire would provide much richer information about quality of life but there
were concerns about the length of the tool used in this study and so the decision was
made to include only these three measures as a way of capturing a snapshot of the
impact of headache on the person with schizophrenia or schizoaffective disorder.

While the SF-36 is recognised as a validated and reliable measure of QOL of people
with physical illness there are doubts about the validity of it as tool in patients with
schizophrenia (Papaioannou et al., 2011). However, in most studies looking at QOL
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of people with schizophrenia or schizoaffective disorder researchers are exploring the
impact of emotional distress, the side effects of medication or negative symptoms of
the mental illness on QOL rather than associated physical illnesses (Ritsner et al.,
2014). In the instance where the impact of a physical health issue on QOL is being
explored the SF-36 is the most appropriate tool. However, unfortunately because most
QOL studies undertaken with this demographic do not use the SF-36 it is difficult to
make comparisons with other QOL studies.

Before reviewing the findings of the impact of headache on QOL it is worth bearing
in mind that in the general population women have a higher prevalence of headache
than men (Stovner et al., 2007) and the American Migraine Prevalence and Prevention
has determined that women also have increased symtpoms and increased disability
associated with headache (Wells et al., 2014). Within the headache population of
people with schizophrenia and schizoaffective disorder there was not an increased
prevalence of headache amongst women and this under representation of women might
mean that overall headache will be shown to have less of an impact on QOL than
expected. Impact on QOL was not analysed by gender.
Our analysis did suggest that headache has a moderate impact on RP with less inpact
on BP and SF. More frequent headaches were associated with greater impact on QOL.
Many respondent identified that within the previous four weeks the presence of
headache had impacted on their normal ability to work or perform regular daily
activities. This finding is consistent with studies undertaken in the general population
indicating that headache inpacts on role physical (Leiper et al., 2006; Solomon et al.,
1993; Stovner et al., 2007; Stovner et al., 2006).

While direct comparison against SF 36-data for this population is not possible it is
known that two thirds of people with psychotic illness have severe dysfunction in their
ability to socialise and one third had severe impairment in their ability to look after
themselves (Morgan et al., 2011). About one fifth of people with psychotic illness do
not do their own shopping and cooking. It could be argued that people with
schizophrenia and schizoaffective disrorder already have significant reduction in
quality of social functioning (Cuyún Carter et al., 2011; Morgan et al., 2012; Ritsner
et al., 2014) and the presence of headache may not have as much of an impact on an
already dimished quality of life.
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Unlike the general population the presence of headache had less impact on bodily pain.
This is not an unexpected finding considering people with schizophrenia have reduced
responses to pain with lower intensity of pain associated with medical causes and a
diminished response to prolonged pain (Bonnet et al., 2009; Potvin & Marchand, 2008;
Engels et al., 2014; Levesque et al., 2012).

The presence of either CGH or OH was shown to have more impact on BP, SF and RP
than MH and TTH which differs from literature in the general population which has
found CGH, TTH and MH to all have similar impacts on BP, SF and RP (van
Suijlekom et al., 2003). In particular CGH is known to have a significant impact on a
person’s SF something that has already been identified as a reduced QOL measure in
people with schizophrenia and schizoaffective disorder. The person within this
demographic experiencing treatable CGH would be further disadvantaged. It must be
noted that the small number of people with CGH in this study has possibly impacted
on the results and studies of larger sample size would need to be conducted to
determine if this is a trend or an aberration.

6.8

Management of headache

Once a headache type has been identified, to reduce the negative impact on QOL the
person needs to receive best practice treatment. Lake et al. (2005, p. 498) state
‘Psychiatric comorbidity’ is often a negative prognostic indicator for headache
treatment’ highlighting that behavioural and psychological factors such as nonattendance at appointments may contribute to the treatment outcome (Lake et al.,
2005). Kuritzky et al. (1999) suggests that poor treatment outcome might be related to
people not reporting their headache in the first instance for fear of hospitalisation
(Kuritzky et al., 1999). This claim was not supported by our study with only 7 of the
57 people (12%) who experienced headache relating it’s presence to hospitalisation.
Still people not reporting headache, for whatever reason is probably contributing to
poor outcomes. According to Vinding et al. (2007) about 50% of people in the general
population experiencing headaches seek medical help. Only one person in this study
group was taking medication prescribed by their GP and only 1 other was receiving
treatment from a chiropractor suggesting that much less than 50% of headache
sufferers (3.5%) have sought medical help to manage their symptoms. Without
accurate clinical diagnosis there will always be poor treatment outcomes and even if
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diagnosis is correct if the right pathway for management of the headache is not
followed subsequent suboptimal intervention or treatment will result in poor outcomes.
This section explores the management of headaches experienced by people in this
study in relation to best practice.

Within a population of people attending a headache clinic Vinding et al. (2007)
identified that 56% were accessing physiotherapy and 36% were accessing
chiropractic for some management of their headache. These numbers were
significantly reduced in the general population with 9% accessing physiotherapy and
5% accessing chiropractic (Vinding et al., 2007). However, in comparison the numbers
in this sample population were very poor with only 1 person (1.8%) accessing
chiropractic and none accessing physiotherapy despite physiotherapy being available
at the hospital. There are limitations to the physiotherapy service at this mental health
facility but regardless of that the fact that no one with headache was accessing the
service suggests it is either undervalued by staff and consumers, mental health workers
are not aware of the services offered by physiotherapists or mental health workers and
patients are not informed about the benefits of receiving appropriate physiotherapy.
This suggests that more education around the role of physiotherapy and promotion of
the benefits of physiotherapeutic services in this area is required.

Forty one percent (24/58) of people reported associated neck pain while experiencing
headache. This is lower than the 70% found in people with intermittent headache
reported by Hall et al. (2007) or the 69% of patients with MH determined by Florencio
et al. (2014). Not one person identified accessing physiotherapy for assessment of their
neck pain.
6.8.1 Management of CGH
Physiotherapists are particularly interested in CGH with manual therapy in
conjunction with exercise well recognised in the management of CGH (Bogduk &
Govind, 2009; Jull et al., 2002). No participant in the study accessed physiotherapy for
treatment of their CGH although one person did report that correcting their posture
helped relieve their CGH.
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One person was receiving cervical manipulation from a chiropractor which might
sound like good management of their CGH, however, it has been identified that manual
therapy/manipulation without exercise prescription is a sub-standard treatment for
CGH (Bogduk & Govind, 2009; Fumal & Schoenen, 2008; Jull et al., 2002).
Physiotherapy using a combination of manual therapy, exercise and education is
recognised as the most effective form of non-invasive management of this headache
type and should be the treatment of choice. There is limited physiotherapy available to
people in this population and it must be made more available and accessible if they are
to receive optimum treatment.
6.8.2 Management of MH
Best practice treatment for MH consists of both acute and prophylactic measures
(Kelley & Tepper, 2012a; Zielman et al., 2012). The WHO (2012) recommend
symptomatic measures be implemented and trialled unsuccessfully three times before
specific measures are implemented. People with schizophrenia and schizoaffective
disorder experiencing migraine were mostly treating their symptoms with ‘over the
counter’ medication and sleep with no one taking specific measures.

In accordance with the findings of Kelley and Tepper (2012a) the most common
medication being used by the sample population was simple analgesics, however, very
few people were reporting rapid relief. One person took no medication opting to sleep
to relieve the headache and symptoms. The majority (12/18) took paracetamol
(Panadol) and slept including the people who reported their headache lasting 12, 48
and 72 hours. These people were obviously not receiving optimum treatment because
if paracetamol was to be effective it should provide at least 2 hours of relief (Derry &
Moore, 2013). Only one person was taking analgesic medication prescribed by their
GP and their headache still lasted for 48 hours suggesting that they too were not
receiving the best treatment for their MH. Those people with poorly managed MH
would benefit from a specialist neurologist review and might possibly be considered
for specific measures such as triptans and ergotamine to reduce the negative impact
that MH is having on their lives. Symptomatic relief described by the WHO includes
all symptoms, not just pain, yet while three people reported vomiting occasionally and
a further 6 people were occasionally nauseous none took any antiemetic medication.
Once again best practice treatment was not being utilised.
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Prophylactic measures are usually recommended when people experience migraine
two or more times a month. In this survey 11/18 people (61.1%) reported experiencing
MH at least once each month and 7/18 (39%) of these at least once/fortnight. None of
these people were on prophylactic treatment for their migraine. Referral to a
neurologist who can prescribe appropriate prophylactic measures for these people may
mean they experience less disruption to their lives. Other preventative measures
include CBT and relaxation and once again no-one reported accessing services that
provided these.

With best practice treatment for MH being both acute (symptomatic and/or specific)
and prophylactic measures (Kelley & Tepper, 2012a; Zielman et al., 2012) it is quite
unsatisfactory that so few people with schizophrenia and schizoaffective disorder are
receiving adequate symptomatic, specific or prophylactic treatment for their migraine.
6.8.3 Management of TTH
Medication and sleep are also the most common treatments adopted by people with
schizophrenia and schizoaffective disorder who experience TTH. The use of
pharmacology for TTH is complex and many variables impact on which medication is
the most appropriate for each person (Fumal & Schoenen, 2008). It is not possible to
consider all those variables in this study to determine if participants are taking the best
medication for their TTH.

There is evidence to support the use of relaxation for TTH and to a lesser extent
massage (Fumal & Schoenen, 2008). It is disturbing to note that no people used
relaxation as a form of treatment for headache and only two people with TTH accessed
massage, although it is unknown if this was from a professional massage therapist.
This would suggest that no health professional has explored the headache and given
appropriate advice on management.

Physiotherapy and exercise have been shown to reduce the frequency and intensity of
TTH (Ashina & Bendsten, 2013) and education on ergonomics and posture to reduce
the load on myofascial tissues associated with TTH might also be effective
(Fernández-de-las-Peñas et al., 2006). No person experiencing TTH reported,
accessing a physiotherapist for treatment, receiving an exercise prescription or
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undertaking an ergonomics or postural review, suggesting that people are receiving
sub-optimal measures to address their headache issues.
6.8.4 Summary of management of headache
The majority of people with schizophrenia and schizoaffective disorder who
experience MH, TTH or CGH are not receiving appropriate nor adequate treatment to
manage this potentially disabling condition. The suggestion earlier that many people
with schizophrenia and schizoaffective disorder report a headache and are
recommended to take paracetamol unfortunately appears to be the case.

It has already been identified that a negative prognostic indicator for treatment of
headache is a comorbid psychiatric condition (Lake, 3rd et al., 2006). There could be
a couple of explanations for this as identified by Birgenheir et al. (2013) who suggests
that people with severe psychotic illness may be undertreated for pain conditions
because


They are considered difficult to treat and not accepted into mainstream health
systems



Pain management (including headache) is considered less important to
psychiatric management and overlooked or discounted



Mental Health workers may see the pain (including headache) as a symptom
of a person’s psychotic mental illness rather than a separate condition and not
refer them to appropriate services



Mental Health workers may either not understand and/or underestimate the
impact of headache on QOL and fail to act on information



Mental Health workers may have an understanding of the impact of headache
but not know about how headache can be managed and so fail to act on
information from the patient



The person themselves does not report presence of pain for their own reasons
which may include perceptions of all of the above, fear of being hospitalised
etc.



It is difficult to access services for various reasons including waiting lists,
transport issues, fear of unfamiliar places, fear of stigma etc.



Financial constraints
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6.9

Summary of Discussion

This was a cross sectional cohort study that consecutively recruited 100 participants
with schizophrenia or schizoaffective disorder from the Fremantle Hospital Mental
Health Services. This cohort represented a good cross section of people with psychotic
illness in Australia. Demographic data collected in the study sample was comparable
to that collected in the Australian Government’s survey ‘People living with psychotic
illness 2010’.

Twelve month prevalence of headache is slightly higher than the general population.
Previous surveys have identified that people with schizophrenia will mainly only
engage in surveys if they can see the relevance to them. It is possible that many people
who don’t experience headache chose not to engage in the study resulting in a slightly
higher prevalence. The prevalence is also higher than a previous study conducted in
1999, but the recruitment criteria were different in both studies suggesting differences
might have been related to demographic differences.

None of the clinical characteristics assessed (inpatient/outpatient status, length of
illness, or medications) impacted on the presence of headache suggesting that
headache might not be related directly to the mental illness. Regardless of the headache
type, 41% of people experiencing headache also reported associated neck pain. There
was no evidence of anybody either seeking or being referred to physiotherapy to assess
and manage this pain. Headache frequency was found to be negatively correlated with
quality of life, while there was no relationship with intensity or duration.

CGH had the same prevalence and clinical characteristics in this population as in the
general population with age being the only significant factor to impact on the presence
of CGH. It was disappointing to note that while CGH can be successfully managed
with physiotherapeutic intervention no one in this study reported receiving
physiotherapist treatment.
MH also had a prevalence rate comparable to the general population. The most
noticeable differences in clinical characteristics of people experiencing MH were the
disparate prevalence in females/males compared to the general population. There were
also a much higher percentage of people with early age of onset of MH. While
medication with headache as a side effect had some impact on the presence of MH
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most participants had started getting MH well before they started taking this
medication. Unfortunately for the majority of people with MH the management of the
condition did not follow best practice guidelines and no one was under the care of a
neurologist, nor was anyone on prophylactic regimes despite meeting the criteria.

Stress is a recognised trigger for TTH and it could be presumed that people with
schizophrenia and schizoaffective disorder are subject to considerable stress especially
as inpatients, though our data found no relationship between TTH and
inpatient/outpatient status. It would be expected that there would be some
discrepancies in prevalence of this headache type within the literature as many
previous studies have not used the ICHD to identify TTH, rather classify TTH when
the characteristics do not fit MH or CGH. The low prevalence of TTH may be
associated with diminished pain responses to prolonged pain. Regardless of the
prevalence there was no associations found between clinical characteristics and
presence of TTH. It is obvious that people experiencing TTH were not accessing
adequate treatment for the condition.

Inpatients are more likely to experience OH but those taking medications that do not
list headache as a side effect are also more likely to have OH. This can only make one
wonder what the mechanism is that is driving OH in the inpatient population. More
research will need to be undertaken to determine this. Some possibilities could be
around reduced caffeine intake, increased smoking, withdrawal from illicit drugs,
dehydration, sleep disturbances, reduced physical activity or ECT. Adequate
management of this type of headache can only be achieved once the mechanism
driving the headache is known.

The data available from our survey suggest that the mechanisms behind most
headaches experienced by people with schizophrenia and schizoaffective disorder are
the same as for the general population, however, overall the management of headache
in this population is very poor. Very few people were identified as receiving adequate
treatment for their particular headache type. Models to address this problem could
include education in the form of training sessions, educational pamphlets and posters;
employment of mainstream health professionals into mental health services;
implementation of mainstream health clinics that people with schizophrenia and
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schizoaffective disorder can access and screening tools for mental health workers.
More research will need to be undertaken to determine if any of these measures are
useful and/or cost effective.
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CHAPTER SEVEN
Possible solutions to issues impacting on management of
headache as identified in the discussion
7.1
The

Introduction
discussion

highlighted

some

potential

perceptions,

prejudices

and

misunderstanding of both health workers and patients around mental health issues and
headache issues. This sections aims to address and provide possible solutions to these
problems. The hope is that these measures will result in better management of
headache and improved quality of life for people with schizophrenia and
schizoaffective disorder who experience headaches.

7.2

Perceptions and prejudices

Flawed perceptions and prejudices are not restricted to people in the general health
workforce but also apply to mental health workers. It has been identified that many
people who work in the mental health field perceive their role is to only address the
mental health needs of their clients. Many are not cognisant of the importance of
addressing the physical health needs of their clients in their overall holistic
management or are uncertain about their role in the monitoring of physical health
(Happell et al., 2012; Fagiolini, 2008). Regardless of the reasons, it is obvious that
many people with severe mental illness are not linked to appropriate medical services
for their physical health needs (Griswold et al., 2010). Griswold et al., (2010)
recommend improved access for care coordination resulting in better health outcomes.

Within the physical health workforce many health professionals, including
physiotherapists, do not believe that they are adequately prepared to work with and
support patients who have a comorbid mental health issue (Arvaniti, 2009). In this
instance staff will draw on their previous experiences, understandings and beliefs
about mental illness and unfortunately many people have negative perceptions of
people with psychotic illness, possibly partly due to the way people are portrayed in
the media (MacNeela, Scott, Treacy, Hyde, & O'Mahony, 2012). Education about
mental health issues helps improve attitudes towards people with mental illness.
Inclusion of more education into undergraduate medical, nursing and allied health
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courses could help address negative perceptions and prejudices towards people with
psychotic illness (Probst & Peuskens, 2010). Better perceptions and reduced
prejudices would result in more positive and welcoming environments within the
wider health care community thus enabling people with severe mental health issues
better access to services that provide specialist care for their physical needs (Kuhnigk
et al., 2009).

One solution to the problem of access to physical healthcare for people with
schizophrenia or schizoaffective disorder is to promote the role that physiotherapy can
play in improving the wellbeing of people who access the mental health services.
Physiotherapists are key health workers in the management of people experiencing
chronic pain and musculoskeletal conditions including CGH, TTH and neck pain
(Australian Physiotherapy Association, 2011, 2012) and in the management of chronic
illnessess such as diabetes (Australian Physiotherapy Association, 2008, 2009, 2011).
Physiotherapists cannot treat the primary causes behind MH, however, they can
recognise these headache and provide treatment to secondary symptoms such as
associated neck pain, soft tissue pain and tension as well as address postural and
ergonomic anomalies. Physiotherapists are well equipped to refer people to
appropriate services for management of the headache condition. Physiotherapy
interventions as part of a multidisciplinary team approach are known to assist with
management of factors that possibly impact on OH such as excessive nicotine intake,
reduced physical activity levels and associated sleep disturbances.

As an outcome of this research a brochure has been developed to promote the role of
physiotherapy in maintaining good physical and mental health and wellbeing for
people accessing mental health services (APPENDIX Three). This brochure includes
information about how physiotherapy can be beneficial in the management of
musculoskeletal conditions as well as in chronic disease. Further research needs to be
undertaken to evaluate the impact to patients and the cost effectiveness of employing
physiotherapists into mental health services.
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7.3

Pain management (including headache) is less important than

psychiatric management
There is a belief amongst some mental health workers that psychiatric management is
the only aspect of the health management for the person with psychotic illness in which
they should be involved (Happell et al., 2012). During an acute psychotic episode
management of the psychotic illness would certainly take precedence over physical
illness, especially if the physical health condition is not life-threatening.

There is no argument that psychotic illness has a serious impact on quality of life and
mental wellbeing, however chronic pain, including headache, also has significant
impacts on quality of life, overall wellbeing and as has been demonstrated the
combined impact of mental illness and headache does further reduced quality of life,
especially role physical (Cuyún Carter et al., 2011; Leiper et al., 2006; Smitherman &
Baskin, 2008; Wang & Juang, 2002). What many mental health workers fail to
recognise is the impact physical health issues, including pain, can have on the overall
well-being of the person and the close relationship between physical and mental
wellbeing (Happell et al., 2012). A person experiencing pain from frequent, poorly
managed headaches is at risk of compromise of their mental health and wellbeing. The
brochure developed to highlight the role of physiotherapy also focuses on the impact
of pain on a person’s mental health and the role physiotherapy plays in the
management of pain. This brochure can be found in Appendix 3.

This study has provided evidence that prevalence of headache in this population is
similar to that of the general population. A non-stabilised, acute psychotic episode
(patients in locked wards) was an exclusion criterion so no comment can be made
about prevalence, characteristics or impact of headache during a very acute phase of
illness, however, headache experienced at other times is not normally a side effect of
psychotic illness. Headache does have an impact on quality of life and functioning,
especially if headache is frequent. Education of mental health workers about the
impact of headache is essential if clients of that service are to receive appropriate and
timely treatment. A brochure addressing some basic information about headache,
questions to ask and some simple management strategies can be found in Appendix 4.
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Further studies will need to be undertaken to evaluate the effectiveness of providing
this information to mental health staff.

7.4

Pain (including headache) as a symptom of a person’s psychotic

mental illness
Our data suggests that headache is not simply a side effect of schizophrenia and
schizoaffective disorder and is not normally associated with antipsychotic or any
mental health medication. Literature indicates that response to pain is diminished in
this population and it is still unknown if the characteristics driving headache in this
demographic are in fact more severe in order to illicit a response and prompt behaviour
to seek assistance for the pain (Bonnot et al., 2009).

CGH is triggered by noxious input from structures innervated by the upper cervical
nerve roots being referred along the sensory distribution of the trigeminal nerve via
the ‘cervico-trigeminal relay’. Migraine is a headache activated by the
trigeminovascular system and physical and/or psychological stress can increase
muscle tension in the head area resulting in perception of pain and TTH. Education of
mental health workers about the pathophysiology of headache may help them develop
a better understanding of the condition. The brochure in Appendix 4 could assist a little
with this but a series of professional development training sessions could be developed
for case managers.

7.5

No understanding of the impact of headache on QOL

Education of mental health workers about the impact of headache is essential if clients
of that service are to receive appropriate and timely treatment. Frequency of headache
was identified as the most significant factor impacting on QOL. It is important that
mental health workers are aware of this and carefully monitor the frequency of
headache experienced by their clients. The brochure in Appendix 4 contains this
information.

7.6

No understanding about how headache can be managed

Education about management of different headache types may assist mental health
workers to be better equipped to help their clients who experience headache. If a
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service employed physiotherapists they could provide this education on a regular basis
to remind staff of the impact of headache and assist with case management for the
client.

Lake et al. (2006 & 2005) advocate that the development of a screening tool for
managing people presenting in psychiatric clinics with comorbid headaches would be
a step towards improving management and treatment outcomes for this group of
people. The questions included in the brochure (Appendix 4) should assist case
managers with this process. A screening tool would be of little use without knowing
what to do with the information so the brochure provides information for a referral
pathway to appropriate services. This should assist mental health workers to provide
better advice to their clients.

7.7

Non self-reporting of the presence of pain.

It has been suggested that many people with schizophrenia and schizoaffective
disorder do not report pain or headache to their mental health worker. There are
different reasons why this might be the case, such as fear of hospitalisation, not
wanting to bother anyone, believing that nothing can be done to help anyway etc.

It is important to emphasise a few things to people with schizophrenia and
schizoaffective disorder.
1. People with schizophrenia and schizoaffective disorder experience
headaches the same as the general population
2. Headache is not connected to mental illness
3. Reporting headache will not result in you being admitted to hospital
4. Effective treatment does exist for headache
5. To access the best treatment you need to be assessed by an appropriate
health professional.

The brochure developed in Appendix 4 was done so with the intent of being useful for
both health care practitioners and patients. It is hoped that by making this available
throughout the service that patients themselves might identify a pathway for
management of headache. Further studies will need to be undertaken to evaluate the
effectiveness of providing this information to patients.
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7.8

Difficulty accessing services

There are many reasons, some valid and some not, why a person with a psychotic
illness will not access mainstream health services. There are a few solutions to this
problem.
1. Employ staff who can provide appropriate management. Physiotherapists
working in the mental health field have skills to lead the promotion of physical
health amongst users of mental health services (Stubbs et al., 2014). A
systematic review by Vancampfort et al. (2012) found that targeted
physiotherapeutic interventions not only improved physical health but also
improved psychiatric symptoms in many patients. Employing physiotherapists
could be cost effective when considering the overall wellbeing of patients
accessing mental health services.
2. Broker in expert services and conduct regular clinics that are easy for patients
to access.
3. Ensure case manager or support workers assist people with schizophrenia and
schizoaffective disorder as required to negotiate appointment times and
accompany clients to appointment that are in mainstream health services.
4. Provide ‘Care Navigators’ as described by Griswold et al. (Griswold, Homish,
Pastore, & Leonard, 2010). Trained care navigators help patients with severe
psychiatric conditions to access health services by assisting with
communication and education and guiding the individual through the complex
healthcare system.
The 2001 study ‘Duty to Care’ highlights not only the poor physical health of people
with mental health but also their poor access to services (Coghlan et al., 2001). Linking
patients to primary care has been shown to produce better outcomes (Griswold et al.,
2010; Griswold et al., 2008).

7.9

Financial constraints

Eighty percent of people with schizophrenia and schizoaffective disorder receive their
income through Government pensions and are not in a financial position to access
private physiotherapy (Morgan et al., 2011). Physiotherapists are included in all
outpatient departments in Australian General Hospitals but it is obvious that none of

157

the people with CGH in this study have accessed these services. Employing
appropriate staff or brokering in staff for regular clinics could be suitable ways to
address these problems.
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CHAPTER EIGHT
Limitations, considerations, recommendations and conclusion
8.1

Limitations and considerations for future research

The sample size calculation used for this study was based on a prevalence rate for any
headache, however a larger sample size would have provided richer data for exploring
issues related to individual headache types. This is particularly the case for CGH. A
larger sample size would mean that trends observed amongst MH, CGH and TTH
could be more reliable.

It could be argued that this study is restricted because the participants were recruited
from one health facility in Perth. When demographic data collected from the sample
population was compared to that of an Australian wide survey of people with
schizophrenia and schizoaffective disorder it was demonstrated that the sample was a
good representation of people with schizophrenia and schizoaffective disorder in
Australia. In 2011, 216,266 people lived in the catchment area for the facility in the
southern regions of the greater city of Perth in Western Australia representing 12.5 %
of the total population for Perth at that time.

Collecting data about length of patient illness from files, as required by Fremantle
Hospital and Health Service ethics committee, proved to be very difficult. Lack of this
information would impact on the ability to determine chronicity of illness. Many
patients with long term psychotic illnesses have multiple files with the ones containing
original admission and diagnosis data being up to thirty years old and many files
needed to be requested from archives. Many participants had come to Alma Street
Mental Health Services from other countries, interstate or other health facilities in
Perth and their original files were no longer available. Fortunately most patients
volunteered the information about how long they had been unwell with a mental illness
without being asked. It is assumed therefore that this is a question that they are
regularly asked in medical type interviews and they are comfortable answering.

Recruiting all outpatients from the depot clinic may have impacted on the data
collected if all were involuntary patients on an enforced Community Treatment Order
(CTO) due to non-compliance of medication or aggression. However, since many
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people voluntarily opted for a depot injection as it made it easier for them to manage
their medication there was in fact a cross-section of outpatients. It is not known if the
cross-section of outpatients would have been different if case managers had enough
time to engage and recruit other participants who did not attend the depot clinic.

Getting access to an accurate list of ALL medications was challenging as people with
schizophrenia and schizoaffective disorder are often prescribed medication from their
psychiatrist as well as their GP and in some instances other medical people. Not all
participants could remember what they were taking and medications not prescribed in
the hospital were not often recorded in case notes. All avenues were explored to try
and ensure accurate data was obtained.

Prior to data collection it was recognised that some participants may be overwhelmed
and/or suspicious if presented with too much written information to read prior to
undertaking the questionnaire. Human Research Ethic Committee (HREC)
requirements include providing a plain language statement as well as a consent form
to be read and signed. During data collection the majority of participants did not want
to read the information sheet or the consent form but specifically asked for an oral
version. It is not known whether this is because of poor literacy, difficulty to
concentrate or an aversion to reading lengthy documents. Morgan et al. (2011)
identified that in Australia 1 in 5 people with a psychotic illness have trouble reading
and writing. In future this is something that needs to be considered when researching
this demographic.

It became evident quite quickly that due to the length of the questionnaire, maintaining
attention of the participant was sometimes a challenge, in keeping with the Schafer et
al. (2011) observation that people with schizophrenia have an aversion to questionnaire
surveys. Two considerations for future research are to


Conduct trails of shorter versions of the questionnaire to determine if
classification can still be accurately determined with less information and
without compromising validity and reliability.



Continue to use researchers who have experience working with this population
to ensure they have strategies to maintain engagement of the participant.
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Gathering data on more than 1 headache when a person experienced multiple headache
types was difficult. Only one person completed a second questionnaire despite 11
people identifying that they experienced more than one headache type. The
questionnaire is lengthy and people lost concentration and focus after completing only
one. As a result some valuable data was not collected. There is no immediate solution
to this problem but a shorter questionnaire may prove useful. Throughout this study,
in order to gather the most appropriate data, people were asked to report about their
most problematic and troublesome headache first.

Many participants had difficulty rating the intensity of the associated symptoms that
accompany headache of nausea, vomiting, photophobia, phonophobia, lightheadedness, dizziness, blurred vision, eye swelling, loss of appetite and confused
thinking. When working with this population again it might be worth considering if
knowledge of intensity is crucial to classification of headache or if knowledge of
presence of the symptoms is more important as this was a point where many people
began to lose impetus to continue with the questionnaire. Pilot studies would need to
be undertaken to determine the appropriateness of a tool that explores frequency of
symptoms but not intensity of symptoms.

Collecting data on quality of life of all participants might have given richer information
about the impact of headache. As indicated the SF-36 is not used much to evaluate
QOL in psychiatric research so making comparisons between this study and the norms
for this population was difficult. Gathering SF-36 information from all participants,
regardless of presence of headache would have provided a reasonable comparison to
determine the impact of headache on QOL and will be considered in future research.

Rich information was obtained from the client interviews but more rich information
would have been obtained if case managers were also interviewed or surveyed.
Determining how many case managers knew if their client’s experienced headache
would have provided valuable information about how headache is considered amongst
mental health workers and directed educational support. It would also have given some
insight into the holistic management of the patient. In the instance where case
managers were aware of the presence of headache further information about what they
perceived was the impact of that headache and what were they doing to assist the
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person would have directed what to target in management strategies developed to
address the problems. This is something that is being considered for future studies.

This research has highlighted the prevalence of headache in this population.
Physiotherapists are seen as experts in treating CGH and have a role to play in the
management of TTH and therefore should be considered in the health workforce of
mental health services. There is some research beginning to emerge from Europe
exploring the physical and mental health benefits to people with schizophrenia
receiving physiotherapeutic intervention for physical conditions (Vancampfort et al,
2012; Stubbs et al, 2014). More research needs to be undertaken to explore the cost
effectiveness of employing physiotherapists in mental health settings to provide expert
input on prevention and/or management of physical health issues and the impact this
has on metal wellbeing.

8.2

Recommendations for clinical practice

There is a need for more education for patients and mental health workers in the
psychiatric setting about headache and an understanding that headache is not simply
related to psychotic illness such as schizophrenia or schizoaffective disorder.
Education should highlight that the person with schizophrenia or schizoaffective
disorder does not have to tolerate the pain and discomfort associated with headache
and that appropriate treatment is available. To this end pamphlets with information
about headache and its management will be provided in the outpatient waiting rooms
and ward areas at Alma Street (Appendix 4). A future research project could survey
people with schizophrenia and schizoaffective disorder to determine if there is any
changes in the management and effect on QOL secondary to headache with this
information being available.

Information and education about headaches, impacts and management of headaches
should be provided to psychiatrist, case managers and mental health workers. At the
Alma Street centre this will take the form of a lecture with handouts for future
reference. Once again a future research project could evaluate if there are any changes
in the management and quality of life of their clients with schizophrenia and
schizoaffective disorder who experience headache.
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Perhaps one of the most important recommendations for clinical practice is to alert
physiotherapists that the prevalence and characteristics of CGH in people with
schizophrenia and schizoaffective disorder is the same as for the general population
and they should be taking an active interest in this group of people as they are currently
missing out on best practice treatment.
Another important recommendation for clinical practice is to highlight to neurologists
and headache specialists that the prevalence and characteristics of CGH in people with
schizophrenia and schizoaffective disorder is the same as for the general population.
It is also important to highlight that the prevalence of MH is similar but with different
clinical characteristics around gender and age of onset and they should be taking an
active interest in this group of people as they are currently missing out on best practice
treatment. More research should be conducted to determine the reason that inpatients
are more likely to experience OH so that appropriate measures can be taken to address
this issue.

Finally there is a need to advertise the role that physiotherapy can play in the
management of other physical health issues and the advantages to employing
physiotherapists in this setting. A pamphlet has been developed for distribution
providing information about the role and benefits of physiotherapy for the overall
wellbeing of the person with schizophrenia or schizoaffective disorder (Appendix 3).

8.3

Conclusion

This study has shown that the prevalence rate of headache amongst people with
schizophrenia and schizoaffective disorder is similar to that of the general population.
Medication, acuity or chronicity of schizophrenia and schizoaffective disorder do not
play significant roles in the presence of headache. The prevalence of CGH and MH
are within the same parameters as the general population. The mechanisms driving
these headaches appear not to be related to psychosis or mental illness. There are some
differences in gender distribution and age of onset of MH which should be explored
further. More investigation is required to have a better understanding of why inpatients
are more likely to experience OH.

The frequency of headache has been shown to have the most impact on QOL and it
was evident that very few people are receiving appropriate treatment for their
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headaches. Physiotherapy was not included in the management of headache of any
people including those with CGH. It is recommended that better education is provided
for both patients and mental health workers about headache and its management as
well as the role of physiotherapy in managing the physical health and mental wellbeing
of people accessing mental health services.
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APPENDIX ONE
Questionnaire
Code Number ________________
Location of interview
Depot Clinic



Inpatient



Outpatient



Length of illness ___________________________________________

BMI

Height_________________________________________
Weight ________________________________________
Calculated______________________________________
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Headache Questionnaire
Thank you for participating in this headache study. Please answer the following
questions about you and your headache to the best of your ability. It is important that
you try to answer All the questions.
1. What is your age? _____________years
2. What is your gender?
Male



Female



3. Have you had a headache in the last 12 months?

Yes



No



4. Please list all your current medication.
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________

5. Please list any conditions you are receiving treatment for (eg diabetes, high
cholesterol, asthma, arthritis).
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
If you haven’t experienced a headache in the last 12 months please go straight to
the end of the questionnaire.
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6. Are you suffering from the headache today?

Yes



No



7. Have you experienced a headache in the last month?

Yes



No



8. Some people can experience more than one type of headache. Different types of
headache can


Feel different (have different pain)



Have different triggers



Be in different parts of the head



Have a different effect on day to day functioning

Do you suffer from more than one type of headache? Yes



No



If YES, how many different types of headache do you have? _________
If you suffer from more than one headache type, please complete a separate
form for each headache type.
Headache No ____________
9. About how long have you been getting headache? ____years ____months
10. About how often do you have headache?
Almost every day



Three or four per week



One or two per week



One per fortnight



One per month



Other

 how often _______

11. On average how long does your headache last ______hours ______ days
12. Do your headaches last about the same length of time? Yes



No





No



13. Does your headache go away completely between episodes?
Yes
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14. Please shade in the chart the area where you usually feel your headache or any
other pain. If applicable, please mark as number 1, where you first feel pain when
a headache starts and mark as number 2 where pain spreads to, and so forth.
R

R

L

L

L

R

15. Does your headache usually start:

16. My headache is:

in the head



in the neck



always on one side



can be on either side



on both sides



on both sides but one side is always


worse
17. I have neck pain or stiffness with my headache

Yes



No

18. I feel my headache as (tick as many boxes as applies to your headache)
Aching



Throbbing



Pulsating



Stabbing



Shooting



Band-like



Tightness



Sharp



19. Please mark on the line below, how bad your headache is when you get it.

No headache

Worst headache imaginable
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20. Please tick () which if any of the following symptoms accompany your
headaches and rate their intensity

Accompanying

How often

symptoms

Never

Intensity

Occasionally

Often

Mild

Moderate

Severe

Nausea
Vomiting
Light sensitivity
Noise sensitivity
Lightheaded/dizzy
Unsteadiness
Blurred vision
Eye swelling
Loss of appetite
Confused thinking
Shoulder or arm pain
on the same side as the
headache
Other._____________

21. Do you feel any of the following sensations for a period of minutes to an hour
before the onset of your headache?
Yes

No

things such as blind spots, flashing or zigzag lights





feeling of pin/needle or numbness





feeling of weakness





feeling of difficulty speaking
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22. Please tick (√) any of the following which can either give you a headache or
make it worse (tick as many boxes as applies to your headache)
Certain foods (e.g. chocolate, cheeses)



Alcohol (e.g. red wine, beer, spirits)



Awkward head or neck postures or neck movement



Sustained neck postures (e.g. reading)



Pressure over the neck or base of skull on the headache side



Medication



Routine physical activity or walking stairs



Lifestyle factors (e.g. excessive sleep, fasting or dieting, fatigue)



Exercises/sports



Environmental factors (e.g. strong odours, smoke, weather changes)



Stress or anxiety



Other. Pleases describe_______________________



I do not know what brings on my headache



23. I would like to know what you think started your headaches
I do not know



I think I know what caused my headache



Please describe_____________________________
24. Please tick (√) any of the following which can relieve your headache
Medication



Heat/ice applications



Physical activity



Neck exercise or change of position



Alcohol



Relaxation



Massage



Sleeping/rest



Unknown



Cannabis or other street drugs



Other
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Please describe
_______________________________________________________
25. Do other members of your family suffer from similar headaches?
Yes



No



Unsure 

26. When you have a headache do you notice or do other people comment on
changes in your thinking, feeling or actions?

Yes



No



If Yes, what changes are noticed?
______________________________________________________________
______________________________________________________________
27. Do your think recurrent headaches are ever related to you being admitted to
hospital?

Yes



No



28. During the past four weeks, have you had any of the following problems with your
work or

other regular daily activities as a result of your headache?

Yes

No

Cut down on the amount of time you spent on work or other activities 



Accomplished less than you would like





Were limited in the kind of work or other activities





Had difficulty performing the work or other activities





(for example, it took extra effort)

29. How much headache pain have you had during the past four weeks? (Circle one)

None

1

Very mild

2

Mild

3

Moderate

4

Severe

5

Very severe

6
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30. During the past four weeks, how much did headache interfere with your normal
work (including both work outside the home and housework)?
Not at all



A little bit



Moderately



Quite a bit



Extremely



31. During the past four weeks to what extent has your headache interfered with your
normal social activities with family, friends, neighbours, or groups?
Not at all



Slightly



Moderately



Quite a bit



Extremely



32. During the past four weeks how many days has your headache keep you from
doing your usual activities?
Number of days _______________
None



Thank you very much for your assistance in this research into headaches. I really
appreciate your taking the time to answer these questions. If you would like to be
contacted about the classification of your headache please let Jo know and she will
arrange for this.
A poster in the waiting room will be displayed when we have analysed all the results.
I hope you enjoy your DÔME voucher.
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APPENDIX TWO
Algorithm for headache classification
Is the headache unilateral and side locked, precipitated
by neck movement and/or sustained awkward neck
position and pain starts in neck?

Yes

Cervicogenic headache

No
Does this person have unilateral, moderate to severe,
pulsating/throbbing, time locked pain which
prohibits activity with associated aura?

Yes

Migraine Headache with aura

No
Does

this

person

have

mild

to

moderate,

pressing/tightening pain which is always bilateral and

Yes

no neck symptoms?

Tension Type Headache

No
Which classification best does the patient best suit?
CGH Defining factors

Migraine Defining
factors

TTH Defining factors

Other Defining
factors

Less episodic

Lasting 4-72 hours

lasting 30 min – 7 days

Motor weakness

Chronic/continuous

Episodic

Less episodic

Triggered by
medication

*Unilateral without side shift

Time locked

Chronic/continuous

Starts in neck

Fronto-temporal location

Starts in head

Neck stiffness/injury

Starts in head

Headache precipitated by 1 or more of
*Neck movement
*sustained awkward head position
*pressure over upper cervical or
occipital region on symptomatic side

2 of the following
*Unilateral
*Pulsating/throbbing/shar
p/stabbing
*Moderate to severe
*Aggravated by routine
exercise, food,
environment, stress,

At least 2 of the following
*Bilateral
*Pressing/tightening
pain/bandlike
*Mild to moderate pain
*Not aggravated by exercise

Ipsilateral neck, shoulder or arm pain
Varying duration of moderate – severe
pain
Ache/ sharp/ non-throbbing, nonlancinating pain or fluctuating
continuous pain
May have associated nausea,
photophobia or phonophobia,
dizziness, ipsilateral blurred vision,
difficulties swallowing ,
ipsilateral eye oedema,
Aggravated by sport/exercise, stress
Relief with hotpacks, neck exercises,
change of position, massage, relaxation

At least one of the
following
*Nausea/Vomiting
photophobia or
phonophobia
May have associated fully
reversible aura including
visual –flickering lights,
spots, lines or loss of
vision
Sensory-pins and needles,
numbness
Relief with medication,
rest
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Least pain
Both of the following
*no nausea/vomiting
*no more than one of
photophobia or phonophobia
Unless chronic then mild
nausea may be associated
Not made worse by normal
physical activity
Aggravated by stress
Relief with physical activity,
relaxation, massage, rest
alcohol

Inconsistent
characteristics of
other three
headache types
Aggravated by
food, alcohol,
lifestyle,
environment, stress
Eased by alcohol,
street drugs

APPENDIX THREE
Pamphlet about Role of Physiotherapy
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APPENDIX FOUR
Pamphlet about Headache
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APPENDIX FIVE

INFORMATION SHEET
Exploring headache amongst users of Alma Street Services
Jo Connaughton from the School of Physiotherapy at the University of Notre Dame
invites you to be a part of her doctoral research project investigating headaches in
people accessing Alma Street Services. Jo worked as the Senior Physiotherapist at
Alma Street between 2002 and 2007. Approval for this project has been granted by the
Research Committee of the College of Health Sciences under the authority of the
Human Research Ethics Committee of the University of Notre Dame Australia and the
South Metropolitan Area Health Services Human Research Ethics Committee.
Nature and Purpose of the Study
The aim of the project is to find out how many people who access Alma Street
experience headaches and how often, what type of headaches, how the headaches
impact on each person and what, if any treatment, each person is receiving for the
headaches. Your case manager has identified you are over 18 and might be willing to
be part of this study. You do not need to experience headaches to be part of this study.
What the Study Will Involve
If you decide to participate in this study a researcher will guide you through 30
questions from a questionnaire. This should take about 15 minutes to complete.
Benefits
The results of the project will help provide guidelines for identification of headaches
and the management of headache for clients of Alma Street and other mental health
services.
Confidentiality
All questionnaires will be de-identified and then data will be kept at the University in a
password protected computer.
This information will only be available to the
researcher for the express purpose of performing the study. All of the collected
information will be destroyed after 5 years. If publications arise from this research,
the identity of participants will not be revealed in any of the published material.
Voluntary Participation and Withdrawal from Study
Your participation in this study is entirely voluntary and you may withdraw at any time
from the project.
If you should have any complaints or concerns about the way in which the study is being
conducted, you may contact the Chair of the South Metropolitan Area Health Service Human
Research Ethics Committee on 9431 2929 or the Executive Officer of The University of Notre
Dame Australia, phone (08) 9433 0964.
If you have any questions about this study please contact Associate Professor Joanne
Connaughton on 9433 0186.
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CONSENT FORM
TO BE USED IN CONJUNCTION WITH THE INFORMATION SHEET

Exploring headache amongst users of Alma Street Services

Participant’s Name:.............................................. Date of Birth………………..

1.

I agree entirely voluntarily to take part in this study exploring headache amongst
users of Alma Street Services. I am over 18 years of age.

2.

I have read and understood the information sheet about this project and my questions
have been answered to my satisfaction.

3.

I understand that I am entirely free to withdraw from the study at any time without
prejudice or affect on access to treatment at Alma Street.

4.

I understand that all information gathered by the researcher will be treated as strictly
confidential.

5.

I understand that the protocol adopted by the University Of Notre Dame Australia
Human Research Ethics Committee for the protection of privacy will be adhered to
and relevant sections of the Privacy Act are available at http://www.nhmrc.gov.au/

6.

I understand that I will not be referred to by name in any report concerning this
study. In turn, I cannot restrict in any way the use of the results that arise from this
study.

Signature by patient

Signed..............................................

Signature by researcher

Signed:........................................................

Date:.....................................................Date:........................................................
If participants have any complaint regarding the manner in which a research project is conducted,
it should be directed to the Executive Officer of the Human Research Ethics Committee, Research
Office, The University of Notre Dame Australia, PO Box 1225 Fremantle WA 6959, Phone (08)
9433 0943.
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